<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004040" GROUP_ID="DEPRESSN" ID="005501111420094859" MERGED_FROM="" MODIFIED="2008-11-03 14:08:46 +0100" MODIFIED_BY="Rachel Churchill" NOTES="&lt;p&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.1&lt;br&gt;Exported from Review Manager 4.2&lt;/p&gt;&lt;p&gt;Old title: REFS TIDIED - Olanzapine alone or in combination for acute mania&lt;/p&gt;" NOTES_MODIFIED="2008-11-03 13:05:59 +0000" NOTES_MODIFIED_BY="Rachel Churchill" REVIEW_NO="056" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="10.0">
<COVER_SHEET MODIFIED="2008-11-03 14:08:46 +0100" MODIFIED_BY="Rachel Churchill">
<TITLE>Olanzapine alone or in combination for acute mania</TITLE>
<CONTACT MODIFIED="2008-11-03 14:08:46 +0100" MODIFIED_BY="Rachel Churchill"><PERSON ID="7496" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>John</FIRST_NAME><LAST_NAME>Geddes</LAST_NAME><POSITION>Professor of Epidemiological Psychiatry</POSITION><EMAIL_1>john.geddes@psych.ox.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Psychiatry</DEPARTMENT><ORGANISATION>University of Oxford</ORGANISATION><ADDRESS_1>Warneford Hospital</ADDRESS_1><CITY>Oxford</CITY><ZIP>OX3 7JK</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1865 226480</PHONE_1><FAX_1>+44 1865 793101</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-11-03 14:08:46 +0100" MODIFIED_BY="Rachel Churchill"><PERSON ID="13209" ROLE="AUTHOR"><FIRST_NAME>Jennifer</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Rendell</LAST_NAME><EMAIL_1>jennifer.rendell@psych.ox.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Psychiatry</DEPARTMENT><ORGANISATION>University of Oxford</ORGANISATION><ADDRESS_1>Warneford Hospital</ADDRESS_1><CITY>Oxford</CITY><ZIP>OX3 7JX</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>01865 226465</PHONE_1><FAX_1>01865 223900</FAX_1></ADDRESS></PERSON><PERSON ID="13146" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Harm</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Gijsman</LAST_NAME><POSITION>Psychiater</POSITION><EMAIL_1>harm.gijsman@doctors.org.uk</EMAIL_1><ADDRESS><DEPARTMENT>Stichting Forum GGZ Nijmegen</DEPARTMENT><ORGANISATION/><ADDRESS_1>Nijmeegsebaan 61 </ADDRESS_1><CITY>6525 DX Nijmegen</CITY><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>0243283540</PHONE_1><PHONE_2>0243283252</PHONE_2><FAX_1>0031(0)243283597</FAX_1></ADDRESS></PERSON><PERSON ID="13172" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Paul</FIRST_NAME><MIDDLE_INITIALS>K</MIDDLE_INITIALS><LAST_NAME>Keck</LAST_NAME><EMAIL_1>paul.keck@uc.edu</EMAIL_1><ADDRESS><DEPARTMENT>Department of Psychiatry</DEPARTMENT><ORGANISATION>University of Cincinnati College of Medicine</ORGANISATION><ADDRESS_1>231 Albert Sabin Way, ML 559</ADDRESS_1><CITY>Cincinnati</CITY><ZIP>45267-0559 </ZIP><REGION>OH </REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>(513) 558-8626</PHONE_1><FAX_1>(513) 558-6131</FAX_1></ADDRESS></PERSON><PERSON ID="13150" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Guy</FIRST_NAME><LAST_NAME>Goodwin</LAST_NAME><POSITION>WA Handley Professor of Psychiatry</POSITION><EMAIL_1>guy.goodwin@psych.ox.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Psychiatry</DEPARTMENT><ORGANISATION>University of Oxford</ORGANISATION><ADDRESS_1>Department of Psychiatry</ADDRESS_1><ADDRESS_2>Warneford Hospital</ADDRESS_2><CITY>Oxford</CITY><ZIP>OX3 7JX</ZIP><REGION>Oxon</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>01865 226451</PHONE_1></ADDRESS></PERSON><PERSON ID="7496" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>John</FIRST_NAME><LAST_NAME>Geddes</LAST_NAME><POSITION>Professor of Epidemiological Psychiatry</POSITION><EMAIL_1>john.geddes@psych.ox.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Psychiatry</DEPARTMENT><ORGANISATION>University of Oxford</ORGANISATION><ADDRESS_1>Warneford Hospital</ADDRESS_1><CITY>Oxford</CITY><ZIP>OX3 7JK</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1865 226480</PHONE_1><FAX_1>+44 1865 793101</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-11-03 13:05:59 +0000" MODIFIED_BY="Rachel Churchill" NOTES="&lt;p&gt;Minor update: 25/02/04&lt;/p&gt;&lt;p&gt;Feedback added: 20/08/03&lt;/p&gt;&lt;p&gt;Response to feedback added: 25/02/04&lt;/p&gt;" NOTES_MODIFIED="2008-11-03 13:05:59 +0000" NOTES_MODIFIED_BY="Rachel Churchill">
<UP_TO_DATE>
<DATE DAY="16" MONTH="11" YEAR="2002"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="16" MONTH="11" YEAR="2002"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="28" MONTH="2" YEAR="2009"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2003"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2003"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="3" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="16" MONTH="11" YEAR="2002"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Department of Psychiatry, University of Oxford</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-11-03 12:58:40 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-11-03 12:55:18 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-11-03 12:55:18 +0000" MODIFIED_BY="[Empty name]">Olanzapine compared to placebo or other medicine as treatment for mania</TITLE>
<SUMMARY_BODY>
<P>High withdrawal rates from the trials limit the confidence that can be placed on the results. Olanzapine was superior to placebo in reduction of manic symptoms both as monotherapy and combined with mood stabilizers, though caused weight gain. Olanzapine was more efficacious than divalproex and caused less nausea but more weight gain, somnolence and movement disorders. Olanzapine was comparable to haloperidol in efficacy, caused less movement disorders but greater weight gain.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Olanzapine, an atypical antipsychotic, is used in the treatment of mania both as monotherapy and combined with other medicines. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To review the efficacy and tolerability of olanzapine in the treatment of mania</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>The Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Register (CCDANCTR), The Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE, MEDLINE, CINAHL and PsycINFO were searched.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised trials comparing olanzapine with placebo or other drug in acute manic or mixed episodes. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Two reviewers independently extracted data from trial reports</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Six trials (1422 participants) were included in the review. There was a high rate of failure to complete treatment on all treatments which may have biased the estimates of relative efficacy. Olanzapine was superior to placebo at reducing manic symptoms as monotherapy (Young Mania Rating Scale (YMRS) - weighted mean difference (WMD): -5.94, 95% CI -9.09 to -2.80) and in combination with lithium/valproate (YMRS) (WMD -4.01, 95% confidence interval -6.06 to -1.96). Olanzapine monotherapy was superior at reducing psychotic symptoms (PANSS positive symptoms subscale WMD: -3.54, 95% CI -5.28 to -1.80). Olanzapine was superior to divalproex at reducing manic symptoms (standardised mean difference (SMD): -0.29, 95% CI -0.50 to -0.08). Olanzapine did not lead to a statistically higher rate of clinical response than haloperidol (RR: 1.03, 95% CI 0.77 to 1.38). Fewer patients discontinued treatment on olanzapine than placebo (RR: 0.62, 95% CI 0.48 to 0.80). Olanzapine caused greater weight gain than placebo (WMD 1.91Kg, 95% CI 1.29 to 2.53) and somnolence (RR: 2.13 95% CI 1.62 to 2.79) but not more depressive symptoms (RR: 0.95, 95% CI 0.65 to 1.40) or movement disorder (WMD: -0.33, 95% CI -0.74 to 0.09). Olanzapine caused more prolactin elevation than placebo (RR: 4.35 95%CI 1.77 to 10.70). Olanzapine caused greater weight gain (WMD: 1.54, 95% CI 1.02 to 2.05); somnolence (RR: 1.80 95% CI 1.32 to 2.46) and movement disorders (SAS - WMD: 0.72 95% CI 0.11 to 1.33) than divalproex but less nausea ( RR: 0.36 95% CI 0.20 to 0.65). Olanzapine caused more weight gain than haloperidol (RR: 3.59, 95% CI 1.49 to 8.64) but less movement disorder (EPS RR: 0.10, 95% CI 0.04 to 0.24). </P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Olanzapine is an effective treatment for mania and may be more efficacious than divalproex, though leads to more weight gain. Clinicians should consider both the relative efficacy and the different incidence of specific adverse effects of available drugs. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-11-03 12:58:27 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND>
<P>Bipolar disorder is a mental disorder characterised by episodes of elevated or irritable mood (manic or hypomanic episodes) and episodes of low mood, loss of energy and sadness (depressive episodes). Some people also experience mixed episodes in which manic and depressive symptoms are present at the same time. Psychotic symptoms may occur in mania and are called mood-congruent when they occur during a manic episode and are consistent with the mood disturbance. Manic episodes may also occur in patients who have symptoms of both schizophrenia and mood disorder (schizoaffective disorder).</P>
<P>The costs of manic episodes are high both for patients and for health services. For patients, in addition to the period of acute illness, manic episodes often leave an aftermath of psychological, social and financial problems. Direct medical costs are high because admission to a psychiatric intensive care unit is often necessary. </P>
<P>Drugs are the first line treatment for acute mania. The main objectives in treating mania are to control dangerous behaviour, produce appropriate acute sedation and shorten the episode of mood disturbance. A number of different drugs are used in the treatment of mania - either as monotherapy or in combination. Lithium has been used to treat mania for many years and has been shown to be effective (<LINK REF="REF-Goodwin-1990" TYPE="REFERENCE">Goodwin 1990</LINK>). Antipsychotics (also called neuroleptics, major tranquilisers) have been used for many years, particularly when mania is accompanied by psychosis. In North America, antipsychotics have mainly been considered as adjunctive to primary therapy with a "mood stabiliser" such as lithium or valproate. By contrast, in Europe, antipsychotics are usually themselves considered as a primary therapy for mania, either alone or in combination with mood stabilisers.</P>
<P>All drug treatments for mania are potentially associated with serious adverse effects and with a risk of precipitating depression. The recognised adverse effects of conventional antipsychotics include movement disorders (EPS; parkinsonian symptoms, dystonia, akathisia, tardive dyskinesia), neuroleptic malignant syndrome, EEG changes, cardiovascular problems (hypotension, tachycardia, arrhythmias) and alterations in liver function. Nevertheless, compared to lithium, antipsychotics are sometimes considered to possess a wider ratio between doses that possess efficacy and those that induce adverse effects and this is important in the treatment of patients with mania. The rapid control of agitation and overactivity may be offset by the risks of serious adverse effects and poor tolerability. Newer "atypical antipsychotics" (olanzapine, risperidone, ziprasidone, quetiapine, clozapine, amisulpiride, sertindole, zotepine and aripiprazole) may be an important advance if they share the advantages of the older antipsychotics in mania, but have fewer adverse effects.</P>
<P>Olanzapine is an atypical antipsychotic that is more effective than placebo, and comparable to conventional antipsychotics, in the treatment of schizophrenia (<LINK REF="REF-Duggan-2002" TYPE="REFERENCE">Duggan 2002</LINK>). Olanzapine causes fewer movement disorders but greater weight gain than conventional antipsychotics and it may increase the risk of diabetes (<LINK REF="REF-Koro-2002" TYPE="REFERENCE">Koro 2002</LINK>). </P>
<P>This systematic review assessed the evidence for the efficacy and tolerability of olanzapine compared with placebo or other active treatments.</P>
</BACKGROUND>
<OBJECTIVES>
<P>1.To determine the efficacy of olanzapine compared with placebo or other active treatment in alleviating the acute symptoms of manic or mixed episodes. </P>
<P>2. To review the effect of olanzapine on general health and social functioning. </P>
<P>3.To review acceptability of treatment with olanzapine. </P>
<P>4. To investigate the adverse effects of treatment with olanzapine. </P>
<P>5.To determine overall mortality rates on treatment with olanzapine. </P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>Randomised controlled trials which compared olanzapine with placebo or other active treatments. For trials with a crossover design only results from the first randomisation period were considered.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Patients of both sexes and all ages with a diagnosis of bipolar or schizoaffective disorder: manic or mixed episode, however diagnosed, with or without psychotic symptoms. Most recent studies were likely to have used DSMIV or ICD10 criteria. Older studies may have used ICD9, DSM III / DSM IIIR of other diagnostic systems.</P>
<P>Studies of acute treatment with olanzapine which recruited patients with diagnoses other than bipolar disorder or schizoaffective disorder and did not stratify randomisation according to diagnosis were not included in this review.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Olanzapine in comparison with placebo or other antimanic treatment either as monotherapy or adjunctive treatment in the treatment of an acute manic or mixed episode. <BR/> </P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>1. Efficacy in the treatment of manic or mixed episode</P>
<P>The primary measure of efficacy for this review was changes in manic symptom ratings. </P>
<P>Secondary measures of efficacy included were:-<BR/>a. achievement of response or remission of manic symptoms <BR/>b. change in depression rating scales and achievement of response or remission of depressive symptoms for patients experiencing a mixed episode<BR/>c. change in psychotic symptom rating scales<BR/>d. change in rating scales of severity of psychiatric symptoms<BR/>e. use of rescue medication <BR/>f. time to onset of symptom reduction or response<BR/>g. requirement for inpatient care e.g. length of stay</P>
<P>2. General health and social functioning, measured by quality of life scales.</P>
<P>3. Acceptability of treatment<BR/>Completion of trial treatment, which includes elements of tolerability and efficacy, was used as an indicator of the overall acceptability of treatments. </P>
<P>4. Specific adverse effects, measured by patients experiencing:- <BR/>a. movement disorders - parkinsonian symptoms, dystonia, akathisia, tardive dyskinesia<BR/>b. cardiovascular effects - hypotension, tachycardia, arrhythmias and ECG changes<BR/>c. switch to depression for patients experiencing a manic episode<BR/>d. weight gain<BR/>e. sedation<BR/>f. GI disturbance - nausea, vomiting, constipation<BR/>g. haematological changes<BR/>h. diabetes<BR/>i. alopecia</P>
<P>and by requirement for medication for treatment emergent adverse effects.</P>
<P>5. Mortality rates during treatment.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>Electronic searches:</P>
<P>a/ The following specified electronic databases were searched with subject headings (psychotic affective disorders, bipolar disorder, mania, olanzapine) and text words (mania*, manic*, olanzapine)<BR/>The Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Register (CCDANCTR-Studies)<BR/>The Cochrane Central Register of Controlled Trials (CENTRAL)</P>
<P>b/ The following additional databases were searched to check the completeness of the CCDANCTR and CENTRAL using terms as above.<BR/>EMBASE (1980-2002)<BR/>MEDLINE (1966-2002)<BR/>CINAHL (1982-2002)<BR/>PsycINFO (1872-2002)</P>
<P>Reference Checking:<BR/>The reference lists of all identified randomised controlled trials, other relevant papers and major textbooks of affective disorder written in English were checked.</P>
<P>Personal Communication:<BR/>The authors of significant papers were identified from authorship lists over the last five years. They, and other experts in the field, were contacted and asked of their knowledge of other studies, published or unpublished, relevant to the review article.</P>
<P>Eli Lilly (pharmaceutical company that manufactures olanzapine) was requested to provide relevant published and unpublished data. </P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>a) Selection of trials and data extraction. Studies relating to olanzapine generated by the search strategies were checked to ensure they met the previously defined inclusion criteria. Two reviewers independently extracted data concerning participant characteristics, intervention details and outcome measures from the included studies. Subgroup analyses were recorded where the subgroups were defined a priori; if appropriate, the results were included in the meta-analysis. All disagreements were resolved by discussion.</P>
<P>b) Quality assessment. Quality was assessed according to the Cochrane criteria for quality assessment (<LINK REF="REF-Sackett-1997" TYPE="REFERENCE">Sackett 1997</LINK>). This pays particular attention to the adequacy of the randomisation procedure. On this basis, studies were given a quality rating of A (adequate), B (unclear), and C (inadequate). If the raters disagreed the final rating was made by consensus with the involvement (if necessary) of another member of the review group. In addition, a general appraisal of study quality was made by assessing key methodological issues such as blinding, completeness of follow-up and reporting of study withdrawals. Where inadequate details of randomisation and other characteristics of trials were provided, the authors were contacted in order to obtain further information.</P>
<P>Non-concurrence in selection and quality assessment was reported as appropriate.</P>
<P>c) Data Analysis. Data were entered into Revman 4.2 software by one reviewer. <BR/>Intention to Treat data (ITT) data were used when available. Where ITT data were not available, end-point data for trial completers were used. </P>
<P>Continuous data were analysed using weighted mean differences (with 95% confidence intervals) or standardised mean differences (where different measurement scales were used). Where standard deviations were not recorded, authors were asked to supply the data. In the absence of data from the authors the mean standard deviation from other studies was used. When there were missing data and the method of "last observation carried forward " was used to do an ITT analysis, then the LOCF data were used, with due consideration of the potential bias and uncertainty introduced. </P>
<P>For dichotomous, or event-like, data, relative risks were calculated with 95% confidence intervals. Where participants withdrew from a trial before the endpoint, it was assumed they would have experienced the negative outcome by the end of the trial (e.g. failure to respond to treatment). Where the proportion of participants withdrawing from treatment was substantial (more than 20%), sensitivity analyses were performed to investigate the effect of the possible different outcomes of those participants who withdrew in each group (for example, all the patients in the experimental group experience the negative outcome and all those allocated to the comparison group experience the positive outcome). </P>
<P>Heterogeneity between studies was assessed using the chi-square test with a p-value of less than or equal to 0.1 being taken to indicate heterogeneity. If significant heterogeneity was identified, potential sources were considered. Fixed and random effects analyses were done routinely to investigate the effect of the choice of method on the estimates. Material differences between the models were reported. </P>
<P>Skewed data and non-quantitative data were presented descriptively. <BR/>Monotherapy and adjunctive treatment trials were analysed separately and, where appropriate, combined results were also reported. <BR/>Where data were reported, subgroup analyses were performed to assess the possibility of differences in the efficacy of olanzapine in the treatment of psychotic and non-psychotic mania. If data were available, analysis by length of treatment was performed to ascertain whether any treatment differences detected varied with time.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-11-03 12:58:27 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION>
<P>The search for randomised controlled trials of antipsychotics identified 26 papers relating to trials of olanzapine for indications other than mania (schizophrenia, major depressive disorder, anorexia nervosa and anxiety in Alzheimer's disease) which have not been included. From the remaining references, eight randomised controlled trials of olanzapine in mania were identified. (Several of the trials were presented at a number of conferences and subgroup analyses have been published. In this review only the main publications have been included in the list of references.)</P>
<P>Three of the eight trials were placebo-controlled trials, two of olanzapine monotherapy versus placebo (<LINK REF="STD-HGEH-Trial_x002c_-1999" TYPE="STUDY">HGEH Trial, 1999</LINK>*; <LINK REF="STD-HGGW-Trial-2000" TYPE="STUDY">HGGW Trial 2000</LINK>*) and one of olanzapine versus placebo as adjunctive treatment to lithium or valproate (<LINK REF="STD-HGFU-Trial-2002" TYPE="STUDY">HGFU Trial 2002</LINK>*). Three trials were comparisons of olanzapine with mood stabilisers (lithium and lamotrigine - <LINK REF="STD-Berk-1999" TYPE="STUDY">Berk 1999</LINK>; divalproex ( <LINK REF="STD-HGHQ-Trial-2002" TYPE="STUDY">HGHQ Trial 2002</LINK>*; <LINK REF="STD-Zajecka-2000" TYPE="STUDY">Zajecka 2000</LINK>). One trial compared olanzapine with haloperidol (<LINK REF="STD-HGHD-Trial-2002" TYPE="STUDY">HGHD Trial 2002</LINK>*). <LINK REF="STD-Zajecka-2000" TYPE="STUDY">Zajecka 2000</LINK> and <LINK REF="STD-HGHD-Trial-2002" TYPE="STUDY">HGHD Trial 2002</LINK> have not yet been published but some data from conference posters were available. The authors have been asked to supply the data for these trials. One trial, which compared intramuscular injections of olanzapine, lorazepam and placebo, was excluded from the analysis because response was defined as a rapid reduction in agitation (i.e. within 2 hours of treatment) rather than reduction of manic symptoms (<LINK REF="STD-Meehan-2001" TYPE="STUDY">Meehan 2001</LINK>). Seven trials reporting eight comparisons with olanzapine (1467 participants) are therefore included in this review. </P>
<P>For one trial (<LINK REF="STD-Zajecka-2000" TYPE="STUDY">Zajecka 2000</LINK>) efficacy data was reported after three weeks randomised treatment and adverse event data after twelve weeks and in two trials (<LINK REF="STD-HGHD-Trial-2002" TYPE="STUDY">HGHD Trial 2002</LINK>, <LINK REF="STD-HGFU-Trial-2002" TYPE="STUDY">HGFU Trial 2002</LINK>) the acute treatment phase was followed by a continuation phase. </P>
<P>* Studies by Tohen et al have been identified by Olanzapine Study Group initials.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>1. Randomisation / concealment of allocation<BR/>All trials were described as randomised, but none gave details of the method used to achieve random allocation or allocation concealment. All trials were therefore rated "B" (unclear) for allocation concealment according to Cochrane criteria (<LINK REF="REF-Sackett-1997" TYPE="REFERENCE">Sackett 1997</LINK>). Additional information has been requested from the authors.</P>
<P>2. Intention to treat analysis. <BR/>Five trials reported a modified intention-to-treat analysis using the last observation carried forward (LOCF) to deal with missing continuous data and excluding participants for whom there were no post-baseline measures from analyses of efficacy measures. When withdrawal from the trial is random and not associated with the trial intervention, the LOCF approach is usually assumed to give a conservative estimate of the effectiveness of a treatment in an acute illness. When withdrawal is non-random (i.e. associated with one of the treatments) it can give a biased estimate of that treatment effect. For dichotomous data we imputed an ITT analysis by assuming that all trial withdrawals failed to respond. <BR/>Two trials (<LINK REF="STD-HGHD-Trial-2002" TYPE="STUDY">HGHD Trial 2002</LINK>; <LINK REF="STD-Zajecka-2000" TYPE="STUDY">Zajecka 2000</LINK>) did not give details of how data on patients who withdrew from the trial prematurely were handled. </P>
<P>3. Blinding<BR/>All trials were reported to have been double-blind, in which the treatment allocation was masked from both the clinicians and patients. </P>
<P>4. Numbers of participants<BR/>The number of randomised participants was 45 (<LINK REF="STD-Berk-1999" TYPE="STUDY">Berk 1999</LINK>), 115 (<LINK REF="STD-HGGW-Trial-2000" TYPE="STUDY">HGGW Trial 2000</LINK>), 120 (<LINK REF="STD-Zajecka-2000" TYPE="STUDY">Zajecka 2000</LINK>), 139 (<LINK REF="STD-HGEH-Trial_x002c_-1999" TYPE="STUDY">HGEH Trial, 1999</LINK>), 251 (<LINK REF="STD-HGHQ-Trial-2002" TYPE="STUDY">HGHQ Trial 2002</LINK>), 344 (<LINK REF="STD-HGFU-Trial-2002" TYPE="STUDY">HGFU Trial 2002</LINK>) and 453 (<LINK REF="STD-HGHD-Trial-2002" TYPE="STUDY">HGHD Trial 2002</LINK>). </P>
<P>5. Selection of participants<BR/>Six trials were multi-centre recruiting patients from sites in the USA and Canada (<LINK REF="STD-HGEH-Trial_x002c_-1999" TYPE="STUDY">HGEH Trial, 1999</LINK>; <LINK REF="STD-HGGW-Trial-2000" TYPE="STUDY">HGGW Trial 2000</LINK>; <LINK REF="STD-HGFU-Trial-2002" TYPE="STUDY">HGFU Trial 2002</LINK>; <LINK REF="STD-HGHQ-Trial-2002" TYPE="STUDY">HGHQ Trial 2002</LINK>; <LINK REF="STD-HGHD-Trial-2002" TYPE="STUDY">HGHD Trial 2002</LINK>; <LINK REF="STD-Zajecka-2000" TYPE="STUDY">Zajecka 2000</LINK>). The fifth trial (<LINK REF="STD-Berk-1999" TYPE="STUDY">Berk 1999</LINK>) was a single centre study and recruited inpatients. The four trials that reported exclusion criteria all excluded patients with a recent history of substance abuse / dependence (<LINK REF="STD-Berk-1999" TYPE="STUDY">Berk 1999</LINK>; <LINK REF="STD-HGEH-Trial_x002c_-1999" TYPE="STUDY">HGEH Trial, 1999</LINK>; <LINK REF="STD-HGGW-Trial-2000" TYPE="STUDY">HGGW Trial 2000</LINK>; <LINK REF="STD-HGHQ-Trial-2002" TYPE="STUDY">HGHQ Trial 2002</LINK>).</P>
<P>6. Diagnosis of Mania<BR/>In six trials mania was diagnosed according to DSM-IV criteria - for 5 trials criteria for bipolar disorder manic or mixed episode were used (<LINK REF="STD-HGEH-Trial_x002c_-1999" TYPE="STUDY">HGEH Trial, 1999</LINK>; <LINK REF="STD-HGGW-Trial-2000" TYPE="STUDY">HGGW Trial 2000</LINK>; <LINK REF="STD-HGFU-Trial-2002" TYPE="STUDY">HGFU Trial 2002</LINK>; <LINK REF="STD-HGHQ-Trial-2002" TYPE="STUDY">HGHQ Trial 2002</LINK>; <LINK REF="STD-HGHD-Trial-2002" TYPE="STUDY">HGHD Trial 2002</LINK>) and in 1 trial (<LINK REF="STD-Berk-1999" TYPE="STUDY">Berk 1999</LINK>) criteria for manic episode only were used. In 4 trials the inclusion criteria included a minimum score of 20 on the Young Mania Rating (YMRS) (<LINK REF="STD-HGEH-Trial_x002c_-1999" TYPE="STUDY">HGEH Trial, 1999</LINK>; <LINK REF="STD-HGGW-Trial-2000" TYPE="STUDY">HGGW Trial 2000</LINK>; <LINK REF="STD-HGHQ-Trial-2002" TYPE="STUDY">HGHQ Trial 2002</LINK>; <LINK REF="STD-HGHD-Trial-2002" TYPE="STUDY">HGHD Trial 2002</LINK>). In 1 trial, patients were treated with lithium or valproate for 2 weeks and were then required to have a minimum score on the YMRS of 16 on two consecutive measurements between 2 and 7 days apart (<LINK REF="STD-HGFU-Trial-2002" TYPE="STUDY">HGFU Trial 2002</LINK>). One trial did not specify a minimum YMRS score (<LINK REF="STD-Berk-1999" TYPE="STUDY">Berk 1999</LINK>). One trial did not report the basis for a diagnosis of mania (<LINK REF="STD-Zajecka-2000" TYPE="STUDY">Zajecka 2000</LINK>).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-11-03 12:58:27 +0000" MODIFIED_BY="[Empty name]">
<P>The only data for <LINK REF="STD-Berk-1999" TYPE="STUDY">Berk 1999</LINK> which were presented in a form that could be included were on withdrawal from treatment . Since this alone is not very informative, this trial has been excluded from the analysis. The authors have been asked to provide additional data.</P>
<P>1. EFFICACY OF OLANZAPINE IN THE TREATMENT OF MANIA</P>
<P>The proportion of participants who withdrew from treatment exceeded 20% for each intervention in all trials. However it was not possible to do the planned sensitivity analyses for because dichotomous data on responders included LOCF data for some participants.</P>
<P>a) Olanzapine versus placebo</P>
<P>i) Response or remission of manic symptoms<BR/>The trials used a number of measures of reduction of manic symptoms but each trial report defined, a priori, the mean change on the Young Mania Rating Scale (YMRS) total score from baseline to endpoint as the primary outcome measure. On this measure, there was evidence that olanzapine was more efficacious than placebo both as monotherapy (fixed effects weighted mean difference (WMD): -5.94, 95% confidence interval -9.09 to -2.80; p=0.0002, chi-square for heterogeneity 0.15, df=1, p=0.69; 2 trials, 246 participants) and as adjunctive treatment to lithium or valproate (WMD: -4.01, 95% confidence interval -6.06 to -1.96, p=0.0001, 2 trials, 334 participants). Meta-analysis of these results did not reveal significant heterogeneity between the monotherapy trials and the adjunctive treatment trial (fixed effects WMD: -4.59, 95% confidence interval -6.31 to -2.87; p&lt;0.00001, chi-square for heterogeneity 1.18, df=2, p=0.56; 3 trials, 580 participants).</P>
<P>There was also evidence that olanzapine was more efficacious than placebo when manic symptoms were measured in terms of mean change in CGI-BP mania score - monotherapy (fixed effects WMD: -0.75, 95% confidence interval -1.12 to -0.38; p&lt;0.0.0001, chi-square for heterogeneity 0.89, df=1, p=0.35; 2 trials, 246 participants); adjunctive treatment (WMD: -0.32 95% confidence interval -0.62 to -0.02, p=0.04, 1 trial, 334 participants) and meta-analysis (fixed effects WMD: -0.49, 95% confidence interval -0.73 to -0.26; p&lt;0.0001, chi-square for heterogeneity 3.96, df=2, p=0.14; 3 trials, 580 participants).</P>
<P>Olanzapine was found to be superior to placebo on dichotomous measures. A smaller proportion of patients on olanzapine failed to respond to treatment at endpoint (defined a priori as 50% or more reduction in YMRS between baseline and endpoint) - monotherapy (fixed effects RR: 0.64, 95% confidence interval 0.52 to 0.81; p=0.0001, chi-square for heterogeneity 0.17, df=1, p=0.68; 2 trials, 254 participants), adjunctive treatment (RR: 0.63, 95% confidence interval 0.49 to 0.80, p=0.0001, 1 trial, 344 participants) and meta-analysis (fixed effects RR: 0.64, 95% confidence interval 0.54 to 0.75; p&lt;0.00001, chi-square for heterogeneity 0.21, df=2, p=0.9; 3 trials, 598 participants). The relative risk reduction for olanzapine monotherapy (RRR: 0.36) is comparable with that for adding olanzapine to a mood stabiliser (RRR: 0.37). There was evidence from 2 trials (<LINK REF="STD-HGGW-Trial-2000" TYPE="STUDY">HGGW Trial 2000</LINK>; <LINK REF="STD-HGFU-Trial-2002" TYPE="STUDY">HGFU Trial 2002</LINK>) that olanzapine was more likely than placebo to produce remission of symptoms (defined as YMRS of 12 or less at end point) - monotherapy (RR: 0.60, 95% confidence interval 0.41 to 0.87, p=0.007, 1 trial, 115 participants), adjunctive treatment (RR: 0.70, 95% confidence interval 0.50 to 0.99, p=0.04, 1 trial, 344 participants and meta-analysis (fixed effects RR: 0.66, 95% CI 0.51 to 0.85; p=0.001, chi-square for heterogeneity 0.39 df=1, p=0.53; 2 trials; 459 participants).</P>
<P>The difference between olanzapine and placebo in terms of failure to respond and failure to achieve remission remained statistically significant when patients for whom there were no post baseline measurements were excluded from the analyses (see figures).</P>
<P>One trial reported an analysis of the subgroup of patients not experiencing psychotic symptoms at baseline. Olanzapine as adjunctive treatment to mood stabiliser was more efficacious than placebo in terms of mean change on the YMRS both as monotherapy (WMD: -4.93, 95% confidence interval -7.24 to -2.62, p&lt;0..0001, 1 trial, 226 participants). Data for the subgroup of patients with psychotic symptoms could not be analysed.</P>
<P>ii) Change in depressive symptoms<BR/>The trials all reported mean change in depressive symptoms as measured by the 21-item Hamilton Depression Rating Scale (HAMD-21) and the CGI -BP depression scale for all participants. No statistically significant difference was found between olanzapine monotherapy and placebo in terms of reduction of depressive symptoms on the HAMD-21 (random effects WMD: -1.53, 95% confidence interval -4.93 to 1.87; p=0.38, chi-square for heterogeneity 3.79, df=1 p=0.05; 2 trials, 244 participants) or the CGI-BP depression scale (random effects WMD: 0.05, 95% confidence interval -0.59 to 0.69; p=0.87, chi-square for heterogeneity 4.22, df=1, p =0.04; 2 trials, 244 participants). Random effects analyses have been used to allow for the observed heterogeneity between the trials however, fixed effects analyses also failed to find a difference between interventions. In contrast, olanzapine as adjunctive treatment to lithium or valproate was found to be more efficacious than placebo on both the HAMD-21 (WMD: -4.09, 95% confidence interval -5.71 to -2.47, p&lt;0.00001, 1 trial, 334 participants) and GGI-BP depression (WMD: -0.62, 95% confidence interval -0.94 to -0.30, p=0.0001, 1 trial, 334 participants). Meta-analysis did not find a difference between olanzapine and placebo using the random effects analyses - HAMD-21 (random effects WMD: -2.48, 95% confidence interval -5.18 to 0. 23; p=0.07, chi-square for heterogeneity 9.54, df=2, p = 0.008; 3 trials, 578 participants) and CGI-BP depression (random effects WMD: -0.19, 95% confidence interval -0.80 to 0.42; p=0.55, chi-square for heterogeneity 14.59, df=2, p = 0.0007; 3 trials, 580 participants). Using the fixed effects meta-analyses, olanzapine was found to be more efficacious than placebo - HAMD-21 (fixed effects WMD: -2.73 95% confidence interval -3.90 to -1.55) and CGI-BP depression (fixed effects WMD: -0.24, 95% confidence interval -0.46 to -0.02). The proportion of participants in one trial (<LINK REF="STD-HGEH-Trial_x002c_-1999" TYPE="STUDY">HGEH Trial, 1999</LINK>) with a mixed episode at baseline was 17.3% compared to over 40% in the other two trials and it is possible that this is the cause of the observed heterogeneity.</P>
<P>Two trials (<LINK REF="STD-HGGW-Trial-2000" TYPE="STUDY">HGGW Trial 2000</LINK>; <LINK REF="STD-HGFU-Trial-2002" TYPE="STUDY">HGFU Trial 2002</LINK>) reported reduction in HAMD-21 score for patients with moderate to severe depression at baseline (HAMD-21 at least 20). There was evidence that olanzapine was more efficacious than placebo at reducing depressive symptoms both as monotherapy (WMD: -5.98, 95% confidence interval -11.19 to -0.77, p=0.02, 1 trial, 42 participants), as adjunctive treatment (WMD: -8.74, 95% confidence interval -12.74 to -4.74, p&lt;0.0001, 1 trial, 72 participants) and as meta-analysis (fixed effects WMD: -7.72, 95% confidence interval -10.89 to -4.55; p&lt;0.00001, chi-square for heterogeneity 0.68, df=1, p=0.41; 2 trials, 114 participants).</P>
<P>iii) Change in psychotic symptom rating scales<BR/>Olanzapine monotherapy was more efficacious than placebo in reduction of positive symptoms, measured as the mean reduction on PANSS positive symptoms subscale fixed effects WMD: -3.54, 95% confidence interval -5.28 to -1.80; p&lt;0.0001, chi-square for heterogeneity 1.39, df=1, p=0.24; 2 trials, 244 participants).<BR/>Olanzapine was also found to cause a greater reduction in PANSS total score both as monotherapy fixed effects WMD: -10.00, 95% confidence interval -14.84 to -5.16; p&lt;0.0001, chi-square for heterogeneity 1.25, df=1, p=0.26; 2 trials, 244 participants) and as adjunctive treatment (WMD: -5.94, 95% confidence interval -9.60 to -2.28, p=0.001, 1 trial, 344 participants) and when combined (fixed effects WMD: -7.42, 95% confidence interval -10.33 to -4.50; p&lt;0.00001, chi-square for heterogeneity 2.97, df=2, p=0.23; 3 trials, 578 participants).</P>
<P>iv) Change in severity of psychiatric symptoms rating scales<BR/>There was evidence that olanzapine was more efficacious than placebo in improvement in overall severity of bipolar illness measured on the Clinical Global Impression (CGI) bipolar scale for severity of overall illness although this was not significant for olanzapine monotherapy when the random effects analysis was used to allow for heterogeneity between trials - monotherapy (random effects WMD: -0.63, 95% confidence interval -1.30 to 0.05; p=0.07, chi-square for heterogeneity 3.69, df=1, p=0.05; 2 trials, 246 participants), adjunctive treatment (WMD: -0.31, 95% confidence interval -0.60 to -0.02, p=0.03, 1 trial, 334 participants) and combined (random effects WMD: -0.49, 95% confidence interval -0.87 to -0.10; p=0.01, chi-square for heterogeneity 5.12, df=2, p=0.08; 3 trials, 580 participants). The reason for the observed heterogeneity is unclear but may in part be due to the differences in depressive symptoms at baseline.</P>
<P>v) Use of rescue medication<BR/>No statistically significant difference was found between olanzapine and placebo in the number of patients that took one or more doses of a benzodiazepine - as monotherapy (RR: 0.89, 95% confidence interval 0.70 to 1.14, p=0.36, 1 trial, 115 participants), as adjunctive treatment (RR: 0.85, 95% confidence interval 0.61 to 1.18, p=0.33, 1 trial, 344 participants) and combined (fixed effects RR: 0.87, 95% confidence interval 0.70 to 1.07; p=0.19, chi-square for heterogeneity 0.06, df=1, p=0.80; 2 trials, 459 participants).</P>
<P>vi) Time to onset of symptom reduction or response<BR/>No data were reported</P>
<P>vii) Requirement for inpatient care e.g. length of stay.<BR/>No data were reported.</P>
<P>b) Olanzapine versus mood stabiliser<B>
<BR/>
</B>For <LINK REF="STD-Zajecka-2000" TYPE="STUDY">Zajecka 2000</LINK> efficacy was assessed 3 weeks after randomization.</P>
<P>Notes re continuous data: <LINK REF="STD-Zajecka-2000" TYPE="STUDY">Zajecka 2000</LINK> did not record standard deviations for mean changes and so values from <LINK REF="STD-HGHQ-Trial-2002" TYPE="STUDY">HGHQ Trial 2002</LINK>, where available, have been used.</P>
<P>i) Response or remission of manic symptoms<BR/>Olanzapine was more efficacious than divalproex on the primary measure of response, mean change on the Young Mania Rating Scale (<LINK REF="STD-HGHQ-Trial-2002" TYPE="STUDY">HGHQ Trial 2002</LINK>) and the Mania Rating Scale (<LINK REF="STD-Zajecka-2000" TYPE="STUDY">Zajecka 2000</LINK>), (fixed effects standardised mean difference SMD: -0.29, 95% confidence interval -0.50 to -0.08; p=0.006, chi-square for heterogeneity 0.08, df=1, p=0.78; 2 trials, 363 participants) and in the proportion of patients who failed to respond to treatment at endpoint where response was defined a priori as 50% or more reduction in YMRS between baseline and endpoint (RR: 0.78, 95% confidence interval 0.61 to 0.99, p=0.04, 1 trial, 251 participants). However, when participants for whom there were no post-baseline measurements were excluded from this analysis of failure to respond to treatment the difference between olanzapine and divalproex was no longer significant (RR: 0.79, 95% confidence interval 0.62 to 1.01, p=0.06, 1 trial, 248 participants). There was evidence that olanzapine was more efficacious than divalproex in terms of the proportion of patients who failed to achieve remission (defined a priori as YMRS at end point of 12 or less) (RR: 0.79, 95% confidence interval 0.64 to 0.97, p=0.03, 1 trial, 251participants).<BR/>(Standardised mean difference (SMD) has been used because the trials used different mania rating scales).</P>
<P>One trial reported analyses of subgroups of patients according to the presence or absence of psychotic symptoms at baseline. Olanzapine was more efficacious than divalproex in terms of mean change on the YMRS for patients not experiencing psychotic symptoms (WMD: -0.63, 95% confidence interval -0.97 to -0.28, p=0.0003, 1 trial, 137 participants) but not for patients experiencing psychotic symptoms (WMD: 0.01, 95% confidence interval -0.36 to 0.38, p=0.96, 1 trial, 114 participants). There is no indication that randomisation was stratified according to presence of psychotic features and so that it is possible that other non-random differences between the groups account for the observed difference.</P>
<P>ii) Change in depressive symptoms<BR/>There was no evidence that olanzapine was more efficacious than divalproex in reducing depressive symptoms (fixed effect WMD: -1.01, 95% confidence interval -2.43 to 0.41; p=0.16, chi-square for heterogeneity 0.86, df=1, p=0.35; 2 trials, 355 participants). Not all patients had depressive symptoms at baseline, but there was no evidence that olanzapine was more efficacious than divalproex for participants moderate to severe depression at baseline (HAMD-21 at least 20) (WMD; -2.20, 95% confidence interval -6.40 to 2.00, p=0.31, 1 trial, 53 participants).</P>
<P>iii) Change in psychotic symptom rating scales<BR/>No data were reported on change in psychotic symptoms.</P>
<P>iv) Change in severity of psychiatric symptoms rating scales<BR/>Data reported on change in BPRS for one trial could not be analysed because it was not possible to estimate standard deviations (<LINK REF="STD-Zajecka-2000" TYPE="STUDY">Zajecka 2000</LINK>).</P>
<P>v) Use of rescue medication<BR/>No data that could be analysed were reported.</P>
<P>vi) Time to onset of symptom reduction or response<BR/>No data were reported.</P>
<P>vii) Requirement for inpatient care e.g. length of stay.<BR/>No data were reported.</P>
<P>c) Olanzapine versus other antipsychotics<BR/>i) Response or remission of manic symptoms<BR/>Continuous data on reduction of manic symptoms was not reported.<BR/>No statistically significant difference was found between olanzapine and haloperidol in terms of the proportion of participants who failed to respond (defined as reduction in YMRS of at least 50% between baseline and endpoint) either when withdrawals were included as non responders (RR: 1.03, 95% confidence interval 0.77 to 1.38, p=0.85, 1 trial, 453 participants) or when they were excluded from the analysis (RR: 1.07, 95% confidence interval 0.79 to 1.46, p=0.65, 1 trial, 444 participants). No statistically significant difference was seen between olanzapine and haloperidol when response was defined in terms of a reduction in YMRS of at least 70% or at least 80% (see figures).<BR/>
<BR/>The primary measure of efficacy, defined a priori, was the proportion of patients in remission at 6 weeks where remission was defined as Young Mania Rating Scale (YMRS) of 12 or less and Hamilton Depression Rating Scale (HAMD-21) of 8 or less. There was no statistically significant difference between olanzapine and haloperidol on this measure (RR: 0.89, 95% confidence interval 0.74 to 1.06, p=0.2, 1 trial, 453 participants).</P>
<P>ii) Change in depressive symptoms<BR/>Data for mean change on HAMD-21and MADRS were reported but no standard deviations were given so the data could not be analysed.</P>
<P>iii) Change in psychotic symptom rating scales<BR/>No data were reported</P>
<P>iv) Change in severity of psychiatric symptoms rating scales<BR/>No data were reported</P>
<P>v) Use of rescue medication<BR/>No data were reported</P>
<P>vi) Time to onset of symptom reduction or response<BR/>No data were reported</P>
<P>vii) Requirement for inpatient care e.g. length of stay.<BR/>No data were reported.</P>
<P>2. GENERAL HEALTH AND SOCIAL FUNCTIONING</P>
<P>a) Olanzapine versus placebo</P>
<P>i) Quality of life scales<BR/>One trial (<LINK REF="STD-HGEH-Trial_x002c_-1999" TYPE="STUDY">HGEH Trial, 1999</LINK>) measured quality of life using the SF-36 but did not report the results for the total score.</P>
<P>b) Olanzapine versus mood stabilizer</P>
<P>i) Quality of life scales<BR/>One trial (<LINK REF="STD-Zajecka-2000" TYPE="STUDY">Zajecka 2000</LINK>) measured quality of life using the Quality of Life Enjoyment and Satisfaction Scale (Q-LES-Q) but did not report the results for the total score.</P>
<P>c) Olanzapine versus other antipsychotics</P>
<P>No data were reported.</P>
<P>3. ACCEPTABILITY OF TREATMENT AS MEASURED BY COMPLETION OF THE TRIAL</P>
<P>a) Olanzapine versus placebo<BR/>i) Failure to complete treatment<BR/>The proportion of participants who failed to complete treatment ranged from 29% for the placebo group in the adjunctive treatment trial (<LINK REF="STD-HGFU-Trial-2002" TYPE="STUDY">HGFU Trial 2002</LINK>) to 65% for the placebo group in one monotherapy trial (<LINK REF="STD-HGEH-Trial_x002c_-1999" TYPE="STUDY">HGEH Trial, 1999</LINK>). A smaller proportion of participants failed to complete treatment in the olanzapine monotherapy group than in the placebo treated group (RR: 0.62, 95% confidence interval 0.48 to 0.80; p=0.0003, chi-square for heterogeneity 0.14, df=1, p=0.71; 2 trials, 254 participants). In contrast no statistically significant difference was found between the proportion of patients that completed treatment in the olanzapine plus mood stabiliser and the placebo plus mood stabiliser groups (R: 1.05, 95% confidence interval 0.74 to 1.49, p=0.78, 1 trial, 344 participants).</P>
<P>It was not possible to assess the extent to which failure to complete treatment was caused by lack of efficacy or adverse effects because reasons cited included patient or physician decisions which are likely to be related to efficacy and/or adverse effects.</P>
<P>b) Olanzapine versus mood stabiliser<BR/>i) Failure to complete treatment.<BR/>
<LINK REF="STD-Zajecka-2000" TYPE="STUDY">Zajecka 2000</LINK> reported data on failure to complete treatment at 12 weeks.<U>
<BR/>
</U>
<BR/>No statistically significant difference was found between olanzapine divalproex in terms of the proportion of patients who failed to complete treatment (RR: 0.90, 95% confidence interval 0.73 to 1.12, p=0.35, chi-square for heterogeneity 0.11, df=1, p= 0.74; 2 trials, 371 participants).</P>
<P>
<U>
<BR/>
</U>
</P>
<P>c) Olanzapine versus other antipsychotic<BR/>i) Failure to complete treatment.<BR/>In the olanzapine group 29% of participants failed to complete treatment compared to 36% in the haloperidol group. This difference was not significant (fixed effects RR: 0.82, 95% confidence interval 0.62 to 1.07, p=0.14, 1 trial, 453 participants).</P>
<P>4. ADVERSE EFFECTS</P>
<P>a) Olanzapine versus placebo<BR/>The trials reported dichotomous data for a number of treatment emergent adverse effects. It was unclear how these adverse effects were measured both in terms of severity and duration and further information on these is being sought from the authors.</P>
<P>i) Weight gain<BR/>For all three trials olanzapine was associated with significantly greater weight gain than placebo when measured as mean change in weight - monotherapy (fixed effects WMD 1.91, 95% confidence interval 1.29 to 2.53, p&lt;0.00001, chi- square for heterogeneity 0.44, df =1 p= 0.5, 2 trials, 249 participants), adjunctive treatment (WMD 2.85, 95% confidence interval 2.24 to 3.46, p&lt;0.00001, 1 trial; 332 participants) and when combined (random effects WMD 2.27, 95% confidence interval 1.56 to 2.99, p&lt;0.00001, chi- square for heterogeneity 4.90, df =2 p=0.09, 3 trials; 581 participants). The mean weight change on olanzapine ranged from +1.65Kg on monotherapy (<LINK REF="STD-HGEH-Trial_x002c_-1999" TYPE="STUDY">HGEH Trial, 1999</LINK>) to +3.08Kg on adjunctive treatment and on placebo from -0.44 Kg on monotherapy (<LINK REF="STD-HGEH-Trial_x002c_-1999" TYPE="STUDY">HGEH Trial, 1999</LINK>) to +0.23Kg as adjunctive treatment. Two trials also reported weight gain in terms of the proportion of patients who gained weight. These trials also showed that olanzapine was associated with a higher incidence of weight gain - monotherapy (RR 7.89, 95% confidence interval 1.01 to 61.39, p=0.05, 1 trial, 139 participants), adjunctive treatment (RR 3.77, 95% confidence interval 1.86 to 7.61, p=0.0002, 1 trial, 344 participants) and when combined (fixed effects RR 4.12, 95% confidence interval 2.13 to 7.98, p&lt;0.0001, chi- square for heterogeneity 0.45 df =1 p=0.5, 2 trials, 483 participants). Heterogeneity was observed between the monotherapy trials and the adjunctive treatment trial for mean change in weight but not for the proportion of patients who gained weight. One possible reason for this is the longer duration of the adjunctive treatment trial.</P>
<P>ii) Movement disorders<BR/>No statistically significant difference was found between olanzapine monotherapy and placebo in terms of movement disorders measured on the Simpson-Angus Scale (fixed effects WMD-0.33, 95% confidence interval -0.74 to 0.09, p=0.12, chi-square for heterogeneity 0.21, df=1, p=0.65; 2 trials, 241 participants), the Barnes Akathisia Scale (fixed effects WMD -0.13, 95% confidence interval -0.32 to 0.06, p=0.17, chi-square for heterogeneity 0.84, df=1, p=0.36; 2 trials, 246 participants) and the Abnormal Involuntary Movement Scale (AIMS) (WMD -0.25, 95% confidence interval -0.58 to 0.08, p=0.14, 1 trial, 135 participants).</P>
<P>One trial reported use of medication to treat movement disorders. The mean dose of anticholinergic medication (benztropine) taken by participants in the olanzapine monotherapy group was significantly greater than that taken by participants in the placebo group (WMD: 0.11, 95% confidence interval 0.03 to 0.19, p=0.008, 1 trial, 115 participants). However usage in both groups was low with approximately 60% of patients treated with olanzapine on 0.6mg/day or less compared to a usual maintenance dose of 1-4mg/day.<BR/>Compared to placebo, olanzapine as adjunctive treatment was found to cause more tremor (RR 1.77, 95% confidence interval 1.05 to 3.01, p=0.03, 1 trial, 344 participants).</P>
<P>iii) Depression<BR/>No statistically significant difference was found between olanzapine and placebo in terms of treatment emergent depression as monotherapy (fixed effects RR 0.84, 95% confidence interval 0.44 to 1.60, p=0.6, chi-square for heterogeneity 0.76 df=1p=0.38, 2 trials, 249 participants), as adjunctive treatment (RR 1.03, 95% confidence interval 0.63 to 1.67, p=0.91, 1 trial, 344 participants) or when the results were combined (RR 0.95, 95% confidence interval 0.65 to 1.40, p=0.81, chi-square for heterogeneity 1.00 df=2 p=0.61, 3 trials, 593 participants).</P>
<P>iv) Other adverse effects<BR/>Olanzapine was found to be associated with higher incidence than placebo of 7 adverse effects. Four adverse effects were reported for all 3 trials, 598 participants - somnolence (RR 2.13 95% CI 1.62 to 2.79, p&lt;0.0001), dry mouth (RR 3.64 95% CI 2.24 to 5.91, p&lt;0.00001), dizziness (RR 2.37 95% CI 1.39 to 4.04, p=0.001) and asthenia (RR 1.69 95% CI 1.09 to 2.64, p=0.02). Three were reported for the adjunctive treatment trial (<LINK REF="STD-HGFU-Trial-2002" TYPE="STUDY">HGFU Trial 2002</LINK>), increased appetite (RR 3.01 95% CI 1.54 to 5.88, p=0.001, 344 participants), speech disorder (RR 7.53 95% CI 1.01 to 56.32, p=0.05, 344 participants), and raised prolactin (RR 4.35 95% CI 1.77 to 10.70, p=0.001, 334 participants).</P>
<P>Compared to placebo, olanzapine monotherapy was also found to be associated with increased levels on two liver functions tests - raised ALT (RR 10.32 95% CI 2.85 to 37.35, p=0.0004, 2 trials, 254 participants) and raised AST (RR 22.88 95% CI 1.37 to 381.40, p=0.03, 1 trial, 115 participants). However in the trial which reported both tests (<LINK REF="STD-HGGW-Trial-2000" TYPE="STUDY">HGGW Trial 2000</LINK>) only one participant (treated with olanzapine) met predefined criteria for clinically significant abnormality and for the other trial it was reported that ALT levels returned to normal during continued treatment. Both trials reported that no patient displayed symptoms of hepatic dysfunction. Olanzapine was associated with greater increase in supine systolic blood pressure than placebo (WMD 8.90 95% CI 2.70 to 15.10, p=0.005).</P>
<P>Olanzapine was found to be associated with lower incidence of 3 adverse effects - nervousness reported in all three trials, 598 participants (RR 0.63 95% CI 0.40 to 0.98, p=0.04); agitation reported for two monotherapy trials (<LINK REF="STD-HGEH-Trial_x002c_-1999" TYPE="STUDY">HGEH Trial, 1999</LINK>; <LINK REF="STD-HGGW-Trial-2000" TYPE="STUDY">HGGW Trial 2000</LINK>), 254 participants (RR 0.59 95% CI 0.35 to 1.01, p=0.05) and ECG abnormality reported in one monotherapy trial (<LINK REF="STD-HGGW-Trial-2000" TYPE="STUDY">HGGW Trial 2000</LINK>), 115 participants (RR 0.38 95% CI 0.18 to 0.83, p=0.02).</P>
<P>No statistically significant difference was found between olanzapine and placebo in incidence of 10 adverse effects. One was reported for all three trials - headache, 598 participants (RR 0.90 95% CI 0.63 to 1.29, p=0.57). Four were reported for the two monotherapy trials (<LINK REF="STD-HGEH-Trial_x002c_-1999" TYPE="STUDY">HGEH Trial, 1999</LINK>; <LINK REF="STD-HGGW-Trial-2000" TYPE="STUDY">HGGW Trial 2000</LINK>), 254 participants - constipation (RR 2.09 95% CI 0.87 to 5.04, p=0.1); hostility (RR 0.51 95% CI 0.21 to 1.22, p=0.13); personality disorder (RR 0.41 95% CI 0.16 to 1.02, p=0.06) and anxiety (RR 0.65 95% CI 0.11 to 3.67, p=0.62). Two were reported only in the adjunctive treatment trial (<LINK REF="STD-HGFU-Trial-2002" TYPE="STUDY">HGFU Trial 2002</LINK>), 344 participants - diarrhoea (RR 0.80 95% CI 0.45 to 1.40, p=0.43) and thirst (RR 1.65 95% CI 0.73 to 3.73, p=0.23), one only in the 3-week monotherapy trial (<LINK REF="STD-HGEH-Trial_x002c_-1999" TYPE="STUDY">HGEH Trial, 1999</LINK>; <LINK REF="STD-HGEH-Trial_x002c_-1999" TYPE="STUDY">HGEH Trial, 1999</LINK>), 139 participants - pain (RR 2.63 95% CI 0.73 to 9.50, p=0.14) and two only in the 4 week monotherapy trial (<LINK REF="STD-HGGW-Trial-2000" TYPE="STUDY">HGGW Trial 2000</LINK>), 115 participants - dyspepsia (RR 2.55 95% CI 0.69 to 9.36, p=0.16) and QT interval prolongation (RR 0.73 95% CI 0.13 to 4.19, p=0.72).</P>
<P>b) Olanzapine versus mood stabiliser</P>
<P>
<LINK REF="STD-Zajecka-2000" TYPE="STUDY">Zajecka 2000</LINK> reported adverse event data at 12 weeks.</P>
<P>i) Weight gain<BR/>Olanzapine was associated with significantly greater weight gain than divalproex (fixed effects WMD: 1.54, 95% confidence interval 1.02 to 2.05; p&lt;0.0001; chi-square for heterogeneity 0.03, df=1, p = 0.86; 2 trials, 366 participants) and a higher proportion of patients on olanzapine than on divalproex gained weight (fixed effects RR: 1.90, 95% confidence interval 1.07 to 3.37; p=0.03, chi-square for heterogeneity 0.80, df = 1, p = 0.37, 2 trials, 371 participants).</P>
<P>ii) Movement disorders<BR/>Olanzapine was associated with more movement disorders than divalproex measured on the Simpson-Angus Scale (WMD: 0.72, 95% confidence interval 0.11 to 1.33, p=0.02, 1 trial, 241 participants). Olanzapine was also associated with a higher incidence of neck rigidity (RR: 4.54, 95% CI 1.00 to 20.58, p=0.05, 1 trial, 251 participants). No statistically significant difference was found between olanzapine and divalproex on the Barnes Akathisia Scale (WMD: 0.02, 95% confidence interval -0.23 to 0.27, p=0.87, 1 trial, 241 participants) or the Abnormal Involuntary Movement Scale (AIMS) (WMD: -0.17, 95% confidence interval -0.61 to 0.27, p=0.45, 1 trial, 247 participants).<BR/>Olanzapine was found to cause more tremor than divalproex (RR: 3.02, 95% confidence interval 1.00 to 9.12, p=0.05, 1 trial, 251 participants).</P>
<P>iii) Other adverse effects<BR/>Olanzapine was found to be associated with higher incidence than divalproex of 5 adverse effects - somnolence (RR: 1.80, 95% CI 1.32 to 2.46, p=0.0002, chi-square for heterogeneity 0.18, df=1, p = 0.67; 2 trials, 371 participants), dry mouth (RR: 5.29, CI 2.59 to 10.81, p&lt;0.00001, 1 trial, 251 participants), increased appetite (RR: 5.04, 95% CI 1.50 to 16.98, p=0.009, 1 trials, 251 participants), speech disorder (RR: 10.03, 95% CI 1.89 to 53.25, p=0.007, chi-square for heterogeneity 0.00, df = 1, p = 0.99, 2 trials, 371 participants) and oedema (RR: 18.76, 95% CI 1.11 to 317.87, p=0.04, 1 trial, 120 participants).</P>
<P>Olanzapine was found to be associated with lower incidence than divalproex of two adverse effects - nausea (RR: 0.36, 95% CI 0.20 to 0.65, p=0.0007, 1 trial, 251 participants) and lowered platelet count (RR: 0.05, 95% CI 0.00 to 0.87, p=0.04, 1 trial, 227 participants).</P>
<P>No statistically significant difference was found between olanzapine and divalproex for fourteen adverse effects - headache (RR: 0.97, 95% CI 0.62 to 1.54, p=0.91, 1 trial, 251 participants), pain (RR: 0.95, 95% CI 0.51 to 1.76, p=0.88, 1 trial, 251 participants), asthenia (RR: 1.19, 95% CI 0.65 to 2.16, p=0.58, 1 trial, 251 participants), dizziness (RR: 1.34, 95% CI 0.72 to 2.50, p=0.35, 1 trial, 251 participants), agitation (RR: 1.01, 95% CI 0.50 to 2.03, p=0.93, 1 trial, 251 participants), nervousness (RR: 0.62, 95% CI 0.33 to 1.19, p=0.15, 1 trial, 251 participants), constipation (RR: 1.21, 95% CI 0.64 to 2.29, p=0.58, 1 trial, 251 participants), dyspepsia (RR: 1.30, 95% CI 0.67 to 2.49, p=0.44, 1 trial, 251 participants), vomiting (RR: 0.56, 95% CI 0.27 to 1.16, p=0.12, 1 trial, 251 participants), diarrhoea (RR: 0.47, 95% CI 0.21 to 1.06, p=0.07, 1trial, 251 participants) sleep disorder (RR: 7.06, 95% CI 0.88 to 56.52, p=0.07, 1 trial, 251 participants), tongue oedema (RR: 13.10, 95% CI 0.75 to 230.15, p=0.08, 1 trial, 251 participants), rhinitis ((RR: 4.42, 95% CI 0.98 to 19.96, p=0.05, 1 trial, 120 participants) and raised ALT/SGPT (RR: 12.56, 95% CI 0.72 to 220.38, p=0.08, 1 trial, 230 participants).</P>
<P>c) Olanzapine versus other antipsychotic<BR/>Treatment emergent adverse events that were common (incidence of 10% or greater) or significant were reported.</P>
<P>i) Weight gain<BR/>Olanzapine was associated with weight gain in a higher proportion of participants than haloperidol (RR: 3.59, 95% confidence interval 1.49 to 8.64, p=0.004, 1 trial, 453 participants).</P>
<P>ii) Movement disorders<BR/>A smaller proportion of participants on olanzapine than on haloperidol experienced movement disorders - EPS (RR: 0.10, 95% confidence interval 0.04 to 0.24, p&lt;0.00001, 1 trial, 453 participants). Olanzapine was associated with a lower incidence than haloperidol of 6 adverse effects - akathisia (RR: 0.21, 95% CI 0.12 to 0.38, p&lt;0.00001, 1 trial, 453 participants), tremor (RR: 0.33, 95% CI 0.17 to 0.64, p=0.001, 1 trial, 453 participants), hypertonia (RR: 0.22, 95% CI 0.11 to 0.45, p&lt;0.0001, 1 trial, 453 participants), dystonia (RR: 0.20, 95% CI 0.06 to 0.69, p=0.01, 1 trial, 453 participants), hypokinesia (RR: 0.12, 95% CI 0.01 to 0.93, p=0.04, 1 trial, 453 participants) and increased salivation (RR: 0.06, 95% CI 0.01 to 0.47, p=0.007, 1 trial, 453 participants). Olanzapine may cause less tardive dyskinesia than haloperidol although difference just failed to reach statistical significance - probably due to the low incidence of this event (RR: 0.07, 95% CI 0.00 to 1.27, p=0.07, 1 trial, 453 participants).</P>
<P>iii) Depression<BR/>A smaller proportion of participants on olanzapine than on haloperidol who had a baseline HAMD-21 of 8 or less experienced treatment emergent depression (defined as HAMD-21 of 15 or greater at anytime during the 6 week acute treatment phase (RR: 0.38, 95% confidence interval 0.16 to 0.95, p=0.04, 1 trial, 453 participants).</P>
<P>iii) Other adverse effects<BR/>No statistically significant difference was found between olanzapine and haloperidol in terms of the proportion of participants who withdrew from treatment due to adverse effects (RR: 0.66, 95% CI 0.34 to 1.26, p=0.2, 1 trial, 453 participants).</P>
<P>Olanzapine was associated with a higher incidence than haloperidol of 1 adverse effect - infection (RR: 9.36, 95% CI 1.21 to 72.51, p=0.03, 1 trial, 453 participants).<BR/>No statistically significant difference was found between olanzapine and haloperidol in terms of the proportion of patients experiencing 3 adverse effects - insomnia (RR: 0.78, 95% CI 0.47 to 1.28, p=0.33, 1 trial, 453 participants), somnolence (RR: 1.50, 95% CI 0.81 to 2.78, p=0.2, 1 trial, 453 participants) and fever (RR: 15.91, 95% CI 0.92 to 274.10, p=0.06, 1 trial, 453 participants).</P>
<P>5. MORTALITY RATES</P>
<P>a) Olanzapine versus placebo</P>
<P>No deaths were reported.</P>
<P>b) Olanzapine versus mood stabiliser</P>
<P>One patient randomised to olanzapine died of diabetic ketoacidosis. The patient had no personal or family history of diabetes and had a glucose level on entry to the trial of 86mg/dL which is within the normal range but the level at autopsy was 843mg/dL.</P>
<P>c) Olanzapine versus haloperidol</P>
<P>No deaths were reported.<BR/>
</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>Results from six trials were included in this review. All were undertaken by the manufacturers of one of the interventions and all assessed efficacy in patients with well defined clinical presentation rather than effectiveness in the more diverse patient population seen in routine clinical practice. None of the trials reported the design in sufficient detail in terms of allocation concealment and maintenance of blinding, for an accurate assessment of quality to be made. Although the search was thorough it is still possible that there are unpublished trials which have not been identified but the small number of trials identified hinders the detection of any publication bias. </P>
<P>The main feature of all the trials was the high rate of failure to complete treatment according to the trial protocol. This is similar to the findings in acute schizophrenia in which it has been reported that about a third of participants failed to complete treatment. (<LINK REF="REF-Wahlbeck-2001" TYPE="REFERENCE">Wahlbeck 2001</LINK>). High withdrawal rates reduce the reliability of the assessment of other outcomes. The five trials that gave details of the analyses reported using last observation carried forward (LOCF) in assessments of efficacy. For trials of treatment for mania there is reason to suppose that the greater the proportion of patients who fail to complete treatment and the shorter the average time on randomised treatment the more conservative the resultant estimates of efficacy. This is because the natural course of a manic episode is to remit over time and, for each individual, this effect of improvement over time will be lost to the analysis from the time that the patient stops trial treatment and the last observation is taken. There is, however, no way to tell precisely what effect failure to complete treatment has on the assessment of efficacy for any individual trial. In the trials of olanzapine monotherapy versus placebo there a further concern that the rates for olanzapine, though still high, are significantly less than for placebo and it is possible that this differential rate was caused by some non random effect, i.e. related to one or other of the study treatments and this might bias the estimates of the effects of the treatments. Results reported for efficacy must therefore be viewed with caution.</P>
<P>There was evidence that olanzapine reduces the symptoms of mania as measured by clinician administered mania rating scales. Olanzapine was found to be more efficacious than placebo both as monotherapy and as adjunctive treatment to lithium or valproate. There was no evidence for a difference in effect size between monotherapy and adjunctive treatment so it is possible that the effects of the mood stabiliser and olanzapine may be additive.</P>
<P>The only difference in terms of reduction of mania identified between olanzapine and other active treatments was that there was some evidence that olanzapine was more efficacious than divalproex in reduction of manic symptoms. There was also some evidence that olanzapine may be more effective than placebo in reducing the depressive symptoms that occur in mania and in reducing psychotic symptoms.</P>
<P>Mania rating scales measure the severity of a number of core symptoms of the manic phase of bipolar disorder. These measures provide a useful way to assess change in severity over time. They do not necessarily correlate precisely with more pragmatic measures of mental health such as duration of hospital admission and time to return to normal functioning which are likely to be of more interest to both patients and clinicians. </P>
<P>No details were given of the criteria used to assess the incidence of treatment-emergent adverse effects so the clinical significance is unclear but the data reported indicate that olanzapine causes more somnolence than placebo or divalproex but the same as haloperidol. The only significant difference in terms of gastrointestinal adverse effects was that olanzapine caused less nausea than divalproex. In terms of movement disorders there was some evidence that olanzapine was associated with more symptoms than placebo and divalproex but less than haloperidol. None of the trials reported usable data on general health and social functioning and therefore no assessment could be made of which adverse effects were most troublesome.</P>
<P>Olanzapine produced significantly greater weight gain than placebo, mood stabilisers and haloperidol. This is of particular concern because of the possibility that weight gain interferes with glucose metabolism by causing decreased insulin sensitivity. None of the trials reported changes in blood glucose levels so no data were available on incidence of treatment-emergent hyperglycaemia. </P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>There is some evidence that olanzapine is an effective treatment for mania and it reduces psychotic symptoms when present and overall severity of psychiatric illness. Olanzapine may be superior to divalproex in acute mania in terms of symptom reduction but clinicians and patients will need to consider the possible increased risk of adverse effects - particularly weight gain and somnolence. Clinicians need also to be alert to the possibility of alterations in glucose metabolism in patients treated with olanzapine. There was no clear difference in overall acceptability of treatment (as measured by failure to complete the trial) between olanzapine and divalproex. It remains unclear how olanzapine compares to other mood stabilisers such as lithium. On the limited data available, olanzapine was comparable to haloperidol in terms of reduction of mania and remission of mood symptoms. Olanzapine was associated with a higher incidence of weight gain than haloperidol but lower incidence of extra-pyramidal symptoms.</P>
<P>Since the choice of acute treatment may also determine maintenance treatment, clinicians may also want to consider the long term evidence for the safety and/or efficacy of olanzapine in relapse prevention in bipolar disorder (a systematic review of olanzapine as treatment for relapse prevention is currently being undertaken <LINK REF="REF-Cipriani-2003" TYPE="REFERENCE">Cipriani 2003</LINK>).</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Adequately sized randomised trials are needed comparing olanzapine with mood stabilisers and other antipsychotic drugs in the treatment of mania and in the subsequent prevention of manic and depressive relapse. The trials need to be designed to inform prescribing policy rather than assess safety and efficacy for licensing purposes. They should be open to a heterogeneous patient population and should include outcome measures of more relevance to clinicians and patients such as rate of return to normal functioning and quality of life and should record changes in blood glucose levels and onset of diabetes. </P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We thank Heather Wilder, Information Scientist, Centre for Evidence Based Mental Health and the Cochrane Depression, Anxiety and Neurosis Group editorial staff for assistance in developing the search strategy for the review and for conducting several of the database searches.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>JG has received research funding and support from Sanofi-Aventis and GlaxoSmithKline and is currently in discussion with several other companies that manufacture SSRIs about collaboration on planned independent trials and systematic reviews. </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Jennifer Rendell cowrote the protocol, identified studies, extracted data, and drafted the review. </P>
<P>John Geddes cowrote the protocol, extracted data, and drafted the review. </P>
<P>Harm Gijsman identified studies and extracted data.</P>
<P>Guy Goodwin commented on the protocol and text of the review.</P>
<P>Paul Keck commented on the protocol and text of the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES MODIFIED="2008-11-03 12:58:40 +0000" MODIFIED_BY="[Empty name]">
<P>This review is in the process of being updated. We hope to publish the updated version in Issue 2, 2009.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Berk-1999" NAME="Berk 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Berk M, Ichim M, Brook J</AU>
<TI>Olanzapine compared to lithium in mania: a double-blind randomized controlled trial</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1999</YR>
<VL>14</VL>
<NO>6</NO>
<PG>339-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berk M</AU>
<TI>Lamotrigine and the treatment of mania in bipolar disorder</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>1999</YR>
<VL>9</VL>
<NO>Suppl 4</NO>
<PG>119-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ichim L, Berk M, Brook S</AU>
<TI>Lamotrigine compared to lithium in mania: a double-blind randomized controlled trial</TI>
<SO>Annals of Clinical Psychiatry.</SO>
<YR>2000</YR>
<VL>12</VL>
<NO>1</NO>
<PG>5-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-HGEH-Trial_x002c_-1999" NAME="HGEH Trial, 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tohen M, Sanger T, McElroy S, Tollefson GD, Chengappa KN, Daniel DG et al</AU>
<TI>Olanzapine versus placebo in the treatment of acute mania</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1999</YR>
<VL>156</VL>
<NO>5</NO>
<PG>702-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-HGFU-Trial-2002" NAME="HGFU Trial 2002" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tohen M, Chengappa R, Suppes T, Zarate CA Jr, Calabrese JR, Bowden CL et al</AU>
<TI>Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially non-responsive to valproate or lithium monotherapy</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2002</YR>
<VL>59</VL>
<NO>1</NO>
<PG>62-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-HGGW-Trial-2000" NAME="HGGW Trial 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tohen M, Jacobs T, Grundy S. McElroy SL, Banov MC, Janicak PG et al</AU>
<TI>Efficacy of olanzapine in acute bipolar mania</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2000</YR>
<VL>57</VL>
<NO>9</NO>
<PG>841-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-HGHD-Trial-2002" NAME="HGHD Trial 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Tohen M, Zhang F, Feldman P, et al</AU>
<SO>Olanzapine versus haloperidol in the treatment of acute mania. British Association of Psychopharmacologicum, Harrogate, UK</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;olanzapine v haloperidol - presented and 2001 APA AGM&lt;/p&gt;" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Tohen M, Zhang F, Feldman PD, Evans AR, Breier AF</AU>
<SO>. Olanzapine versus haloperidol treatment of acute maniaAnnual Meeting of the Amedican Psychiatric Association, New Orleans</SO>
<YR>2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-HGHQ-Trial-2002" NAME="HGHQ Trial 2002" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tohen M, Baker RW, Altshuler LL, Zarate CA, Suppes T, Ketter TA et al</AU>
<TI>Olanzapine versus divalproex in the treatment of acute mania</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2002</YR>
<VL>159</VL>
<NO>6</NO>
<PG>1011-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zajecka-2000" NAME="Zajecka 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Zajecka JM, Weisler , Swann A et al</AU>
<SO>Divalproex sodium vs. olanzapine for the treatment of mania in bipolar disorder. 39th ACNP Annual Meeting, San Juan, Puerto Rico</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Meehan-2001" NAME="Meehan 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meehan K, Zhang F, Stacy D, Tohen M, Janicak P, Small J et al</AU>
<TI>A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar disorder</TI>
<SO>Journal of Clinical Psychopharmacology.</SO>
<YR>2001</YR>
<VL>21</VL>
<NO>4</NO>
<PG>389-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-Cipriani-2003" NAME="Cipriani 2003" TYPE="COCHRANE_REVIEW">
<AU>Cipriani A, Rendell J, Geddes J</AU>
<TI>Olanzapine in long-term treatment for bipolar disorder (Cochrane Protocol)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>3</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Duggan-2002" NAME="Duggan 2002" TYPE="COCHRANE_REVIEW">
<AU>Duggan L, Fenton M, Dardennes RM, El-Dosoky A, Indran S</AU>
<TI>Olanzapine for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>4</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goodwin-1990" NAME="Goodwin 1990" TYPE="BOOK">
<AU>Goodwin FK, Jamison KR</AU>
<SO>Manic-Depressive Illness</SO>
<YR>1990</YR>
<PB>Oxford University Press</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Koro-2002" NAME="Koro 2002" TYPE="JOURNAL_ARTICLE">
<AU>Koro CE, Fedder DO, L'Italien GJ, Weiss SS, Magder LS, Kreyenbuhl J et al</AU>
<TI>Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study</TI>
<SO>BMJ</SO>
<YR>2002</YR>
<VL>325</VL>
<NO>7258</NO>
<PG>243-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sackett-1997" NAME="Sackett 1997" TYPE="BOOK">
<AU>Sackett D.</AU>
<SO>The Cochrane Collaboration Handbook</SO>
<YR>1997</YR>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wahlbeck-2001" NAME="Wahlbeck 2001" TYPE="JOURNAL_ARTICLE">
<AU>Wahlbeck K, Tuunainen A, Ahokas A, Leucht S</AU>
<TI>Dropout rates in randomised antipsychotic drug trials</TI>
<SO>Psychopharmacologia</SO>
<YR>2001</YR>
<VL>155</VL>
<NO>3</NO>
<PG>230-3</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Berk-1999">
<CHAR_METHODS>
<P>Double-blind randomised controlled trial.<BR/>Trial duration - 4 weeks.<BR/>Single centre trial.<BR/>Washout period for other psychotropic medicines of 1 day.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>45 participants<BR/>Age range 20 - 59.<BR/>Inclusion criteria: DSM-IV criteria for bipolar disorder, manic episode. Exclusion criteria: Neuroleptic depot in previous month; fluoxetine in previous 5 weeks; history of recent drug or alcohol abuse; severe disturbance affecting ability to consent and to adhere to the trial protocol; abnormal liver function or haematological findings; acute medical disorder; medical disorder requiring frequent changes of medication; cardiac disease.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Olanzapine versus lithium and versus lamotrigine.<BR/>Olanzapine 10mg/day. Lithium 800mg /day mean lithium level 0.74mmol/l. Lamotrigine starting dose 25mg in week 1, 50mg in week 2 then 100mg. Rescue medication: lorazepam for control of aggression and antiparkinsonian medication as needed.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mania Scale (MAS), Brief Psychiatric Rating Scale (BPRS), Clinical Global Impression (CGI) severity and improvement scales, Global Assessment of Functioning (GAF). Extra-pyramidal symptoms were measured using the Simpson Angus Scale (SAS) and the Barnes Akathisia Scale. Laboratory tests.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-HGEH-Trial_x002c_-1999">
<CHAR_METHODS>
<P>Double-blind randomised controlled trial.<BR/>Trial duration - 3 weeks. Multi-centre trial.<BR/>Washout period for all medications except benzodiazepines of 2-4 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>139 participants.<BR/>Age range 18 - 65. <BR/>Inclusion criteria: DSM-IV criteria for bipolar disorder manic or mixed episode (with or without psychotic features)of at least 2 weeks duration. Minimum of 20 on YMRS.<BR/>Exclusion criteria: serious, unstable illness, DSM-IV defined substance dependence within the last 3 months, serious risk of suicide.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Olanzapine versus placebo.<BR/>Olanzapine starting dose 10mg/day adjusted as clinically indicated to 5 - 20mg/day - mean modal dose 14.9mg/day.<BR/>Rescue medication - limited use if lorazepam for first 10 days and antiparkinsonian medication as needed.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome - change from baseline to endpoint score on Young Mania Rating Scale (YMRS). <BR/>Response defined as 50% reduction in YMRS; Other rating scales - 21-item Hamilton Depression Rating Scale, Positive and Negative Syndrome Scale (PANSS), Clincial Global Rating (CGI) -Bipolar Version. Quality of life assessed using the Medical Outcomes Study SF36. Extrapyramidal symptoms assessed using the Simpson Angus Rating Scale (SAS), the Barnes Akathisia Scale and the Abnormal Involuntary Movement Scale (AIMS). <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-HGFU-Trial-2002">
<CHAR_METHODS>
<P>Double-blind randomised controlled trial.<BR/>Trial duration - 6 weeks. Multi-centre trial.<BR/>Patients on mood stabiliser for 2 weeks prior to randomisation, no other psychotropic medication allowed.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>344 participants.<BR/>Mean Age 40.6 years. <BR/>Inclusion Criteria: DSM-IV criteria for bipolar disorder manic or mixed episode (with or without psychotic features); at least 2 previous depressed, manic or mixed episodes; documented trial of two weeks on lithium (0.6 to 1.2 mmol/l) or valproate (50-125microg/ml). Minimum 16 on YMRS on 2 assessments 2 - 7 days apart.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Olanzapine versus placebo as adjunct to lithium or valproate. Olanzapine starting dose 10mg/day increased according to tolerability up to 20mg/day. Mean modal dose 10.4 mg/day.<BR/>Lithium and valproate doses continued. Rescue medication - benzodiazepine for up to 14 days in total and benztropine mesylate as needed.<BR/>Lithium serum level</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome - change from baseline to endpoint score on Young Mania Rating Scale (YMRS). <BR/>Response defined as 50% reduction in YMRS; Other rating scales for severity of psychiatric illness - 21-item Hamilton Depression Rating Scale, Positive and Negative Syndrome Scale (PANSS), Clincial Global Rating (CGI) -Bipolar Version. Extrapyramidal symptoms assessed using the Simpson Angus Rating Scale (SAS), the Barnes Akathisia Scale and the Abnormal Involuntary Movement Scale (AIMS). <BR/>Laboratory tests.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-HGGW-Trial-2000">
<CHAR_METHODS>
<P>Double-blind randomised controlled trial.<BR/>Trial duration - 4 weeks. Multi-centre trial.<BR/>All psychotropic medication except benzodiazepines tapered during screening period and discontinued at least 1 day before randomisation.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>115 participants.<BR/>Age range 18 - 70<BR/>Inclusion Criteria: DSM-IV criteria for bipolar disorder manic or mixed episode (with or without psychotic features). <BR/>Minimum of 20 on YMRS.<BR/>Exclusion criteria: serious, unstable illness, DSM-IV defined substance dependence within the last 3 months, serious risk of suicide.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Olanzapine versus placebo.<BR/>Olanzapine starting dose 15mg/day adjusted as clinically indicated to 5 - 20mg/day - mean modal dose 16.4mg/day.<BR/>Rescue medication - limited use of lorazepam for first 10 days and antiparkinsonian medication as needed.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Young Mania Rating Scale, CGI - BP mania scale, CGI - BD scale, 21-item Hamilton Depression Rating Scale, Positive and Negative Syndrome Scale (PANSS). Extrapyramidal symptoms assessed using the Simpson Angus Rating Scale (SAS) and the Barnes Akathisia Scale</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-HGHD-Trial-2002">
<CHAR_METHODS>
<P>Double-blind randomised controlled trial <BR/>Trial duration - acute phase 6 weeks followed by 6 weeks' continuation phase.<BR/>Multi-centre trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>453 participants.<BR/>Age range 18 - 86.<BR/>Acute phase: Inclusion Criteria: DSM-IV criteria for bipolar disorder manic or mixed episode (with or without psychotic features). Minimum of 20 on YMRS.<BR/>Continuation Phase: Inclusion criterion: improvement from baseline on CGI-BP severity of overall illness score.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Olanzapine versus haloperidol. Olanzapine dose 15mg on day 1 then 5 - 20 mg/day. Haloperidol 10mg on day 1 then 3-15mg/day.<BR/>Rescue medication - limited use of lorazepam.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome - remission defined as Young Mania Scale (YMRS) rating of 12 or less and Hamilton Depression Rating Scale (HAMD-21) of 8 or less at week 6.<BR/>Secondary outcomes - Response (reduction in YMRS of at least 50%), Montgomery-Asberg Depression Rating Scale (MADRS), Positive and Negative Syndrome Scale (PANSS), Clincial Global Rating (CGI) -Bipolar Version.<BR/>Extra-pyramidal symptoms were measured using the Simpson Angus Scale (SAS) and the Barnes Akathisia Scale. Laboratory tests and adverse effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-HGHQ-Trial-2002">
<CHAR_METHODS>
<P>Double-blind randomised controlled trial.<BR/>Trial duration - 3 weeks followed by 44 week continuation phase. Multi-centre trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>251 participants.<BR/>Age range 18 - 75.<BR/>Inclusion criteria: DSM-IV criteria for bipolar I disorder manic or mixed episode. Currently hospitalised.<BR/>Minimum of 20 on YMRS.<BR/>Exclusion criteria: serious and unstable medical illness, DSM-IV substance abuse in past 30 days, documented history of intolerance to olanzapine or divalproex and treatment with lithium, an anticonvulsant or an antipsychotic within 24 hours of randomisation.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Olanzapine versus divalproex. Olanzapine starting dose 15mg/day adjusted after day 2 as clinically indicated wthin the range 5 and 20 mg/day. Mean modal dose 17mg/day.<BR/>Divalproex starting dose 750mg/day adjusted after day 2 within the range 500 - 2500 mg/day according to clinical response and to maintain plasma level within the range 50 - 125 microg/ml. Mean modal dose 1401 mg/day.<BR/>Rescue medication - limited use of lorazepam and of benztropine to treat EPS.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome - change from baseline to endpoint score on Young Mania Rating Scale (YMRS).<BR/>Response defined as 50% reduction in YMRS; remission defined as YMRS of 12 or less at endpoint. Other rating scales for severity of psychiatric illness -<BR/>21 item Hamilton Depression Rating Scale. Extrapyramidal symptoms assessed using the Simpson Angus Rating Scale (SAS), the Barnes Akathisia Scale and the Abnormal Involuntary Movement Scale AIMS). <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Zajecka-2000">
<CHAR_METHODS>
<P>Double-blind randomised controlled trial.<BR/>Trial duration - 12 weeks with assessment of efficacy at 3 weeks with patients not meeting improvement criteria withdrawn. Multi-centre trial. Participants who did not meet criteria for improvement after 21 days were discontinued.<BR/>Washout period 1 - 3 days</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>120 participants.<BR/>Age range 18 - 65</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Olanzapine versus divalproex. Olanzapine starting dose 10mg/day. Dose increased by 500 mg on days 3 abd 6 if clinical symptoms of mania persisted. Mean maximum dose 14.7mg day (range 2 - 25mg/day). Divalproex starting dose 20mg/kg/day. Dose increased by 5 mg on days 3 abd 6 if clinical symptoms of mania persisted. Mean maximum dose 2115mg day (range 750 - 3250mg/day).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome - Mania Rating Scale (MRS). Secondary outcomes - Manic Syndrome Scale (MSS), Behaviour and Ideation Scale (BIS), Brief Psychiatric Rating Scale (BPRS), Hamilton Depression Scale (HAMD), Clinical Global Improvement Scale (CGI) and Quality of life enjoyment and satisfaction questionnaire (Q-LES-Q)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Meehan-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial comparing intramuscular formulations of olanzapine, lorazepam and placebo in terms of short term reduction of agitation rather than reduction in manic symptoms.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Berk-1999">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-HGEH-Trial_x002c_-1999">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-HGFU-Trial-2002">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-HGGW-Trial-2000">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-HGHD-Trial-2002">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-HGHQ-Trial-2002">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Zajecka-2000">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Olanzapine v placebo</NAME>
<CONT_OUTCOME CHI2="1.1752615314058432" CI_END="-2.869830788243063" CI_START="-6.3094315806158745" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.589631184429469" ESTIMABLE="YES" I2="0.0" I2_Q="1.988570212153435" ID="CMP-001.01" NO="1" P_CHI2="0.55564238249487" P_Q="0.3124507200589629" P_Z="1.6900121364767633E-7" Q="1.020289166441688" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="344" TOTAL_2="236" UNITS="" WEIGHT="100.0" Z="5.230555734113614">
<NAME>Mean change in YMRS</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.1549723649641553" CI_END="-2.8027207996357717" CI_START="-9.087116613539354" DF="1.0" EFFECT_SIZE="-5.944918706587563" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.01" NO="1" P_CHI2="0.6938283466606332" P_Z="2.087565787544261E-4" STUDIES="2" TAU2="0.0" TOTAL_1="124" TOTAL_2="122" WEIGHT="29.95635850002771" Z="3.7081771743758063">
<NAME>Olanzapine v. placebo as monotherapy</NAME>
<CONT_DATA CI_END="-1.1628815537744437" CI_START="-9.597118446225556" EFFECT_SIZE="-5.38" ESTIMABLE="YES" MEAN_1="-10.26" MEAN_2="-4.88" ORDER="1" SD_1="13.43" SD_2="11.64" SE="2.1516305807094662" STUDY_ID="STD-HGEH-Trial_x002c_-1999" TOTAL_1="70" TOTAL_2="66" WEIGHT="16.63123464340644"/>
<CONT_DATA CI_END="-1.938682015112735" CI_START="-11.361317984887261" EFFECT_SIZE="-6.649999999999999" ESTIMABLE="YES" MEAN_1="-14.78" MEAN_2="-8.13" ORDER="2" SD_1="12.49" SD_2="12.72" SE="2.403777835740625" STUDY_ID="STD-HGGW-Trial-2000" TOTAL_1="54" TOTAL_2="56" WEIGHT="13.32512385662127"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.9550858324424203" CI_START="-6.064914167557579" DF="0.0" EFFECT_SIZE="-4.01" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.02" NO="2" P_CHI2="1.0" P_Z="1.309248627591195E-4" STUDIES="1" TAU2="0.0" TOTAL_1="220" TOTAL_2="114" WEIGHT="70.0436414999723" Z="3.8247123418041213">
<NAME>Olanzapine v. placebo as add-on to mood stabilizer</NAME>
<CONT_DATA CI_END="-1.9550858324424203" CI_START="-6.064914167557579" EFFECT_SIZE="-4.01" ESTIMABLE="YES" MEAN_1="-13.11" MEAN_2="-9.1" ORDER="3" SD_1="8.53" SD_2="9.36" SE="1.0484448611130002" STUDY_ID="STD-HGFU-Trial-2002" TOTAL_1="220" TOTAL_2="114" WEIGHT="70.0436414999723"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.9584020328969474" CI_END="-0.25635865538382263" CI_START="-0.727362599482102" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.4918606274329623" ESTIMABLE="YES" I2="49.474561113836515" I2_Q="67.45340141178188" ID="CMP-001.02" NO="2" P_CHI2="0.13817978093326522" P_Q="0.07962631453706603" P_Z="4.2489612122890955E-5" Q="3.072517692715209" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="344" TOTAL_2="236" UNITS="" WEIGHT="100.0" Z="4.093507611820449">
<NAME>Mean change in CGI-BP mania</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.8858843401817381" CI_END="-0.37747313216693384" CI_START="-1.1224753531423544" DF="1.0" EFFECT_SIZE="-0.7499742426546441" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" NO="1" P_CHI2="0.3465951624203165" P_Z="7.943812268545494E-5" STUDIES="2" TAU2="0.0" TOTAL_1="124" TOTAL_2="122" WEIGHT="39.96998200913189" Z="3.9460889204095464">
<NAME>Olanzapine v. placebo as monotherapy</NAME>
<CONT_DATA CI_END="-0.0902694954451681" CI_START="-1.089730504554832" EFFECT_SIZE="-0.5900000000000001" ESTIMABLE="YES" MEAN_1="-1.07" MEAN_2="-0.48" ORDER="1" SD_1="1.6" SD_2="1.37" SE="0.2549692282596223" STUDY_ID="STD-HGEH-Trial_x002c_-1999" TOTAL_1="70" TOTAL_2="66" WEIGHT="22.20840534015795"/>
<CONT_DATA CI_END="-0.3912033539637295" CI_START="-1.5087966460362705" EFFECT_SIZE="-0.9500000000000001" ESTIMABLE="YES" MEAN_1="-1.83" MEAN_2="-0.88" ORDER="5" SD_1="1.45" SD_2="1.54" SE="0.2851055684920678" STUDY_ID="STD-HGGW-Trial-2000" TOTAL_1="54" TOTAL_2="56" WEIGHT="17.76157666897394"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.016044286409216013" CI_START="-0.6239557135907841" DF="0.0" EFFECT_SIZE="-0.32000000000000006" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.02" NO="2" P_CHI2="1.0" P_Z="0.03907268624581915" STUDIES="1" TAU2="0.0" TOTAL_1="220" TOTAL_2="114" WEIGHT="60.03001799086811" Z="2.0634205807271058">
<NAME>Olanzapine v. placebo as add-on to mood stabilizer</NAME>
<CONT_DATA CI_END="-0.016044286409216013" CI_START="-0.6239557135907841" EFFECT_SIZE="-0.32000000000000006" ESTIMABLE="YES" MEAN_1="-1.48" MEAN_2="-1.16" ORDER="6" SD_1="1.25" SD_2="1.39" SE="0.15508229538315393" STUDY_ID="STD-HGFU-Trial-2002" TOTAL_1="220" TOTAL_2="114" WEIGHT="60.03001799086811"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.2125276663966808" CI_END="0.7498152205618221" CI_START="0.5399983541265188" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6363167332409204" ESTIMABLE="YES" EVENTS_1="136" EVENTS_2="153" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.12504574804500984" LOG_CI_START="-0.26760756387121687" LOG_EFFECT_SIZE="-0.19632665595811336" METHOD="MH" NO="3" P_CHI2="0.8991873831209924" P_Q="0.0" P_Z="6.728872164533662E-8" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="354" TOTAL_2="244" WEIGHT="100.00000000000001" Z="5.398264221777007">
<NAME>Failure to respond - YMRS</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.1690931107840908" CI_END="0.8065099620847096" CI_START="0.5152728817107814" DF="1.0" EFFECT_SIZE="0.6446492940288087" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="89" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="-0.0933902637967841" LOG_CI_START="-0.2879627134156478" LOG_EFFECT_SIZE="-0.19067648860621594" NO="1" P_CHI2="0.6809193144548537" P_Z="1.2231537945054562E-4" STUDIES="2" TAU2="0.0" TOTAL_1="125" TOTAL_2="129" WEIGHT="50.7532927390985" Z="3.841438508882435">
<NAME>Olanzapine v. placebo as monotherapy</NAME>
<DICH_DATA CI_END="0.8700744361087982" CI_START="0.5152274049090031" EFFECT_SIZE="0.6695417789757412" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="53" LOG_CI_END="-0.0604435912797179" LOG_CI_START="-0.2880010449412887" LOG_EFFECT_SIZE="-0.17422231811050332" ORDER="7" O_E="0.0" SE="0.1336683747083691" STUDY_ID="STD-HGEH-Trial_x002c_-1999" TOTAL_1="70" TOTAL_2="69" VAR="0.017867234397176968" WEIGHT="30.85171377482493"/>
<DICH_DATA CI_END="0.9096614358370745" CI_START="0.4037869956315664" EFFECT_SIZE="0.6060606060606061" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="36" LOG_CI_END="-0.04112021636778627" LOG_CI_START="-0.3938476720600262" LOG_EFFECT_SIZE="-0.21748394421390624" ORDER="8" O_E="0.0" SE="0.20719385350268701" STUDY_ID="STD-HGGW-Trial-2000" TOTAL_1="55" TOTAL_2="60" VAR="0.04292929292929293" WEIGHT="19.901578964273565"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7984356679568619" CI_START="0.4935200626845835" DF="0.0" EFFECT_SIZE="0.6277292576419214" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="64" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="-0.09776007035439656" LOG_CI_START="-0.3066951876020432" LOG_EFFECT_SIZE="-0.20222762897821986" NO="2" P_CHI2="1.0" P_Z="1.481884933626044E-4" STUDIES="1" TAU2="0.0" TOTAL_1="229" TOTAL_2="115" WEIGHT="49.246707260901516" Z="3.7940856922241877">
<NAME>Olanzapine v. placebo as add-on to mood stabilizer</NAME>
<DICH_DATA CI_END="0.7984356679568619" CI_START="0.4935200626845835" EFFECT_SIZE="0.6277292576419214" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="64" LOG_CI_END="-0.09776007035439656" LOG_CI_START="-0.3066951876020432" LOG_EFFECT_SIZE="-0.20222762897821986" ORDER="9" O_E="0.0" SE="0.12272952211677808" STUDY_ID="STD-HGFU-Trial-2002" TOTAL_1="229" TOTAL_2="115" VAR="0.015062535599012722" WEIGHT="49.246707260901516"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.38912723212913825" CI_END="0.8483061431411891" CI_START="0.5134491667716798" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6599712738923876" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="80" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-0.07144738797575" LOG_CI_START="-0.289502546581503" LOG_EFFECT_SIZE="-0.1804749672786265" METHOD="MH" NO="4" P_CHI2="0.5327588850904807" P_Q="0.0" P_Z="0.00117715933722652" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="284" TOTAL_2="175" WEIGHT="100.0" Z="3.244357420745012">
<NAME>Failure to achieve remission - YMRS</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8684989676451449" CI_START="0.414508264731859" DF="0.0" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="40" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="-0.06123069344749098" LOG_CI_START="-0.38246680578522185" LOG_EFFECT_SIZE="-0.22184874961635637" NO="1" P_CHI2="1.0" P_Z="0.006786563794853697" STUDIES="1" TAU2="0.0" TOTAL_1="55" TOTAL_2="60" WEIGHT="41.8075350789968" Z="2.7071399669172953">
<NAME>Olanzapine v. placebo as monotherapy</NAME>
<DICH_DATA CI_END="0.8684989676451449" CI_START="0.414508264731859" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="40" LOG_CI_END="-0.06123069344749098" LOG_CI_START="-0.38246680578522185" LOG_EFFECT_SIZE="-0.22184874961635637" ORDER="10" O_E="0.0" SE="0.18869568253158472" STUDY_ID="STD-HGGW-Trial-2000" TOTAL_1="55" TOTAL_2="60" VAR="0.03560606060606061" WEIGHT="41.8075350789968"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.986092014734326" CI_START="0.5012603412570251" DF="0.0" EFFECT_SIZE="0.7030567685589519" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="40" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="-0.006082558053860029" LOG_CI_START="-0.29993665456221663" LOG_EFFECT_SIZE="-0.1530096063080383" NO="2" P_CHI2="1.0" P_Z="0.041240537051432116" STUDIES="1" TAU2="0.0" TOTAL_1="229" TOTAL_2="115" WEIGHT="58.19246492100321" Z="2.0411035355015343">
<NAME>Olanzapine v. placebo as add-on to mood stabilizer</NAME>
<DICH_DATA CI_END="0.986092014734326" CI_START="0.5012603412570251" EFFECT_SIZE="0.7030567685589519" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="40" LOG_CI_END="-0.006082558053860029" LOG_CI_START="-0.29993665456221663" LOG_EFFECT_SIZE="-0.1530096063080383" ORDER="11" O_E="0.0" SE="0.17261135089024587" STUDY_ID="STD-HGFU-Trial-2002" TOTAL_1="229" TOTAL_2="115" VAR="0.029794678456155584" WEIGHT="58.19246492100321"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="9.536019876851118" CI_END="-1.5545566230485999" CI_START="-3.8983800125143526" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.7264683177814764" ESTIMABLE="YES" I2="79.0268893539637" I2_Q="82.60807291872726" ID="CMP-001.05" NO="5" P_CHI2="0.008497310658376889" P_Q="0.016490618315100902" P_Z="5.118223426135119E-6" Q="5.749794116126321" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="343" TOTAL_2="235" UNITS="" WEIGHT="99.99999999999999" Z="4.559882567823724">
<NAME>Mean Change in 21-item HAMD - all participants</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.786225760724797" CI_END="0.4816547887903191" CI_START="-2.919429426926894" DF="1.0" EFFECT_SIZE="-1.2188873190682874" ESTIMABLE="YES" I2="73.58847403202469" ID="CMP-001.05.01" NO="1" P_CHI2="0.05167608898297116" P_Z="0.16007136765619528" STUDIES="2" TAU2="0.0" TOTAL_1="123" TOTAL_2="121" WEIGHT="47.491402593646725" Z="1.4048315743235094">
<NAME>Olanzapine v. placebo as monotherapy</NAME>
<CONT_DATA CI_END="2.2579347381031596" CI_START="-2.0579347381031594" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="-2.9" MEAN_2="-3.0" ORDER="12" SD_1="6.74" SD_2="6.0" SE="1.1010073425454108" STUDY_ID="STD-HGEH-Trial_x002c_-1999" TOTAL_1="69" TOTAL_2="65" WEIGHT="29.492607005851482"/>
<CONT_DATA CI_END="-0.6176852284174497" CI_START="-6.14231477158255" EFFECT_SIZE="-3.38" ESTIMABLE="YES" MEAN_1="-7.83" MEAN_2="-4.45" ORDER="13" SD_1="7.79" SD_2="6.95" SE="1.4093701687231686" STUDY_ID="STD-HGGW-Trial-2000" TOTAL_1="54" TOTAL_2="56" WEIGHT="17.99879558779524"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-2.47274061762382" CI_START="-5.707259382376181" DF="0.0" EFFECT_SIZE="-4.090000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.02" NO="2" P_CHI2="1.0" P_Z="7.170440730606374E-7" STUDIES="1" TAU2="0.0" TOTAL_1="220" TOTAL_2="114" WEIGHT="52.50859740635326" Z="4.956689560205756">
<NAME>Olanzapine v. placebo as add-on to mood stabilizer</NAME>
<CONT_DATA CI_END="-2.47274061762382" CI_START="-5.707259382376181" EFFECT_SIZE="-4.090000000000001" ESTIMABLE="YES" MEAN_1="-4.98" MEAN_2="-0.89" ORDER="14" SD_1="7.61" SD_2="6.9" SE="0.8251475002259818" STUDY_ID="STD-HGFU-Trial-2002" TOTAL_1="220" TOTAL_2="114" WEIGHT="52.50859740635326"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="14.58608266379897" CI_END="-0.020444550337107514" CI_START="-0.46004541885533695" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.24024498459622223" ESTIMABLE="YES" I2="86.28829929118818" I2_Q="90.35674963513029" ID="CMP-001.06" NO="6" P_CHI2="6.802603265817497E-4" P_Q="0.001280848031542825" P_Z="0.03217189283366744" Q="10.369947498646221" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="344" TOTAL_2="236" UNITS="" WEIGHT="99.99999999999999" Z="2.142268366585129">
<NAME>Mean change in CGI-BP depression</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.21613516515275" CI_END="0.40650123449697845" CI_START="-0.2001379731810526" DF="1.0" EFFECT_SIZE="0.10318163065796293" ESTIMABLE="YES" I2="76.28159532774917" ID="CMP-001.06.01" NO="1" P_CHI2="0.040041410666601496" P_Z="0.5049446157947737" STUDIES="2" TAU2="0.0" TOTAL_1="124" TOTAL_2="122" WEIGHT="52.511706507018175" Z="0.6667300016093072">
<NAME>Olanzapine v. placebo as monotherapy</NAME>
<CONT_DATA CI_END="0.7499963555669822" CI_START="-0.029996355566982158" EFFECT_SIZE="0.36" ESTIMABLE="YES" MEAN_1="0.06" MEAN_2="-0.3" ORDER="15" SD_1="1.17" SD_2="1.15" SE="0.19898138876184646" STUDY_ID="STD-HGEH-Trial_x002c_-1999" TOTAL_1="70" TOTAL_2="66" WEIGHT="31.764059066248876"/>
<CONT_DATA CI_END="0.19255199600430867" CI_START="-0.7725519960043086" EFFECT_SIZE="-0.29" ESTIMABLE="YES" MEAN_1="-0.74" MEAN_2="-0.45" ORDER="16" SD_1="1.32" SD_2="1.26" SE="0.2462045220272501" STUDY_ID="STD-HGGW-Trial-2000" TOTAL_1="54" TOTAL_2="56" WEIGHT="20.747647440769303"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.3010407037378062" CI_START="-0.9389592962621938" DF="0.0" EFFECT_SIZE="-0.62" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.02" NO="2" P_CHI2="1.0" P_Z="1.3906771360400064E-4" STUDIES="1" TAU2="0.0" TOTAL_1="220" TOTAL_2="114" WEIGHT="47.48829349298181" Z="3.8098205152043048">
<NAME>Olanzapine v. placebo as add-on to mood stabilizer</NAME>
<CONT_DATA CI_END="-0.3010407037378062" CI_START="-0.9389592962621938" EFFECT_SIZE="-0.62" ESTIMABLE="YES" MEAN_1="-0.5" MEAN_2="0.12" ORDER="17" SD_1="1.33" SD_2="1.45" SE="0.16273732516418873" STUDY_ID="STD-HGFU-Trial-2002" TOTAL_1="220" TOTAL_2="114" WEIGHT="47.48829349298181"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.9745238392795903" CI_END="-4.498446289989024" CI_START="-10.332863654903463" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-7.4156549724462435" ESTIMABLE="YES" I2="32.76234758688683" I2_Q="41.93699279900355" ID="CMP-001.07" NO="7" P_CHI2="0.22599065189759515" P_Q="0.1894015944735835" P_Z="6.283204590879612E-7" Q="1.7222669789360108" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="344" TOTAL_2="234" UNITS="" WEIGHT="100.0" Z="4.982302690641724">
<NAME>Mean change in PANNS - total symptom score</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.2522568603435795" CI_END="-5.161685844219857" CI_START="-14.840742217925293" DF="1.0" EFFECT_SIZE="-10.001214031072575" ESTIMABLE="YES" I2="20.144178748948377" ID="CMP-001.07.01" NO="1" P_CHI2="0.2631219562200884" P_Z="5.113041239744387E-5" STUDIES="2" TAU2="0.0" TOTAL_1="124" TOTAL_2="120" WEIGHT="36.335316512646834" Z="4.050398829338496">
<NAME>Olanzapine v. placebo as monotherapy</NAME>
<CONT_DATA CI_END="-1.9635411371482414" CI_START="-13.97645886285176" EFFECT_SIZE="-7.970000000000001" ESTIMABLE="YES" MEAN_1="-11.06" MEAN_2="-3.09" ORDER="18" SD_1="16.98" SD_2="18.37" SE="3.064576140291322" STUDY_ID="STD-HGEH-Trial_x002c_-1999" TOTAL_1="70" TOTAL_2="64" WEIGHT="23.588372691584446"/>
<CONT_DATA CI_END="-5.5892022319389785" CI_START="-21.930797768061026" EFFECT_SIZE="-13.760000000000002" ESTIMABLE="YES" MEAN_1="-21.19" MEAN_2="-7.43" ORDER="19" SD_1="23.73" SD_2="19.73" SE="4.168850975074661" STUDY_ID="STD-HGGW-Trial-2000" TOTAL_1="54" TOTAL_2="56" WEIGHT="12.74694382106239"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-2.283898825805518" CI_START="-9.596101174194484" DF="0.0" EFFECT_SIZE="-5.94" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.02" NO="2" P_CHI2="1.0" P_Z="0.0014509589169161108" STUDIES="1" TAU2="0.0" TOTAL_1="220" TOTAL_2="114" WEIGHT="63.66468348735316" Z="3.1843172585980053">
<NAME>Olanzapine v. placebo as add-on to mood stabilizer</NAME>
<CONT_DATA CI_END="-2.2838988258055184" CI_START="-9.596101174194482" EFFECT_SIZE="-5.94" ESTIMABLE="YES" MEAN_1="-12.9" MEAN_2="-6.96" ORDER="20" SD_1="15.72" SD_2="16.39" SE="1.865392018952053" STUDY_ID="STD-HGFU-Trial-2002" TOTAL_1="220" TOTAL_2="114" WEIGHT="63.66468348735316"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.3875088321346654" CI_END="-1.7984431626295496" CI_START="-5.283153084400874" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.540798123515212" ESTIMABLE="YES" I2="27.928386699959795" I2_Q="0.0" ID="CMP-001.08" NO="8" P_CHI2="0.2388264509435759" P_Q="1.0" P_Z="6.804467456824438E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="124" TOTAL_2="126" UNITS="" WEIGHT="100.0" Z="3.983021229548547">
<NAME>Mean change in PANNS - positive symptom score</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.3875088321346654" CI_END="-1.7984431626295496" CI_START="-5.283153084400874" DF="1.0" EFFECT_SIZE="-3.540798123515212" ESTIMABLE="YES" I2="27.928386699959795" ID="CMP-001.08.01" NO="1" P_CHI2="0.2388264509435759" P_Z="6.804467456824438E-5" STUDIES="2" TAU2="0.0" TOTAL_1="124" TOTAL_2="126" WEIGHT="100.0" Z="3.983021229548547">
<NAME>Olanzapine v. placebo as monotherapy</NAME>
<CONT_DATA CI_END="-0.40390163811840685" CI_START="-4.936098361881593" EFFECT_SIZE="-2.67" ESTIMABLE="YES" MEAN_1="-4.67" MEAN_2="-2.0" ORDER="21" SD_1="6.57" SD_2="7.1" SE="1.156193878946903" STUDY_ID="STD-HGEH-Trial_x002c_-1999" TOTAL_1="70" TOTAL_2="70" WEIGHT="59.11745898989615"/>
<CONT_DATA CI_END="-2.0749925390108617" CI_START="-7.525007460989138" EFFECT_SIZE="-4.8" ESTIMABLE="YES" MEAN_1="-7.76" MEAN_2="-2.96" ORDER="22" SD_1="7.89" SD_2="6.61" SE="1.3903354768167422" STUDY_ID="STD-HGGW-Trial-2000" TOTAL_1="54" TOTAL_2="56" WEIGHT="40.88254101010385"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.2427758719346709" CI_END="0.008795967759483325" CI_START="-2.3588548933519857" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.1750294627962512" ESTIMABLE="YES" I2="19.53496824465489" I2_Q="0.0" ID="CMP-001.09" NO="9" P_CHI2="0.2649368299070579" P_Q="1.0" P_Z="0.051726708956489995" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="124" TOTAL_2="120" UNITS="" WEIGHT="100.0" Z="1.945401212383969">
<NAME>Mean change in PANNS - negative symptom score</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.2427758719346709" CI_END="0.008795967759483325" CI_START="-2.3588548933519857" DF="1.0" EFFECT_SIZE="-1.1750294627962512" ESTIMABLE="YES" I2="19.53496824465489" ID="CMP-001.09.01" NO="1" P_CHI2="0.2649368299070579" P_Z="0.051726708956489995" STUDIES="2" TAU2="0.0" TOTAL_1="124" TOTAL_2="120" WEIGHT="100.0" Z="1.945401212383969">
<NAME>Olanzapine v. placebo as monotherapy</NAME>
<CONT_DATA CI_END="0.7287096785447142" CI_START="-2.148709678544714" EFFECT_SIZE="-0.71" ESTIMABLE="YES" MEAN_1="-0.9" MEAN_2="-0.19" ORDER="23" SD_1="4.26" SD_2="4.23" SE="0.7340490386012563" STUDY_ID="STD-HGEH-Trial_x002c_-1999" TOTAL_1="70" TOTAL_2="64" WEIGHT="67.70628730581589"/>
<CONT_DATA CI_END="-0.06681098631127114" CI_START="-4.233189013688729" EFFECT_SIZE="-2.15" ESTIMABLE="YES" MEAN_1="-2.78" MEAN_2="-0.63" ORDER="24" SD_1="6.5" SD_2="4.41" SE="1.0628710681015865" STUDY_ID="STD-HGGW-Trial-2000" TOTAL_1="54" TOTAL_2="56" WEIGHT="32.293712694184116"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.1177289077232" CI_END="-0.20037893290171355" CI_START="-0.6408734224101436" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.4206261776559285" ESTIMABLE="YES" I2="60.920165251782166" I2_Q="30.200592791843803" ID="CMP-001.10" NO="10" P_CHI2="0.07739266623668983" P_Q="0.23132831925891406" P_Z="1.8174841628056275E-4" Q="1.432676923770705" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="344" TOTAL_2="236" UNITS="" WEIGHT="100.0" Z="3.743121327489793">
<NAME>Mean change in CGI - BP severity of overall bipolar illness</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.685051983952495" CI_END="-0.23743730800957974" CI_START="-0.9308883834531374" DF="1.0" EFFECT_SIZE="-0.5841628457313586" ESTIMABLE="YES" I2="72.86334075191458" ID="CMP-001.10.01" NO="1" P_CHI2="0.05490248261786068" P_Z="9.594832011842188E-4" STUDIES="2" TAU2="0.0" TOTAL_1="124" TOTAL_2="122" WEIGHT="40.35053596005011" Z="3.3021453979505178">
<NAME>Olanzapine v. placebo as monotherapy</NAME>
<CONT_DATA CI_END="0.15209996530397235" CI_START="-0.7520999653039724" EFFECT_SIZE="-0.30000000000000004" ESTIMABLE="YES" MEAN_1="-0.89" MEAN_2="-0.59" ORDER="25" SD_1="1.39" SD_2="1.3" SE="0.23066748617325583" STUDY_ID="STD-HGEH-Trial_x002c_-1999" TOTAL_1="70" TOTAL_2="66" WEIGHT="23.732966213393073"/>
<CONT_DATA CI_END="-0.4497102492856563" CI_START="-1.5302897507143438" EFFECT_SIZE="-0.99" ESTIMABLE="YES" MEAN_1="-1.72" MEAN_2="-0.73" ORDER="26" SD_1="1.46" SD_2="1.43" SE="0.2756631014529248" STUDY_ID="STD-HGGW-Trial-2000" TOTAL_1="54" TOTAL_2="56" WEIGHT="16.617569746657036"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.02482778344339337" CI_START="-0.5951722165566065" DF="0.0" EFFECT_SIZE="-0.30999999999999994" ESTIMABLE="YES" I2="0.0" ID="CMP-001.10.02" NO="2" P_CHI2="1.0" P_Z="0.033121846284068925" STUDIES="1" TAU2="0.0" TOTAL_1="220" TOTAL_2="114" WEIGHT="59.64946403994988" Z="2.130603193199961">
<NAME>Olanzapine v. placebo as add-on to mood stabilizer</NAME>
<CONT_DATA CI_END="-0.02482778344339337" CI_START="-0.5951722165566065" EFFECT_SIZE="-0.30999999999999994" ESTIMABLE="YES" MEAN_1="-1.2" MEAN_2="-0.89" ORDER="27" SD_1="1.16" SD_2="1.31" SE="0.14549870242821225" STUDY_ID="STD-HGFU-Trial-2002" TOTAL_1="220" TOTAL_2="114" WEIGHT="59.64946403994988"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.19106666873298322" CI_START="0.02893333126701679" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.11000000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.11" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.007825892858414046" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="55" TOTAL_2="60" UNITS="" WEIGHT="100.0" Z="2.6594905362342516">
<NAME>Mean dose of anticholinergic medication</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.19106666873298322" CI_START="0.02893333126701679" DF="0.0" EFFECT_SIZE="0.11000000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-001.11.01" NO="1" P_CHI2="1.0" P_Z="0.007825892858414046" STUDIES="1" TAU2="0.0" TOTAL_1="55" TOTAL_2="60" WEIGHT="100.0" Z="2.6594905362342516">
<NAME>Olanzapine v. placebo as monotherapy</NAME>
<CONT_DATA CI_END="0.19106666873298322" CI_START="0.02893333126701679" EFFECT_SIZE="0.11000000000000001" ESTIMABLE="YES" MEAN_1="0.33" MEAN_2="0.22" ORDER="28" SD_1="0.26" SD_2="0.17" SE="0.041361305295621126" STUDY_ID="STD-HGGW-Trial-2000" TOTAL_1="55" TOTAL_2="60" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.06368315940990875" CI_END="1.0721883079670589" CI_START="0.7042699117170235" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8689706352898153" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="83" I2="0.0" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="0.030271067006920165" LOG_CI_START="-0.15226086542620473" LOG_EFFECT_SIZE="-0.0609948992096423" METHOD="MH" NO="12" P_CHI2="0.8007665092836669" P_Q="0.0" P_Z="0.19023516663231413" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="284" TOTAL_2="175" WEIGHT="100.0" Z="1.3098837457971781">
<NAME>Use of benzodiazepines</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1406331750568823" CI_START="0.6984426823269361" DF="0.0" EFFECT_SIZE="0.8925619834710744" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="44" I2="0.0" ID="CMP-001.12.01" LOG_CI_END="0.05714599878916726" LOG_CI_START="-0.15586922844816797" LOG_EFFECT_SIZE="-0.04936161482950036" NO="1" P_CHI2="1.0" P_Z="0.3636893942497258" STUDIES="1" TAU2="0.0" TOTAL_1="55" TOTAL_2="60" WEIGHT="44.76794054459559" Z="0.9083574779071202">
<NAME>Olanzapine v. placebo as monotherapy</NAME>
<DICH_DATA CI_END="1.1406331750568823" CI_START="0.6984426823269361" EFFECT_SIZE="0.8925619834710744" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="44" LOG_CI_END="0.05714599878916726" LOG_CI_START="-0.15586922844816797" LOG_EFFECT_SIZE="-0.04936161482950036" ORDER="29" O_E="0.0" SE="0.12512619892159138" STUDY_ID="STD-HGGW-Trial-2000" TOTAL_1="55" TOTAL_2="60" VAR="0.015656565656565657" WEIGHT="44.76794054459559"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1778412163643734" CI_START="0.6131922051210049" DF="0.0" EFFECT_SIZE="0.8498488411152166" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="39" I2="0.0" ID="CMP-001.12.02" LOG_CI_END="0.07108674757782417" LOG_CI_START="-0.21240337451963784" LOG_EFFECT_SIZE="-0.07065831347090686" NO="2" P_CHI2="1.0" P_Z="0.328559298333686" STUDIES="1" TAU2="0.0" TOTAL_1="229" TOTAL_2="115" WEIGHT="55.23205945540442" Z="0.9770199299128147">
<NAME>Olanzapine v. placebo as add-on to mood stabilizer</NAME>
<DICH_DATA CI_END="1.1778412163643734" CI_START="0.6131922051210049" EFFECT_SIZE="0.8498488411152166" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="39" LOG_CI_END="0.07108674757782417" LOG_CI_START="-0.21240337451963784" LOG_EFFECT_SIZE="-0.07065831347090686" ORDER="30" O_E="0.0" SE="0.16652350101878566" STUDY_ID="STD-HGFU-Trial-2002" TOTAL_1="229" TOTAL_2="115" VAR="0.02773007639155351" WEIGHT="55.23205945540442"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6670094556391256" CI_END="0.7344922204342261" CI_START="0.5224023127841464" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6194355775032645" ESTIMABLE="YES" EVENTS_1="126" EVENTS_2="145" I2="0.0" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="-0.1340127997925537" LOG_CI_START="-0.28199490901634927" LOG_EFFECT_SIZE="-0.20800385440445146" METHOD="MH" NO="13" P_CHI2="0.716408579634825" P_Q="0.0" P_Z="3.591271757726249E-8" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="344" TOTAL_2="236" WEIGHT="100.0" Z="5.5098560956675815">
<NAME>Failure to respond - YMRS (excluding early withdrawals)</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.1503362060587155" CI_END="0.8241359257927465" CI_START="0.5204698108591381" DF="1.0" EFFECT_SIZE="0.6549334847292292" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="82" I2="0.0" ID="CMP-001.13.01" LOG_CI_END="-0.08400115365073185" LOG_CI_START="-0.2836044560814461" LOG_EFFECT_SIZE="-0.18380280486608894" NO="1" P_CHI2="0.6982144318753167" P_Z="3.066359247995101E-4" STUDIES="2" TAU2="0.0" TOTAL_1="124" TOTAL_2="122" WEIGHT="49.96827822596041" Z="3.6096284320749223">
<NAME>Olanzapine v. placebo as monotherapy</NAME>
<DICH_DATA CI_END="0.8852262876273647" CI_START="0.5205979836447835" EFFECT_SIZE="0.6788571428571428" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="50" LOG_CI_END="-0.05294569777009348" LOG_CI_START="-0.283497518312146" LOG_EFFECT_SIZE="-0.1682216080411197" ORDER="31" O_E="0.0" SE="0.13542728063631915" STUDY_ID="STD-HGEH-Trial_x002c_-1999" TOTAL_1="70" TOTAL_2="66" VAR="0.018340548340548345" WEIGHT="31.02828853336531"/>
<DICH_DATA CI_END="0.9438968149075061" CI_START="0.4016717228197324" EFFECT_SIZE="0.6157407407407407" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="32" LOG_CI_END="-0.025075479394323055" LOG_CI_START="-0.39612874097336725" LOG_EFFECT_SIZE="-0.21060211018384511" ORDER="32" O_E="0.0" SE="0.21795852259479795" STUDY_ID="STD-HGGW-Trial-2000" TOTAL_1="54" TOTAL_2="56" VAR="0.047505917571707044" WEIGHT="18.939989692595102"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7519727911624146" CI_START="0.4535214294980532" DF="0.0" EFFECT_SIZE="0.5839826839826839" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="63" I2="0.0" ID="CMP-001.13.02" LOG_CI_END="-0.12379787332032888" LOG_CI_START="-0.34340218712015136" LOG_EFFECT_SIZE="-0.2336000302202401" NO="2" P_CHI2="1.0" P_Z="3.0493270678087665E-5" STUDIES="1" TAU2="0.0" TOTAL_1="220" TOTAL_2="114" WEIGHT="50.03172177403958" Z="4.169750931545764">
<NAME>Olanzapine v. placebo as add-on to mood stabilizer</NAME>
<DICH_DATA CI_END="0.7519727911624146" CI_START="0.4535214294980532" EFFECT_SIZE="0.5839826839826839" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="63" LOG_CI_END="-0.12379787332032888" LOG_CI_START="-0.34340218712015136" LOG_EFFECT_SIZE="-0.2336000302202401" ORDER="33" O_E="0.0" SE="0.12899666098490087" STUDY_ID="STD-HGFU-Trial-2002" TOTAL_1="220" TOTAL_2="114" VAR="0.016640138545253445" WEIGHT="50.03172177403958"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.01410670319041064" CI_END="0.8037247049619205" CI_START="0.4729081633077544" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6165127525271547" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="75" I2="0.0" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="-0.09489268208429988" LOG_CI_START="-0.3252231891587914" LOG_EFFECT_SIZE="-0.21005793562154565" METHOD="MH" NO="14" P_CHI2="0.9054562777227558" P_Q="0.0" P_Z="3.5034174243897857E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="274" TOTAL_2="170" WEIGHT="100.0" Z="3.5749149664478654">
<NAME>Failure to remit- YMRS - (excluding early withdrawals)</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8909544507625057" CI_START="0.41073964234555294" DF="0.0" EFFECT_SIZE="0.6049382716049383" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="36" I2="0.0" ID="CMP-001.14.01" LOG_CI_END="-0.050144498306731164" LOG_CI_START="-0.38643337939354094" LOG_EFFECT_SIZE="-0.21828893885013606" NO="1" P_CHI2="1.0" P_Z="0.010944376143962107" STUDIES="1" TAU2="0.0" TOTAL_1="54" TOTAL_2="56" WEIGHT="40.75686587625604" Z="2.54446984382627">
<NAME>Olanzapine v. placebo as monotherapy</NAME>
<DICH_DATA CI_END="0.8909544507625057" CI_START="0.41073964234555294" EFFECT_SIZE="0.6049382716049383" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="36" LOG_CI_END="-0.050144498306731164" LOG_CI_START="-0.38643337939354094" LOG_EFFECT_SIZE="-0.21828893885013606" ORDER="34" O_E="0.0" SE="0.19753775340720067" STUDY_ID="STD-HGGW-Trial-2000" TOTAL_1="54" TOTAL_2="56" VAR="0.03902116402116402" WEIGHT="40.75686587625604"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8944247162680925" CI_START="0.43600056391117537" DF="0.0" EFFECT_SIZE="0.6244755244755245" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="39" I2="0.0" ID="CMP-001.14.02" LOG_CI_END="-0.048456208126555725" LOG_CI_START="-0.36051294902647507" LOG_EFFECT_SIZE="-0.2044845785765154" NO="2" P_CHI2="1.0" P_Z="0.01020952597750474" STUDIES="1" TAU2="0.0" TOTAL_1="220" TOTAL_2="114" WEIGHT="59.24313412374395" Z="2.5686508693773553">
<NAME>Olanzapine v. placebo as add-on to mood stabilizer</NAME>
<DICH_DATA CI_END="0.8944247162680925" CI_START="0.43600056391117537" EFFECT_SIZE="0.6244755244755245" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="39" LOG_CI_END="-0.048456208126555725" LOG_CI_START="-0.36051294902647507" LOG_EFFECT_SIZE="-0.2044845785765154" ORDER="35" O_E="0.0" SE="0.18330367431039274" STUDY_ID="STD-HGFU-Trial-2002" TOTAL_1="220" TOTAL_2="114" VAR="0.03360023701569054" WEIGHT="59.24313412374395"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.975651552324184" CI_END="0.9519136272525316" CI_START="0.6273960415833655" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7728045300511001" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="113" I2="66.53084634390846" I2_Q="0.0" ID="CMP-001.15" LOG_CI_END="-0.02140245593208829" LOG_CI_START="-0.20245822571465985" LOG_EFFECT_SIZE="-0.11193034082337405" METHOD="MH" NO="15" P_CHI2="0.0503970094030064" P_Q="0.0" P_Z="0.01537871667520137" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="354" TOTAL_2="244" WEIGHT="100.0" Z="2.423335495516741">
<NAME>Failure to complete treatment</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.14325517338344318" CI_END="0.8015124887502426" CI_START="0.4768791674404189" DF="1.0" EFFECT_SIZE="0.6182431627833128" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="80" I2="0.0" ID="CMP-001.15.01" LOG_CI_END="-0.09608970630664157" LOG_CI_START="-0.3215916493910171" LOG_EFFECT_SIZE="-0.20884067784882931" NO="1" P_CHI2="0.7050662640198215" P_Z="2.830885369263677E-4" STUDIES="2" TAU2="0.0" TOTAL_1="125" TOTAL_2="129" WEIGHT="64.2034013995412" Z="3.630303149427702">
<NAME>Olanzapine v. placebo as monotherapy</NAME>
<DICH_DATA CI_END="0.8327438638860587" CI_START="0.42004242873640796" EFFECT_SIZE="0.5914285714285714" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="45" LOG_CI_END="-0.07948855874515323" LOG_CI_START="-0.37670683904156255" LOG_EFFECT_SIZE="-0.22809769889335788" ORDER="36" O_E="0.0" SE="0.17458748910032634" STUDY_ID="STD-HGEH-Trial_x002c_-1999" TOTAL_1="70" TOTAL_2="69" VAR="0.03048079135035657" WEIGHT="36.927213364003975"/>
<DICH_DATA CI_END="0.9750173047363986" CI_START="0.43940733152622774" EFFECT_SIZE="0.6545454545454545" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="35" LOG_CI_END="-0.010987676317015416" LOG_CI_START="-0.3571327011368977" LOG_EFFECT_SIZE="-0.1840601887269566" ORDER="37" O_E="0.0" SE="0.2033273010247058" STUDY_ID="STD-HGGW-Trial-2000" TOTAL_1="55" TOTAL_2="60" VAR="0.04134199134199133" WEIGHT="27.27618803553724"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4887756653657807" CI_START="0.7405693881560892" DF="0.0" EFFECT_SIZE="1.0500198491464867" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="33" I2="0.0" ID="CMP-001.15.02" LOG_CI_END="0.17282926146356734" LOG_CI_START="-0.13043424371738427" LOG_EFFECT_SIZE="0.021197508873091533" NO="2" P_CHI2="1.0" P_Z="0.7840884040946067" STUDIES="1" TAU2="0.0" TOTAL_1="229" TOTAL_2="115" WEIGHT="35.79659860045879" Z="0.273995078494115">
<NAME>Olanzapine v. placebo as add-on to mood stabilizer</NAME>
<DICH_DATA CI_END="1.4887756653657807" CI_START="0.7405693881560892" EFFECT_SIZE="1.0500198491464867" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="33" LOG_CI_END="0.17282926146356734" LOG_CI_START="-0.13043424371738427" LOG_EFFECT_SIZE="0.021197508873091533" ORDER="38" O_E="0.0" SE="0.17813848412185232" STUDY_ID="STD-HGFU-Trial-2002" TOTAL_1="229" TOTAL_2="115" VAR="0.03173331952523143" WEIGHT="35.79659860045879"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9968478335078067" CI_END="1.404246967223822" CI_START="0.6481368600149439" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9540147902532516" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="38" I2="0.0" I2_Q="0.0" ID="CMP-001.16" LOG_CI_END="0.14744349459597672" LOG_CI_START="-0.18833327920124154" LOG_EFFECT_SIZE="-0.020444892302632422" METHOD="MH" NO="16" P_CHI2="0.607487416972494" P_Q="0.0" P_Z="0.8113553320710101" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="353" TOTAL_2="240" WEIGHT="99.99999999999999" Z="0.2386779295530398">
<NAME>Treatment emergent depression</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.7630538422777835" CI_END="1.5972531451863339" CI_START="0.4434501751620293" DF="1.0" EFFECT_SIZE="0.8416069076540318" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="18" I2="0.0" ID="CMP-001.16.01" LOG_CI_END="0.2033737519838454" LOG_CI_START="-0.3531551692207024" LOG_EFFECT_SIZE="-0.07489070861842848" NO="1" P_CHI2="0.3823745540295429" P_Z="0.5978499397196757" STUDIES="2" TAU2="0.0" TOTAL_1="124" TOTAL_2="125" WEIGHT="40.16690470648989" Z="0.5274949282100445">
<NAME>Olanzapine v. placebo as monotherapy</NAME>
<DICH_DATA CI_END="2.7069979927929193" CI_START="0.45427539281691814" EFFECT_SIZE="1.1089285714285715" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.4324879337463903" LOG_CI_START="-0.3426807874056307" LOG_EFFECT_SIZE="0.044903573170379796" ORDER="39" O_E="0.0" SE="0.45533794395175153" STUDY_ID="STD-HGEH-Trial_x002c_-1999" TOTAL_1="70" TOTAL_2="69" VAR="0.2073326432022084" WEIGHT="18.10538072530204"/>
<DICH_DATA CI_END="1.5937698422482358" CI_START="0.24292120704267833" EFFECT_SIZE="0.6222222222222222" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.20242560472722218" LOG_CI_START="-0.6145345695934712" LOG_EFFECT_SIZE="-0.20605448243312444" ORDER="40" O_E="0.0" SE="0.4798864504140592" STUDY_ID="STD-HGGW-Trial-2000" TOTAL_1="54" TOTAL_2="56" VAR="0.2302910052910053" WEIGHT="22.061523981187847"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.672675004839133" CI_START="0.633608319336188" DF="0.0" EFFECT_SIZE="1.029475982532751" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="20" I2="0.0" ID="CMP-001.16.02" LOG_CI_END="0.22341156719312547" LOG_CI_START="-0.1981791290541695" LOG_EFFECT_SIZE="0.012616219069477982" NO="2" P_CHI2="1.0" P_Z="0.9066184130299613" STUDIES="1" TAU2="0.0" TOTAL_1="229" TOTAL_2="115" WEIGHT="59.8330952935101" Z="0.11730493683731492">
<NAME>Olanzapine v. placebo as add-on to mood stabilizer</NAME>
<DICH_DATA CI_END="1.6726750048391332" CI_START="0.633608319336188" EFFECT_SIZE="1.029475982532751" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="20" LOG_CI_END="0.22341156719312552" LOG_CI_START="-0.1981791290541695" LOG_EFFECT_SIZE="0.012616219069477982" ORDER="41" O_E="0.0" SE="0.24764446188326475" STUDY_ID="STD-HGFU-Trial-2002" TOTAL_1="229" TOTAL_2="115" VAR="0.06132777950145176" WEIGHT="59.8330952935101"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.20682338958986127" CI_END="0.08935853285894779" CI_START="-0.7420878317669636" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.3263646494540079" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.17" NO="17" P_CHI2="0.6492686862022001" P_Q="1.0" P_Z="0.12388360494731253" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="122" TOTAL_2="119" UNITS="" WEIGHT="100.0" Z="1.5386752194044309">
<NAME>SAS Scale</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placeo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.20682338958986127" CI_END="0.08935853285894779" CI_START="-0.7420878317669636" DF="1.0" EFFECT_SIZE="-0.3263646494540079" ESTIMABLE="YES" I2="0.0" ID="CMP-001.17.01" NO="1" P_CHI2="0.6492686862022001" P_Z="0.12388360494731253" STUDIES="2" TAU2="0.0" TOTAL_1="122" TOTAL_2="119" WEIGHT="100.0" Z="1.5386752194044309">
<NAME>Olanzapine v. placebo as monotherapy</NAME>
<CONT_DATA CI_END="0.48513485433592823" CI_START="-0.8851348543359283" EFFECT_SIZE="-0.2" ESTIMABLE="YES" MEAN_1="-0.15" MEAN_2="0.05" ORDER="42" SD_1="2.12" SD_2="1.88" SE="0.34956502249030313" STUDY_ID="STD-HGEH-Trial_x002c_-1999" TOTAL_1="68" TOTAL_2="63" WEIGHT="36.81767527299607"/>
<CONT_DATA CI_END="0.12300572456185621" CI_START="-0.9230057245618563" EFFECT_SIZE="-0.4" ESTIMABLE="YES" MEAN_1="-0.27" MEAN_2="0.13" ORDER="43" SD_1="1.16" SD_2="1.61" SE="0.26684455872008805" STUDY_ID="STD-HGGW-Trial-2000" TOTAL_1="54" TOTAL_2="56" WEIGHT="63.18232472700393"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.8432973673717348" CI_END="0.056258025748081086" CI_START="-0.3200769360777214" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.13190945516482017" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.18" NO="18" P_CHI2="0.3584554974738904" P_Q="1.0" P_Z="0.16944883871647157" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="124" TOTAL_2="122" UNITS="" WEIGHT="100.0" Z="1.3739769490936653">
<NAME>Barnes Akathisia Scale</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.8432973673717348" CI_END="0.056258025748081086" CI_START="-0.3200769360777214" DF="1.0" EFFECT_SIZE="-0.13190945516482017" ESTIMABLE="YES" I2="0.0" ID="CMP-001.18.01" NO="1" P_CHI2="0.3584554974738904" P_Z="0.16944883871647157" STUDIES="2" TAU2="0.0" TOTAL_1="124" TOTAL_2="122" WEIGHT="100.0" Z="1.3739769490936653">
<NAME>Olanzapine v. placebo as monotherapy</NAME>
<CONT_DATA CI_END="0.18282140654128648" CI_START="-0.3028214065412865" EFFECT_SIZE="-0.06000000000000001" ESTIMABLE="YES" MEAN_1="-0.17" MEAN_2="-0.11" ORDER="44" SD_1="0.8" SD_2="0.64" SE="0.12389074924673654" STUDY_ID="STD-HGEH-Trial_x002c_-1999" TOTAL_1="70" TOTAL_2="66" WEIGHT="60.05030268621101"/>
<CONT_DATA CI_END="0.057706162265204114" CI_START="-0.5377061622652042" EFFECT_SIZE="-0.24000000000000002" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="-0.16" ORDER="45" SD_1="0.83" SD_2="0.76" SE="0.15189369019710175" STUDY_ID="STD-HGGW-Trial-2000" TOTAL_1="54" TOTAL_2="56" WEIGHT="39.94969731378898"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.07929227091030217" CI_START="-0.5792922709103021" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.25" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.19" NO="19" P_CHI2="1.0" P_Q="1.0" P_Z="0.13674761246931677" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="69" TOTAL_2="66" UNITS="" WEIGHT="100.0" Z="1.4880124418968979">
<NAME>AIMS</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.07929227091030217" CI_START="-0.5792922709103021" DF="0.0" EFFECT_SIZE="-0.25" ESTIMABLE="YES" I2="0.0" ID="CMP-001.19.01" NO="1" P_CHI2="1.0" P_Z="0.13674761246931677" STUDIES="1" TAU2="0.0" TOTAL_1="69" TOTAL_2="66" WEIGHT="100.0" Z="1.4880124418968979">
<NAME>Olanzapine v. placebo as monotherapy</NAME>
<CONT_DATA CI_END="0.07929227091030217" CI_START="-0.5792922709103021" EFFECT_SIZE="-0.25" ESTIMABLE="YES" MEAN_1="-0.25" MEAN_2="0.0" ORDER="46" SD_1="1.1" SD_2="0.84" SE="0.16800934787971492" STUDY_ID="STD-HGEH-Trial_x002c_-1999" TOTAL_1="69" TOTAL_2="66" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.900072328796512" CI_END="2.82649780792166" CI_START="1.9556445451940716" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="2.391071176557866" ESTIMABLE="YES" I2="59.18427594942843" I2_Q="77.55527554611511" ID="CMP-001.20" NO="20" P_CHI2="0.08629051930981835" P_Q="0.034791313275750246" P_Z="5.1574061583773054E-27" Q="4.455389960587878" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="343" TOTAL_2="238" UNITS="" WEIGHT="100.0" Z="10.762808365319719">
<NAME>Weight Gain (continuous data)</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.4446823682086337" CI_END="2.534451633595283" CI_START="1.2893847885772276" DF="1.0" EFFECT_SIZE="1.9119182110862554" ESTIMABLE="YES" I2="0.0" ID="CMP-001.20.01" NO="1" P_CHI2="0.5048711158357178" P_Z="1.7504192417407974E-9" STUDIES="2" TAU2="0.0" TOTAL_1="124" TOTAL_2="125" WEIGHT="48.92204804162678" Z="6.019421126037562">
<NAME>Olanzapine v. placebo as monotherapy</NAME>
<CONT_DATA CI_END="2.9033306123923817" CI_START="1.276669387607618" EFFECT_SIZE="2.09" ESTIMABLE="YES" MEAN_1="1.65" MEAN_2="-0.44" ORDER="47" SD_1="2.54" SD_2="2.35" SE="0.4149722233713628" STUDY_ID="STD-HGEH-Trial_x002c_-1999" TOTAL_1="70" TOTAL_2="69" WEIGHT="28.66129029144763"/>
<CONT_DATA CI_END="2.6273578175495595" CI_START="0.6926421824504404" EFFECT_SIZE="1.66" ESTIMABLE="YES" MEAN_1="2.11" MEAN_2="0.45" ORDER="48" SD_1="2.83" SD_2="2.31" SE="0.4935589761750494" STUDY_ID="STD-HGGW-Trial-2000" TOTAL_1="54" TOTAL_2="56" WEIGHT="20.26075775017915"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.459253804725132" CI_START="2.240746195274868" DF="0.0" EFFECT_SIZE="2.85" ESTIMABLE="YES" I2="0.0" ID="CMP-001.20.02" NO="2" P_CHI2="1.0" P_Z="4.799836502869557E-20" STUDIES="1" TAU2="0.0" TOTAL_1="219" TOTAL_2="113" WEIGHT="51.07795195837322" Z="9.168424247197372">
<NAME>Olanzapine v. placebo as add-on to mood stabilizer</NAME>
<CONT_DATA CI_END="3.459253804725132" CI_START="2.240746195274868" EFFECT_SIZE="2.85" ESTIMABLE="YES" MEAN_1="3.08" MEAN_2="0.23" ORDER="49" SD_1="3.04" SD_2="2.48" SE="0.31084948985330774" STUDY_ID="STD-HGFU-Trial-2002" TOTAL_1="219" TOTAL_2="113" WEIGHT="51.07795195837322"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="3.322594548929394" CI_END="2.7940426103049827" CI_START="1.6185371068822467" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.1265609897176114" ESTIMABLE="YES" EVENTS_1="162" EVENTS_2="48" I2="39.806077131967854" I2_Q="0.0" ID="CMP-001.21" LOG_CI_END="0.4462330249990714" LOG_CI_START="0.2091226605686615" LOG_EFFECT_SIZE="0.32767784278386647" METHOD="MH" NO="21" P_CHI2="0.18989267815950217" P_Q="0.0" P_Z="6.054064482248702E-8" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="354" TOTAL_2="244" WEIGHT="100.0" Z="5.417196940597237">
<NAME>Somnolence</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.5786386163090205" CI_END="4.3786052240276785" CI_START="1.6070436270149977" DF="1.0" EFFECT_SIZE="2.652660856666049" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="17" I2="61.21984702798846" ID="CMP-001.21.01" LOG_CI_END="0.6413357908749127" LOG_CI_START="0.2060276668782747" LOG_EFFECT_SIZE="0.42368172887659367" NO="1" P_CHI2="0.10831515805184766" P_Z="1.3605457264964044E-4" STUDIES="2" TAU2="0.0" TOTAL_1="125" TOTAL_2="129" WEIGHT="29.013248470988017" Z="3.8152328602633707">
<NAME>Olanzapine v. placebo as monotherapy</NAME>
<DICH_DATA CI_END="3.4898833030320615" CI_START="1.0227850619254044" EFFECT_SIZE="1.8892857142857142" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="12" LOG_CI_END="0.5428109049830852" LOG_CI_START="0.009784376402847923" LOG_EFFECT_SIZE="0.27629764069296653" ORDER="50" O_E="0.0" SE="0.31310242141190137" STUDY_ID="STD-HGEH-Trial_x002c_-1999" TOTAL_1="70" TOTAL_2="69" VAR="0.09803312629399587" WEIGHT="20.787537936565492"/>
<DICH_DATA CI_END="11.315456892608509" CI_START="1.855254988859776" EFFECT_SIZE="4.581818181818182" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="5" LOG_CI_END="1.053672094475692" LOG_CI_START="0.2684036080989086" LOG_EFFECT_SIZE="0.6610378512873003" ORDER="51" O_E="0.0" SE="0.46127059603942105" STUDY_ID="STD-HGGW-Trial-2000" TOTAL_1="55" TOTAL_2="60" VAR="0.21277056277056278" WEIGHT="8.225710534422525"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.454598146388597E-31" CI_END="2.6483449836791118" CI_START="1.3797194468880636" DF="0.0" EFFECT_SIZE="1.9115368361741087" ESTIMABLE="YES" EVENTS_1="118" EVENTS_2="31" I2="100.0" ID="CMP-001.21.02" LOG_CI_END="0.4229745573346565" LOG_CI_START="0.13979078563649616" LOG_EFFECT_SIZE="0.28138267148557633" NO="2" P_CHI2="0.0" P_Z="9.820014151456758E-5" STUDIES="1" TAU2="0.0" TOTAL_1="229" TOTAL_2="115" WEIGHT="70.98675152901198" Z="3.8949965153598396">
<NAME>Olanzapine v. placebo as add-on to mood stabilizer</NAME>
<DICH_DATA CI_END="2.6483449836791118" CI_START="1.379719446888064" EFFECT_SIZE="1.911536836174109" ESTIMABLE="YES" EVENTS_1="118" EVENTS_2="31" LOG_CI_END="0.4229745573346565" LOG_CI_START="0.1397907856364963" LOG_EFFECT_SIZE="0.2813826714855764" ORDER="52" O_E="0.0" SE="0.1663435492777769" STUDY_ID="STD-HGFU-Trial-2002" TOTAL_1="229" TOTAL_2="115" VAR="0.02767017638632819" WEIGHT="70.98675152901198"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.3640303388454789" CI_END="5.912175266451477" CI_START="2.241724175875977" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.640531036376461" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-001.22" LOG_CI_END="0.7717473002386773" LOG_CI_START="0.3505821754916871" LOG_EFFECT_SIZE="0.5611647378651822" METHOD="MH" NO="22" P_CHI2="0.8335887384789082" P_Q="0.0" P_Z="1.7609277589440418E-7" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="354" TOTAL_2="244" WEIGHT="99.99999999999997" Z="5.222952286328771">
<NAME>Dry Mouth</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.01706225160765231" CI_END="6.224521080784789" CI_START="1.5030789695227103" DF="1.0" EFFECT_SIZE="3.0587492103600757" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="9" I2="0.0" ID="CMP-001.22.01" LOG_CI_END="0.7941059421173698" LOG_CI_START="0.17698179836934647" LOG_EFFECT_SIZE="0.4855438702433581" NO="1" P_CHI2="0.8960739049967887" P_Z="0.002041417947980437" STUDIES="2" TAU2="0.0" TOTAL_1="125" TOTAL_2="129" WEIGHT="42.65425933976414" Z="3.0841395794741002">
<NAME>Olanzapine v. placebo as monotherapy</NAME>
<DICH_DATA CI_END="7.002446855836412" CI_START="1.248805461516995" EFFECT_SIZE="2.9571428571428573" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="6" LOG_CI_END="0.8452498214863844" LOG_CI_START="0.09649478939893757" LOG_EFFECT_SIZE="0.47087230544266095" ORDER="53" O_E="0.0" SE="0.439822412245351" STUDY_ID="STD-HGEH-Trial_x002c_-1999" TOTAL_1="70" TOTAL_2="69" VAR="0.1934437543133195" WEIGHT="28.92118658118352"/>
<DICH_DATA CI_END="11.472976826583906" CI_START="0.9335627504132272" EFFECT_SIZE="3.272727272727273" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="1.059676116386386" LOG_CI_START="-0.029856485168261417" LOG_EFFECT_SIZE="0.5149098156090622" ORDER="54" O_E="0.0" SE="0.639996843426559" STUDY_ID="STD-HGGW-Trial-2000" TOTAL_1="55" TOTAL_2="60" VAR="0.40959595959595957" WEIGHT="13.733072758580622"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.843098242164511" CI_START="2.115425632633284" DF="0.0" EFFECT_SIZE="4.073265405143134" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="9" I2="0.0" ID="CMP-001.22.02" LOG_CI_END="0.8944876549900371" LOG_CI_START="0.3253977623996723" LOG_EFFECT_SIZE="0.6099427086948547" NO="2" P_CHI2="1.0" P_Z="2.653575535192548E-5" STUDIES="1" TAU2="0.0" TOTAL_1="229" TOTAL_2="115" WEIGHT="57.34574066023584" Z="4.201324807345422">
<NAME>Olanzapine v. placebo as add-on to mood stabilizer</NAME>
<DICH_DATA CI_END="7.843098242164511" CI_START="2.115425632633284" EFFECT_SIZE="4.073265405143134" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="9" LOG_CI_END="0.8944876549900371" LOG_CI_START="0.3253977623996723" LOG_EFFECT_SIZE="0.6099427086948547" ORDER="55" O_E="0.0" SE="0.3342862199479813" STUDY_ID="STD-HGFU-Trial-2002" TOTAL_1="229" TOTAL_2="115" VAR="0.11174727684711012" WEIGHT="57.34574066023584"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.31383469575004" CI_END="4.041869350794464" CI_START="1.3932742059459597" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.373063907749951" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-001.23" LOG_CI_END="0.6065822712906029" LOG_CI_START="0.14403659697671434" LOG_EFFECT_SIZE="0.3753094341336586" METHOD="MH" NO="23" P_CHI2="0.5184471004568956" P_Q="0.0" P_Z="0.0014695595573503055" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="354" TOTAL_2="244" WEIGHT="100.0" Z="3.180628486262298">
<NAME>Dizziness</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.8258973803007752" CI_END="6.380398488979865" CI_START="1.3659911672634406" DF="1.0" EFFECT_SIZE="2.9522140809174897" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="8" I2="0.0" ID="CMP-001.23.01" LOG_CI_END="0.8048478035112322" LOG_CI_START="0.13544789113090908" LOG_EFFECT_SIZE="0.4701478473210707" NO="1" P_CHI2="0.3634615985229609" P_Z="0.005902825879461808" STUDIES="2" TAU2="0.0" TOTAL_1="125" TOTAL_2="129" WEIGHT="42.444896743056916" Z="2.753131068935052">
<NAME>Olanzapine v. placebo as monotherapy</NAME>
<DICH_DATA CI_END="11.199740144624354" CI_START="1.3880788525652905" EFFECT_SIZE="3.942857142857143" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="4" LOG_CI_END="1.0492079463250978" LOG_CI_START="0.14241413777682388" LOG_EFFECT_SIZE="0.5958110420509608" ORDER="56" O_E="0.0" SE="0.5326551718430014" STUDY_ID="STD-HGEH-Trial_x002c_-1999" TOTAL_1="70" TOTAL_2="69" VAR="0.2837215320910973" WEIGHT="21.77008083986035"/>
<DICH_DATA CI_END="6.167839286594114" CI_START="0.5909084088969706" EFFECT_SIZE="1.9090909090909092" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.7901330489186018" LOG_CI_START="-0.22847982976721334" LOG_EFFECT_SIZE="0.2808266095756942" ORDER="57" O_E="0.0" SE="0.5983382471551171" STUDY_ID="STD-HGGW-Trial-2000" TOTAL_1="55" TOTAL_2="60" VAR="0.358008658008658" WEIGHT="20.674815903196567"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.096015976367485" CI_START="0.9244990895284934" DF="0.0" EFFECT_SIZE="1.9459606986899562" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="8" I2="0.0" ID="CMP-001.23.02" LOG_CI_END="0.6123616419215605" LOG_CI_START="-0.03409351220945495" LOG_EFFECT_SIZE="0.28913406485605275" NO="2" P_CHI2="1.0" P_Z="0.0795624988984678" STUDIES="1" TAU2="0.0" TOTAL_1="229" TOTAL_2="115" WEIGHT="57.555103256943084" Z="1.7532302131098223">
<NAME>Olanzapine v. placebo as add-on to mood stabilizer</NAME>
<DICH_DATA CI_END="4.096015976367484" CI_START="0.9244990895284935" EFFECT_SIZE="1.9459606986899562" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="8" LOG_CI_END="0.6123616419215604" LOG_CI_START="-0.0340935122094549" LOG_EFFECT_SIZE="0.28913406485605275" ORDER="58" O_E="0.0" SE="0.37973095754118036" STUDY_ID="STD-HGFU-Trial-2002" TOTAL_1="229" TOTAL_2="115" VAR="0.14419560011514174" WEIGHT="57.555103256943084"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.844142495883565" CI_END="1.0107406868406315" CI_START="0.35020188836097615" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5949481466269638" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="31" I2="45.77425539337836" I2_Q="0.0" ID="CMP-001.24" LOG_CI_END="0.004639748351141617" LOG_CI_START="-0.45568151644063465" LOG_EFFECT_SIZE="-0.2255208840447465" METHOD="MH" NO="24" P_CHI2="0.17446637435808443" P_Q="0.0" P_Z="0.054800631229437645" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="125" TOTAL_2="129" WEIGHT="100.0" Z="1.9204535801285612">
<NAME>Agitation</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.844142495883565" CI_END="1.0107406868406315" CI_START="0.35020188836097615" DF="1.0" EFFECT_SIZE="0.5949481466269638" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="31" I2="45.77425539337836" ID="CMP-001.24.01" LOG_CI_END="0.004639748351141617" LOG_CI_START="-0.45568151644063465" LOG_EFFECT_SIZE="-0.2255208840447465" NO="1" P_CHI2="0.17446637435808443" P_Z="0.054800631229437645" STUDIES="2" TAU2="0.0" TOTAL_1="125" TOTAL_2="129" WEIGHT="100.0" Z="1.9204535801285612">
<NAME>Olanzapine v. placebo as monotherapy</NAME>
<DICH_DATA CI_END="1.5371349973221295" CI_START="0.4172888976829586" EFFECT_SIZE="0.8008928571428572" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" LOG_CI_END="0.1867120106471094" LOG_CI_START="-0.37956316989928846" LOG_EFFECT_SIZE="-0.0964255796260895" ORDER="59" O_E="0.0" SE="0.33263284416030575" STUDY_ID="STD-HGEH-Trial_x002c_-1999" TOTAL_1="70" TOTAL_2="69" VAR="0.11064460901417424" WEIGHT="52.90070849163158"/>
<DICH_DATA CI_END="0.9343284532005367" CI_START="0.14152561072684858" EFFECT_SIZE="0.36363636363636365" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="15" LOG_CI_END="-0.029500425336414695" LOG_CI_START="-0.8491649623241105" LOG_EFFECT_SIZE="-0.43933269383026263" ORDER="60" O_E="0.0" SE="0.4814750064314676" STUDY_ID="STD-HGGW-Trial-2000" TOTAL_1="55" TOTAL_2="60" VAR="0.2318181818181818" WEIGHT="47.09929150836842"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.276872637164748" CI_END="2.6449503127916305" CI_START="1.0861442003324966" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6949328725369193" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-001.25" LOG_CI_END="0.4224175179276878" LOG_CI_START="0.03588748754686396" LOG_EFFECT_SIZE="0.22915250273727591" METHOD="MH" NO="25" P_CHI2="0.5281176137696291" P_Q="0.0" P_Z="0.020130276341342034" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="354" TOTAL_2="244" WEIGHT="100.0" Z="2.3239107806954955">
<NAME>Asthenia</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.03632522819483927" CI_END="5.330881472970455" CI_START="1.1027121905750268" DF="1.0" EFFECT_SIZE="2.4245469652607423" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="8" I2="0.0" ID="CMP-001.25.01" LOG_CI_END="0.7267990265116195" LOG_CI_START="0.04246217576249611" LOG_EFFECT_SIZE="0.3846306011370578" NO="1" P_CHI2="0.8488454959264956" P_Z="0.02758134491307026" STUDIES="2" TAU2="0.0" TOTAL_1="125" TOTAL_2="129" WEIGHT="28.35917669608423" Z="2.203190211824465">
<NAME>Olanzapine v. placebo as monotherapy</NAME>
<DICH_DATA CI_END="6.803664935200642" CI_START="0.9653968555552005" EFFECT_SIZE="2.5628571428571427" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="5" LOG_CI_END="0.8327429174660215" LOG_CI_START="-0.015294120078388637" LOG_EFFECT_SIZE="0.40872439869381644" ORDER="61" O_E="0.0" SE="0.4981411537046244" STUDY_ID="STD-HGEH-Trial_x002c_-1999" TOTAL_1="70" TOTAL_2="69" VAR="0.24814460901417423" WEIGHT="18.065313951371216"/>
<DICH_DATA CI_END="8.30529722906377" CI_START="0.5731679971493342" EFFECT_SIZE="2.1818181818181817" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.9193551795486884" LOG_CI_START="-0.24171806644192653" LOG_EFFECT_SIZE="0.33881855655338095" ORDER="62" O_E="0.0" SE="0.6820201721001478" STUDY_ID="STD-HGGW-Trial-2000" TOTAL_1="55" TOTAL_2="60" VAR="0.46515151515151515" WEIGHT="10.293862744713014"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.425788526970911" CI_START="0.8150567361018488" DF="0.0" EFFECT_SIZE="1.4061135371179039" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="15" I2="0.0" ID="CMP-001.25.02" LOG_CI_END="0.3848529376794718" LOG_CI_START="-0.08881215896758611" LOG_EFFECT_SIZE="0.1480203893559429" NO="2" P_CHI2="1.0" P_Z="0.22058357928378147" STUDIES="1" TAU2="0.0" TOTAL_1="229" TOTAL_2="115" WEIGHT="71.64082330391577" Z="1.2249778764316137">
<NAME>Olanzapine v. placebo as add-on to mood stabilizer</NAME>
<DICH_DATA CI_END="2.425788526970911" CI_START="0.815056736101849" EFFECT_SIZE="1.4061135371179039" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="15" LOG_CI_END="0.3848529376794718" LOG_CI_START="-0.088812158967586" LOG_EFFECT_SIZE="0.1480203893559429" ORDER="63" O_E="0.0" SE="0.27823322245052473" STUDY_ID="STD-HGFU-Trial-2002" TOTAL_1="229" TOTAL_2="115" VAR="0.07741372607520319" WEIGHT="71.64082330391577"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.2839726753039479" CI_END="1.2896065358206148" CI_START="0.6306044356904601" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.901793547206836" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="45" I2="0.0" I2_Q="0.0" ID="CMP-001.26" LOG_CI_END="0.11045722550291595" LOG_CI_START="-0.20024297873699604" LOG_EFFECT_SIZE="-0.04489287661704003" METHOD="MH" NO="26" P_CHI2="0.867633120388108" P_Q="0.0" P_Z="0.5711301069587308" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="354" TOTAL_2="244" WEIGHT="99.99999999999999" Z="0.5663879207743113">
<NAME>Headache</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.21391122245474645" CI_END="1.605892360233409" CI_START="0.5625076089447115" DF="1.0" EFFECT_SIZE="0.9504349908212946" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="24" I2="0.0" ID="CMP-001.26.01" LOG_CI_END="0.20571643202403203" LOG_CI_START="-0.24987159854930857" LOG_EFFECT_SIZE="-0.022077583262638263" NO="1" P_CHI2="0.6437189628065713" P_Z="0.8493421370465638" STUDIES="2" TAU2="0.0" TOTAL_1="125" TOTAL_2="129" WEIGHT="45.681848846929654" Z="0.1899578792972239">
<NAME>Olanzapine v. placebo as monotherapy</NAME>
<DICH_DATA CI_END="2.2708353398744863" CI_START="0.509206078070826" EFFECT_SIZE="1.0753246753246752" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.3561856443137478" LOG_CI_START="-0.2931064210889513" LOG_EFFECT_SIZE="0.03153961161239824" ORDER="64" O_E="0.0" SE="0.38139737326510464" STUDY_ID="STD-HGEH-Trial_x002c_-1999" TOTAL_1="70" TOTAL_2="69" VAR="0.14546395633352155" WEIGHT="21.524078619712245"/>
<DICH_DATA CI_END="1.7566561585418679" CI_START="0.4008700909150288" EFFECT_SIZE="0.8391608391608392" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" LOG_CI_END="0.24468676259861577" LOG_CI_START="-0.3969963454334897" LOG_EFFECT_SIZE="-0.07615479141743699" ORDER="65" O_E="0.0" SE="0.3769278340406716" STUDY_ID="STD-HGGW-Trial-2000" TOTAL_1="55" TOTAL_2="60" VAR="0.14207459207459208" WEIGHT="24.15777022721741"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.9773927970323265E-31" CI_END="1.4043125544357224" CI_START="0.5277489156804416" DF="0.0" EFFECT_SIZE="0.8608858390517778" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="21" I2="100.0" ID="CMP-001.26.02" LOG_CI_END="0.1474637784204763" LOG_CI_START="-0.27757265032629297" LOG_EFFECT_SIZE="-0.06505443595290834" NO="2" P_CHI2="0.0" P_Z="0.5485268644640866" STUDIES="1" TAU2="0.0" TOTAL_1="229" TOTAL_2="115" WEIGHT="54.31815115307033" Z="0.5999690514915055">
<NAME>Olanzapine v. placebo as add-on to mood stabilizer</NAME>
<DICH_DATA CI_END="1.4043125544357224" CI_START="0.5277489156804417" EFFECT_SIZE="0.860885839051778" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="21" LOG_CI_END="0.1474637784204763" LOG_CI_START="-0.27757265032629286" LOG_EFFECT_SIZE="-0.0650544359529083" ORDER="66" O_E="0.0" SE="0.24966850221010684" STUDY_ID="STD-HGFU-Trial-2002" TOTAL_1="229" TOTAL_2="115" VAR="0.06233436099583812" WEIGHT="54.31815115307033"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.025748615569839" CI_END="3.6671447091748317" CI_START="0.11373080704109793" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6458075001971918" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" I2="75.15989954930528" I2_Q="0.0" ID="CMP-001.27" LOG_CI_END="0.5643280479906281" LOG_CI_START="-0.9441218790614829" LOG_EFFECT_SIZE="-0.1898969155354274" METHOD="MH" NO="27" P_CHI2="0.04481081312114199" P_Q="0.0" P_Z="0.6216770475046739" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="1.1956870489832216" TOTALS="YES" TOTAL_1="125" TOTAL_2="129" WEIGHT="100.0" Z="0.49347493549492505">
<NAME>Anxiety</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.025748615569839" CI_END="3.6671447091748317" CI_START="0.11373080704109793" DF="1.0" EFFECT_SIZE="0.6458075001971918" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" I2="75.15989954930528" ID="CMP-001.27.01" LOG_CI_END="0.5643280479906281" LOG_CI_START="-0.9441218790614829" LOG_EFFECT_SIZE="-0.1898969155354274" NO="1" P_CHI2="0.04481081312114199" P_Z="0.6216770475046739" STUDIES="2" TAU2="1.1956870489832216" TOTAL_1="125" TOTAL_2="129" WEIGHT="100.0" Z="0.49347493549492505">
<NAME>Olanzapine v. placebo as monotherapy</NAME>
<DICH_DATA CI_END="3.4873245007402565" CI_START="0.568608909591489" EFFECT_SIZE="1.4081632653061225" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.5424923610048387" LOG_CI_START="-0.24518633958735536" LOG_EFFECT_SIZE="0.14865301070874165" ORDER="67" O_E="0.0" SE="0.46268636780030614" STUDY_ID="STD-HGEH-Trial_x002c_-1999" TOTAL_1="70" TOTAL_2="69" VAR="0.21407867494824015" WEIGHT="55.69164594998087"/>
<DICH_DATA CI_END="1.0733462795866509" CI_START="0.05475354452954382" EFFECT_SIZE="0.24242424242424243" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" LOG_CI_END="0.030739855285922144" LOG_CI_START="-1.26158776105781" LOG_EFFECT_SIZE="-0.6154239528859439" ORDER="68" O_E="0.0" SE="0.7591196389651806" STUDY_ID="STD-HGGW-Trial-2000" TOTAL_1="55" TOTAL_2="60" VAR="0.5762626262626263" WEIGHT="44.30835405001913"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.3352293503575074" CI_END="5.039440137928084" CI_START="0.8664889011388444" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.089645651173493" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="7" I2="25.106499513941174" I2_Q="0.0" ID="CMP-001.28" LOG_CI_END="0.702382290708583" LOG_CI_START="-0.06223699579487203" LOG_EFFECT_SIZE="0.32007264745685543" METHOD="MH" NO="28" P_CHI2="0.24787718635916622" P_Q="0.0" P_Z="0.10081873555435232" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="125" TOTAL_2="129" WEIGHT="100.0" Z="1.6408973001990523">
<NAME>Constipation</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.3352293503575074" CI_END="5.039440137928084" CI_START="0.8664889011388444" DF="1.0" EFFECT_SIZE="2.089645651173493" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="7" I2="25.106499513941174" ID="CMP-001.28.01" LOG_CI_END="0.702382290708583" LOG_CI_START="-0.06223699579487203" LOG_EFFECT_SIZE="0.32007264745685543" NO="1" P_CHI2="0.24787718635916622" P_Z="0.10081873555435232" STUDIES="2" TAU2="0.0" TOTAL_1="125" TOTAL_2="129" WEIGHT="100.0" Z="1.6408973001990523">
<NAME>Olanzapine v. placebo as monotherapy</NAME>
<DICH_DATA CI_END="17.90892719548895" CI_START="0.868065533981035" EFFECT_SIZE="3.942857142857143" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="1.2530695709392656" LOG_CI_START="-0.06144748683734387" LOG_EFFECT_SIZE="0.5958110420509608" ORDER="69" O_E="0.0" SE="0.7721538267023594" STUDY_ID="STD-HGEH-Trial_x002c_-1999" TOTAL_1="70" TOTAL_2="69" VAR="0.5962215320910974" WEIGHT="29.636447307869304"/>
<DICH_DATA CI_END="4.0484899225337285" CI_START="0.4232983263033392" EFFECT_SIZE="1.309090909090909" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.6072930625714568" LOG_CI_START="-0.3733534486974076" LOG_EFFECT_SIZE="0.11696980693702459" ORDER="70" O_E="0.0" SE="0.5760366149978505" STUDY_ID="STD-HGGW-Trial-2000" TOTAL_1="55" TOTAL_2="60" VAR="0.33181818181818185" WEIGHT="70.3635526921307"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="9.497317990825833" CI_START="0.7275093623037927" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.6285714285714286" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.29" LOG_CI_END="0.9776009793694358" LOG_CI_START="-0.13816141337887664" LOG_EFFECT_SIZE="0.4197197829952796" METHOD="MH" NO="29" P_CHI2="1.0" P_Q="0.0" P_Z="0.1403278079835685" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="70" TOTAL_2="69" WEIGHT="100.0" Z="1.4745714026862362">
<NAME>Pain</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.497317990825833" CI_START="0.7275093623037927" DF="0.0" EFFECT_SIZE="2.6285714285714286" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" I2="0.0" ID="CMP-001.29.01" LOG_CI_END="0.9776009793694358" LOG_CI_START="-0.13816141337887664" LOG_EFFECT_SIZE="0.4197197829952796" NO="1" P_CHI2="1.0" P_Z="0.1403278079835685" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="69" WEIGHT="100.0" Z="1.4745714026862362">
<NAME>Olanzapine v. placebo as monotherapy</NAME>
<DICH_DATA CI_END="9.497317990825833" CI_START="0.7275093623037927" EFFECT_SIZE="2.6285714285714286" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.9776009793694358" LOG_CI_START="-0.13816141337887664" LOG_EFFECT_SIZE="0.4197197829952796" ORDER="71" O_E="0.0" SE="0.6554043526132785" STUDY_ID="STD-HGEH-Trial_x002c_-1999" TOTAL_1="70" TOTAL_2="69" VAR="0.4295548654244306" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.4695055193550703" CI_END="1.2212299070970631" CI_START="0.21080844329624512" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5073909494876213" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="14" I2="31.949898327780677" I2_Q="0.0" ID="CMP-001.30" LOG_CI_END="0.08679743133591288" LOG_CI_START="-0.6761119987558168" LOG_EFFECT_SIZE="-0.29465728370995203" METHOD="MH" NO="30" P_CHI2="0.22542404488694323" P_Q="0.0" P_Z="0.1300290142070509" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="125" TOTAL_2="129" WEIGHT="100.0" Z="1.5139874828509274">
<NAME>Hostility</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.4695055193550703" CI_END="1.2212299070970631" CI_START="0.21080844329624512" DF="1.0" EFFECT_SIZE="0.5073909494876213" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="14" I2="31.949898327780677" ID="CMP-001.30.01" LOG_CI_END="0.08679743133591288" LOG_CI_START="-0.6761119987558168" LOG_EFFECT_SIZE="-0.29465728370995203" NO="1" P_CHI2="0.22542404488694323" P_Z="0.1300290142070509" STUDIES="2" TAU2="0.0" TOTAL_1="125" TOTAL_2="129" WEIGHT="100.0" Z="1.5139874828509274">
<NAME>Olanzapine v. placebo as monotherapy</NAME>
<DICH_DATA CI_END="2.0195084847660505" CI_START="0.2706318747703866" EFFECT_SIZE="0.7392857142857143" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.3052456821553436" LOG_CI_START="-0.5676210539259464" LOG_EFFECT_SIZE="-0.13118768588530144" ORDER="72" O_E="0.0" SE="0.5127262415341777" STUDY_ID="STD-HGEH-Trial_x002c_-1999" TOTAL_1="70" TOTAL_2="69" VAR="0.2628881987577639" WEIGHT="58.4021039267253"/>
<DICH_DATA CI_END="1.4628662427204493" CI_START="0.02259799992253065" EFFECT_SIZE="0.18181818181818182" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.16520461819361146" LOG_CI_START="-1.6459299971820993" LOG_EFFECT_SIZE="-0.7403626894942439" ORDER="73" O_E="0.0" SE="1.0638694383326284" STUDY_ID="STD-HGGW-Trial-2000" TOTAL_1="55" TOTAL_2="60" VAR="1.131818181818182" WEIGHT="41.59789607327469"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.595160580535286" CI_END="0.9819762644552893" CI_START="0.404761584792441" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6304492596787501" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="38" I2="0.0" I2_Q="0.0" ID="CMP-001.31" LOG_CI_END="-0.007899009504977827" LOG_CI_START="-0.392800712335106" LOG_EFFECT_SIZE="-0.20034986092004192" METHOD="MH" NO="31" P_CHI2="0.7426129878534257" P_Q="0.0" P_Z="0.04130957397193961" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="354" TOTAL_2="244" WEIGHT="100.0" Z="2.0404093243733716">
<NAME>Nervousness</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.2732788422215543" CI_END="1.0828375731638973" CI_START="0.2732394837688737" DF="1.0" EFFECT_SIZE="0.5439429928741093" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="21" I2="0.0" ID="CMP-001.31.01" LOG_CI_END="0.03456331685709516" LOG_CI_START="-0.5634565438486557" LOG_EFFECT_SIZE="-0.2644466134957803" NO="1" P_CHI2="0.601140784189272" P_Z="0.083023394719673" STUDIES="2" TAU2="0.0" TOTAL_1="125" TOTAL_2="129" WEIGHT="47.578890458855255" Z="1.7334067723892532">
<NAME>Olanzapine v. placebo as monotherapy</NAME>
<DICH_DATA CI_END="1.747462723355218" CI_START="0.2471221439646672" EFFECT_SIZE="0.6571428571428571" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.24240792020381188" LOG_CI_START="-0.6070883368691774" LOG_EFFECT_SIZE="-0.18234020833268275" ORDER="74" O_E="0.0" SE="0.498998306478965" STUDY_ID="STD-HGEH-Trial_x002c_-1999" TOTAL_1="70" TOTAL_2="69" VAR="0.24899930986887508" WEIGHT="20.994522283598656"/>
<DICH_DATA CI_END="1.207498031553913" CI_START="0.1711071694104944" EFFECT_SIZE="0.45454545454545453" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="0.08188643144345012" LOG_CI_START="-0.7667317930878625" LOG_EFFECT_SIZE="-0.3424226808222063" ORDER="75" O_E="0.0" SE="0.49848254581765294" STUDY_ID="STD-HGGW-Trial-2000" TOTAL_1="55" TOTAL_2="60" VAR="0.24848484848484848" WEIGHT="26.5843681752566"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.1721503768959465E-31" CI_END="1.2656379533173394" CI_START="0.39713655754363086" DF="0.0" EFFECT_SIZE="0.7089648086308761" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="17" I2="100.0" ID="CMP-001.31.02" LOG_CI_END="0.10230948975438138" LOG_CI_START="-0.40106013306026966" LOG_EFFECT_SIZE="-0.14937532165294412" NO="2" P_CHI2="0.0" P_Z="0.24473150003437738" STUDIES="1" TAU2="0.0" TOTAL_1="229" TOTAL_2="115" WEIGHT="52.42110954114475" Z="1.163241631395224">
<NAME>Olanzapine v. placebo as add-on to mood stabilizer</NAME>
<DICH_DATA CI_END="1.2656379533173392" CI_START="0.39713655754363075" EFFECT_SIZE="0.708964808630876" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="17" LOG_CI_END="0.10230948975438131" LOG_CI_START="-0.4010601330602698" LOG_EFFECT_SIZE="-0.1493753216529442" ORDER="76" O_E="0.0" SE="0.2956818081611449" STUDY_ID="STD-HGFU-Trial-2002" TOTAL_1="229" TOTAL_2="115" VAR="0.0874277316774441" WEIGHT="52.42110954114475"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.4113094912975301" CI_END="1.0232643802368016" CI_START="0.1620421135363661" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4072001017682229" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="15" I2="29.143819540204486" I2_Q="0.0" ID="CMP-001.32" LOG_CI_END="0.009987856628920103" LOG_CI_START="-0.7903721008920845" LOG_EFFECT_SIZE="-0.3901921221315823" METHOD="MH" NO="32" P_CHI2="0.2348393626382138" P_Q="0.0" P_Z="0.05599861874551417" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="125" TOTAL_2="129" WEIGHT="100.0" Z="1.9110463966685514">
<NAME>Personality Disorder</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.4113094912975301" CI_END="1.0232643802368016" CI_START="0.1620421135363661" DF="1.0" EFFECT_SIZE="0.4072001017682229" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="15" I2="29.143819540204486" ID="CMP-001.32.01" LOG_CI_END="0.009987856628920103" LOG_CI_START="-0.7903721008920845" LOG_EFFECT_SIZE="-0.3901921221315823" NO="1" P_CHI2="0.2348393626382138" P_Z="0.05599861874551417" STUDIES="2" TAU2="0.0" TOTAL_1="125" TOTAL_2="129" WEIGHT="100.0" Z="1.9110463966685514">
<NAME>Olanzapine v. placebo as monotherapy</NAME>
<DICH_DATA CI_END="1.7902267451398934" CI_START="0.21200890118105242" EFFECT_SIZE="0.6160714285714286" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.25290804099473063" LOG_CI_START="-0.6736459048605832" LOG_EFFECT_SIZE="-0.21036893193292627" ORDER="77" O_E="0.0" SE="0.5442623743114137" STUDY_ID="STD-HGEH-Trial_x002c_-1999" TOTAL_1="70" TOTAL_2="69" VAR="0.2962215320910973" WEIGHT="54.615612941525676"/>
<DICH_DATA CI_END="1.2265413833913814" CI_START="0.01980153400419559" EFFECT_SIZE="0.15584415584415584" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.08868220584474404" LOG_CI_START="-1.703301164094458" LOG_EFFECT_SIZE="-0.8073094791248571" ORDER="78" O_E="0.0" SE="1.0526199019630296" STUDY_ID="STD-HGGW-Trial-2000" TOTAL_1="55" TOTAL_2="60" VAR="1.108008658008658" WEIGHT="45.38438705847433"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.4472050006881391" CI_END="7.983440012312883" CI_START="2.128529739561253" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="4.122255388766109" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-001.33" LOG_CI_END="0.9021900663439812" LOG_CI_START="0.32807972246575917" LOG_EFFECT_SIZE="0.6151348944048701" METHOD="MH" NO="33" P_CHI2="0.5036652781213615" P_Q="0.0" P_Z="2.6687179499920892E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="184" WEIGHT="100.0" Z="4.200036635894967">
<NAME>Weight Gain (dichotomous data)</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="61.38385335685383" CI_START="1.013043111425574" DF="0.0" EFFECT_SIZE="7.885714285714286" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" I2="0.0" ID="CMP-001.33.01" LOG_CI_END="1.788054147684771" LOG_CI_START="0.005627927745113227" LOG_EFFECT_SIZE="0.8968410377149421" NO="1" P_CHI2="1.0" P_Z="0.048570695089748865" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="69" WEIGHT="8.639246864326513" Z="1.9723409744705422">
<NAME>Olanzapine v. placebo as monotherapy</NAME>
<DICH_DATA CI_END="61.38385335685383" CI_START="1.013043111425574" EFFECT_SIZE="7.885714285714286" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.788054147684771" LOG_CI_START="0.005627927745113227" LOG_EFFECT_SIZE="0.8968410377149421" ORDER="79" O_E="0.0" SE="1.0470059847446418" STUDY_ID="STD-HGEH-Trial_x002c_-1999" TOTAL_1="70" TOTAL_2="69" VAR="1.0962215320910973" WEIGHT="8.639246864326513"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.606356046753212" CI_START="1.8649645987113028" DF="0.0" EFFECT_SIZE="3.766375545851528" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="8" I2="0.0" ID="CMP-001.33.02" LOG_CI_END="0.8811766504893339" LOG_CI_START="0.27067059232151347" LOG_EFFECT_SIZE="0.5759236214054237" NO="2" P_CHI2="1.0" P_Z="2.174062568938363E-4" STUDIES="1" TAU2="0.0" TOTAL_1="229" TOTAL_2="115" WEIGHT="91.36075313567349" Z="3.6978815875737685">
<NAME>Olanzapine v. placebo as add-on to mood stabilizer</NAME>
<DICH_DATA CI_END="7.606356046753212" CI_START="1.8649645987113028" EFFECT_SIZE="3.7663755458515285" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="8" LOG_CI_END="0.8811766504893339" LOG_CI_START="0.27067059232151347" LOG_EFFECT_SIZE="0.5759236214054237" ORDER="80" O_E="0.0" SE="0.35861428062150474" STUDY_ID="STD-HGFU-Trial-2002" TOTAL_1="229" TOTAL_2="115" VAR="0.12860420226567937" WEIGHT="91.36075313567349"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.747210822099519" CI_END="37.35106989788864" CI_START="2.8499894345425902" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="10.317468419037898" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.34" LOG_CI_END="1.5723030464216816" LOG_CI_START="0.45484324999856035" LOG_EFFECT_SIZE="1.013573148210121" METHOD="MH" NO="34" P_CHI2="0.3873607721526221" P_Q="0.0" P_Z="3.7725397679629606E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="125" TOTAL_2="129" WEIGHT="100.0" Z="3.5555048558301974">
<NAME>Increased ALT/SGPT</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.747210822099519" CI_END="37.35106989788864" CI_START="2.8499894345425902" DF="1.0" EFFECT_SIZE="10.317468419037898" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="2" I2="0.0" ID="CMP-001.34.01" LOG_CI_END="1.5723030464216816" LOG_CI_START="0.45484324999856035" LOG_EFFECT_SIZE="1.013573148210121" NO="1" P_CHI2="0.3873607721526221" P_Z="3.7725397679629606E-4" STUDIES="2" TAU2="0.0" TOTAL_1="125" TOTAL_2="129" WEIGHT="100.0" Z="3.5555048558301974">
<NAME>Olanzapine v. placebo as monotherapy</NAME>
<DICH_DATA CI_END="408.31863221823215" CI_START="1.4878536064676202" EFFECT_SIZE="24.64788732394366" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="0" LOG_CI_END="2.6109991979120704" LOG_CI_START="0.17256020202236763" LOG_EFFECT_SIZE="1.3917796999672192" ORDER="81" O_E="0.0" SE="1.432351136653311" STUDY_ID="STD-HGEH-Trial_x002c_-1999" TOTAL_1="70" TOTAL_2="69" VAR="2.0516297786720323" WEIGHT="20.837054995534004"/>
<DICH_DATA CI_END="27.94715838487835" CI_START="1.5329993345510597" EFFECT_SIZE="6.545454545454546" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="2" LOG_CI_END="1.4463376562115196" LOG_CI_START="0.1855419663345673" LOG_EFFECT_SIZE="0.8159398112730434" ORDER="82" O_E="0.0" SE="0.7405976292730408" STUDY_ID="STD-HGGW-Trial-2000" TOTAL_1="55" TOTAL_2="60" VAR="0.5484848484848485" WEIGHT="79.162945004466"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="9.359420581384267" CI_START="0.6922799105601158" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.5454545454545454" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.35" LOG_CI_END="0.9712489634713833" LOG_CI_START="-0.15971827110339487" LOG_EFFECT_SIZE="0.4057653461839942" METHOD="MH" NO="35" P_CHI2="1.0" P_Q="0.0" P_Z="0.15961099314843266" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="55" TOTAL_2="60" WEIGHT="100.0" Z="1.4063810875901597">
<NAME>Dyspepsia</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.359420581384267" CI_START="0.6922799105601158" DF="0.0" EFFECT_SIZE="2.5454545454545454" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" I2="0.0" ID="CMP-001.35.01" LOG_CI_END="0.9712489634713833" LOG_CI_START="-0.15971827110339487" LOG_EFFECT_SIZE="0.4057653461839942" NO="1" P_CHI2="1.0" P_Z="0.15961099314843266" STUDIES="1" TAU2="0.0" TOTAL_1="55" TOTAL_2="60" WEIGHT="100.0" Z="1.4063810875901597">
<NAME>Olanzapine v. placebo as monotherapy</NAME>
<DICH_DATA CI_END="9.359420581384262" CI_START="0.6922799105601161" EFFECT_SIZE="2.5454545454545454" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.971248963471383" LOG_CI_START="-0.15971827110339473" LOG_EFFECT_SIZE="0.4057653461839942" ORDER="83" O_E="0.0" SE="0.6643357519673251" STUDY_ID="STD-HGGW-Trial-2000" TOTAL_1="55" TOTAL_2="60" VAR="0.4413419913419913" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="15.096407780544993" CI_START="2.7035922194550084" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="8.9" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.36" NO="36" P_CHI2="1.0" P_Q="1.0" P_Z="0.004875784815398676" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="55" TOTAL_2="60" UNITS="" WEIGHT="100.0" Z="2.8151277450097485">
<NAME>Mean change in supine systolic blood pressure</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="15.096407780544993" CI_START="2.7035922194550084" DF="0.0" EFFECT_SIZE="8.9" ESTIMABLE="YES" I2="0.0" ID="CMP-001.36.01" NO="1" P_CHI2="1.0" P_Z="0.004875784815398676" STUDIES="1" TAU2="0.0" TOTAL_1="55" TOTAL_2="60" WEIGHT="100.0" Z="2.8151277450097485">
<NAME>Olanzapine v. placebo as monotherapy</NAME>
<CONT_DATA CI_END="15.096407780544993" CI_START="2.7035922194550084" EFFECT_SIZE="8.9" ESTIMABLE="YES" MEAN_1="5.04" MEAN_2="-3.86" ORDER="84" SD_1="15.98" SD_2="17.92" SE="3.1614906342266824" STUDY_ID="STD-HGGW-Trial-2000" TOTAL_1="55" TOTAL_2="60" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="381.38002334460737" CI_START="1.3720320755426347" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="22.875" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.37" LOG_CI_END="2.581357940995206" LOG_CI_START="0.13736426448176617" LOG_EFFECT_SIZE="1.359361102738486" METHOD="MH" NO="37" P_CHI2="1.0" P_Q="0.0" P_Z="0.029236498244539253" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="55" TOTAL_2="60" WEIGHT="100.0" Z="2.180282894310045">
<NAME>Increased AST</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="381.38002334460737" CI_START="1.3720320755426347" DF="0.0" EFFECT_SIZE="22.875" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" I2="0.0" ID="CMP-001.37.01" LOG_CI_END="2.581357940995206" LOG_CI_START="0.13736426448176617" LOG_EFFECT_SIZE="1.359361102738486" NO="1" P_CHI2="1.0" P_Z="0.029236498244539253" STUDIES="1" TAU2="0.0" TOTAL_1="55" TOTAL_2="60" WEIGHT="100.0" Z="2.180282894310045">
<NAME>Olanzapine v. placebo as monotherapy</NAME>
<DICH_DATA CI_END="381.38002334460737" CI_START="1.3720320755426347" EFFECT_SIZE="22.875" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" LOG_CI_END="2.581357940995206" LOG_CI_START="0.13736426448176617" LOG_EFFECT_SIZE="1.359361102738486" ORDER="85" O_E="0.0" SE="1.4356139835478066" STUDY_ID="STD-HGGW-Trial-2000" TOTAL_1="55" TOTAL_2="60" VAR="2.060987509758002" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.8321695049001223" CI_START="0.1751868136341278" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.38181818181818183" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-001.38" LOG_CI_END="-0.07978820310238595" LOG_CI_START="-0.7564985864182633" LOG_EFFECT_SIZE="-0.4181433947603245" METHOD="MH" NO="38" P_CHI2="1.0" P_Q="0.0" P_Z="0.015429110087408828" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="55" TOTAL_2="60" WEIGHT="100.0" Z="2.4221469458996023">
<NAME>ECG abnormality</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8321695049001223" CI_START="0.1751868136341278" DF="0.0" EFFECT_SIZE="0.38181818181818183" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="20" I2="0.0" ID="CMP-001.38.01" LOG_CI_END="-0.07978820310238595" LOG_CI_START="-0.7564985864182633" LOG_EFFECT_SIZE="-0.4181433947603245" NO="1" P_CHI2="1.0" P_Z="0.015429110087408828" STUDIES="1" TAU2="0.0" TOTAL_1="55" TOTAL_2="60" WEIGHT="100.0" Z="2.4221469458996023">
<NAME>Olanzapine v. placebo as monotherapy</NAME>
<DICH_DATA CI_END="0.8321695049001222" CI_START="0.17518681363412786" EFFECT_SIZE="0.38181818181818183" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="20" LOG_CI_END="-0.079788203102386" LOG_CI_START="-0.7564985864182632" LOG_EFFECT_SIZE="-0.4181433947603245" ORDER="86" O_E="0.0" SE="0.39750302893016803" STUDY_ID="STD-HGGW-Trial-2000" TOTAL_1="55" TOTAL_2="60" VAR="0.158008658008658" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.19096275790933" CI_START="0.1262062324072205" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.39" LOG_CI_END="0.6223138015863292" LOG_CI_START="-0.8989191979188922" LOG_EFFECT_SIZE="-0.13830269816628143" METHOD="MH" NO="39" P_CHI2="1.0" P_Q="0.0" P_Z="0.7215562035291645" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="55" TOTAL_2="60" WEIGHT="100.0" Z="0.35637973598888534">
<NAME>Corrected QT interval prolongation</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.19096275790933" CI_START="0.1262062324072205" DF="0.0" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-001.39.01" LOG_CI_END="0.6223138015863292" LOG_CI_START="-0.8989191979188922" LOG_EFFECT_SIZE="-0.13830269816628143" NO="1" P_CHI2="1.0" P_Z="0.7215562035291645" STUDIES="1" TAU2="0.0" TOTAL_1="55" TOTAL_2="60" WEIGHT="100.0" Z="0.35637973598888534">
<NAME>Olanzapine v. placebo as monotherapy</NAME>
<DICH_DATA CI_END="4.19096275790933" CI_START="0.12620623240722056" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6223138015863292" LOG_CI_START="-0.898919197918892" LOG_EFFECT_SIZE="-0.13830269816628143" ORDER="87" O_E="0.0" SE="0.8935797941341603" STUDY_ID="STD-HGGW-Trial-2000" TOTAL_1="55" TOTAL_2="60" VAR="0.7984848484848484" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="10.697635782005566" CI_START="1.7710674673195697" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="4.352727272727273" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-001.40" LOG_CI_END="1.0292878075655536" LOG_CI_START="0.24823510558674242" LOG_EFFECT_SIZE="0.638761456576148" METHOD="MH" NO="40" P_CHI2="1.0" P_Q="0.0" P_Z="0.0013468747854553946" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="220" TOTAL_2="114" WEIGHT="100.0" Z="3.2058001884629785">
<NAME>Prolactin elevation</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="10.697635782005566" CI_START="1.7710674673195697" DF="0.0" EFFECT_SIZE="4.352727272727273" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="5" I2="0.0" ID="CMP-001.40.02" LOG_CI_END="1.0292878075655536" LOG_CI_START="0.24823510558674242" LOG_EFFECT_SIZE="0.638761456576148" NO="2" P_CHI2="1.0" P_Z="0.0013468747854553946" STUDIES="1" TAU2="0.0" TOTAL_1="220" TOTAL_2="114" WEIGHT="100.0" Z="3.2058001884629785">
<NAME>Olanzapine v. placebo as add-on to mood stabilizer</NAME>
<DICH_DATA CI_END="10.697635782005566" CI_START="1.7710674673195697" EFFECT_SIZE="4.352727272727273" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="5" LOG_CI_END="1.0292878075655536" LOG_CI_START="0.24823510558674242" LOG_EFFECT_SIZE="0.638761456576148" ORDER="88" O_E="0.0" SE="0.45879422341558296" STUDY_ID="STD-HGFU-Trial-2002" TOTAL_1="220" TOTAL_2="114" VAR="0.21049213943950787" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.88342574900984" CI_START="1.5431101927404285" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.013100436681223" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-001.41" LOG_CI_END="0.7696302768687329" LOG_CI_START="0.18839693992600176" LOG_EFFECT_SIZE="0.47901360839736734" METHOD="MH" NO="41" P_CHI2="1.0" P_Q="0.0" P_Z="0.0012355565007765314" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="229" TOTAL_2="115" WEIGHT="100.0" Z="3.2305422311174765">
<NAME>Increased Appetite</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.88342574900984" CI_START="1.5431101927404285" DF="0.0" EFFECT_SIZE="3.013100436681223" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="9" I2="0.0" ID="CMP-001.41.02" LOG_CI_END="0.7696302768687329" LOG_CI_START="0.18839693992600176" LOG_EFFECT_SIZE="0.47901360839736734" NO="2" P_CHI2="1.0" P_Z="0.0012355565007765314" STUDIES="1" TAU2="0.0" TOTAL_1="229" TOTAL_2="115" WEIGHT="100.0" Z="3.2305422311174765">
<NAME>Olanzapine v. placebo as add-on to mood stabilizer</NAME>
<DICH_DATA CI_END="5.883425749009839" CI_START="1.5431101927404287" EFFECT_SIZE="3.013100436681223" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="9" LOG_CI_END="0.7696302768687328" LOG_CI_START="0.18839693992600184" LOG_EFFECT_SIZE="0.47901360839736734" ORDER="89" O_E="0.0" SE="0.34141933927158014" STUDY_ID="STD-HGFU-Trial-2002" TOTAL_1="229" TOTAL_2="115" VAR="0.11656716522864233" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.007432831321015" CI_START="1.0468826459785214" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.774381368267831" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-001.42" LOG_CI_END="0.47819593648988956" LOG_CI_START="0.019898000627773357" LOG_EFFECT_SIZE="0.24904696855883146" METHOD="MH" NO="42" P_CHI2="1.0" P_Q="0.0" P_Z="0.033158721922622966" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="229" TOTAL_2="115" WEIGHT="100.0" Z="2.1301561741314314">
<NAME>Tremor</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.007432831321015" CI_START="1.0468826459785214" DF="0.0" EFFECT_SIZE="1.774381368267831" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="15" I2="0.0" ID="CMP-001.42.02" LOG_CI_END="0.47819593648988956" LOG_CI_START="0.019898000627773357" LOG_EFFECT_SIZE="0.24904696855883146" NO="2" P_CHI2="1.0" P_Z="0.033158721922622966" STUDIES="1" TAU2="0.0" TOTAL_1="229" TOTAL_2="115" WEIGHT="100.0" Z="2.1301561741314314">
<NAME>Olanzapine v. placebo as add-on to mood stabilizer</NAME>
<DICH_DATA CI_END="3.007432831321015" CI_START="1.0468826459785214" EFFECT_SIZE="1.774381368267831" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="15" LOG_CI_END="0.47819593648988956" LOG_CI_START="0.019898000627773357" LOG_EFFECT_SIZE="0.24904696855883146" ORDER="90" O_E="0.0" SE="0.26920647613677734" STUDY_ID="STD-HGFU-Trial-2002" TOTAL_1="229" TOTAL_2="115" VAR="0.07247212679398127" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4018693649229979" CI_START="0.4537815731616253" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7975854097097355" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-001.43" LOG_CI_END="0.14670754520237722" LOG_CI_START="-0.343153143613503" LOG_EFFECT_SIZE="-0.0982227992055629" METHOD="MH" NO="43" P_CHI2="1.0" P_Q="0.0" P_Z="0.43187252133582443" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="229" TOTAL_2="115" WEIGHT="100.0" Z="0.7859914187805791">
<NAME>Diarrhoea</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4018693649229979" CI_START="0.4537815731616253" DF="0.0" EFFECT_SIZE="0.7975854097097355" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="17" I2="0.0" ID="CMP-001.43.02" LOG_CI_END="0.14670754520237722" LOG_CI_START="-0.343153143613503" LOG_EFFECT_SIZE="-0.0982227992055629" NO="2" P_CHI2="1.0" P_Z="0.43187252133582443" STUDIES="1" TAU2="0.0" TOTAL_1="229" TOTAL_2="115" WEIGHT="100.0" Z="0.7859914187805791">
<NAME>Olanzapine v. placebo as add-on to mood stabilizer</NAME>
<DICH_DATA CI_END="1.4018693649229979" CI_START="0.4537815731616253" EFFECT_SIZE="0.7975854097097355" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="17" LOG_CI_END="0.14670754520237722" LOG_CI_START="-0.343153143613503" LOG_EFFECT_SIZE="-0.0982227992055629" ORDER="91" O_E="0.0" SE="0.28774659345996517" STUDY_ID="STD-HGFU-Trial-2002" TOTAL_1="229" TOTAL_2="115" VAR="0.08279810204781446" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.6786958078826035" CI_END="-4.545443846005315" CI_START="-10.888340504837288" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-7.716892175421301" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.44" NO="44" P_CHI2="0.41003653456097744" P_Q="0.41003653456097744" P_Z="1.850865573703976E-6" Q="0.6786958078826035" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="72" TOTAL_2="42" UNITS="" WEIGHT="100.0" Z="4.769061061508734">
<NAME>Mean change in 21-item HAMD - depressed participants</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.7710345355122898" CI_START="-11.188965464487708" DF="0.0" EFFECT_SIZE="-5.9799999999999995" ESTIMABLE="YES" I2="0.0" ID="CMP-001.44.01" NO="1" P_CHI2="1.0" P_Z="0.024443920848576432" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="21" WEIGHT="37.069124078938344" Z="2.250079158223449">
<NAME>Olanzapine v. placebo as monotherapy</NAME>
<CONT_DATA CI_END="-0.7710345355122898" CI_START="-11.188965464487708" EFFECT_SIZE="-5.9799999999999995" ESTIMABLE="YES" MEAN_1="-12.79" MEAN_2="-6.81" ORDER="92" SD_1="8.79" SD_2="8.43" SE="2.65768427663741" STUDY_ID="STD-HGGW-Trial-2000" TOTAL_1="21" TOTAL_2="21" WEIGHT="37.069124078938344"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-4.742156844431675" CI_START="-12.737843155568324" DF="0.0" EFFECT_SIZE="-8.74" ESTIMABLE="YES" I2="0.0" ID="CMP-001.44.02" NO="2" P_CHI2="1.0" P_Z="1.8287754509310187E-5" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="21" WEIGHT="62.93087592106166" Z="4.284831735087141">
<NAME>Olanzapine v. placebo as add-on to mood stabilizer</NAME>
<CONT_DATA CI_END="-4.742156844431675" CI_START="-12.737843155568324" EFFECT_SIZE="-8.74" ESTIMABLE="YES" MEAN_1="-10.31" MEAN_2="-1.57" ORDER="93" SD_1="8.19" SD_2="7.73" SE="2.039753376645082" STUDY_ID="STD-HGFU-Trial-2002" TOTAL_1="51" TOTAL_2="21" WEIGHT="62.93087592106166"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.7309022660569493" CI_START="0.729743836429364" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6500311915159076" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-001.45" LOG_CI_END="0.5718138725015365" LOG_CI_START="-0.13682956446741693" LOG_EFFECT_SIZE="0.21749215401705974" METHOD="MH" NO="45" P_CHI2="1.0" P_Q="0.0" P_Z="0.22894602409917608" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="229" TOTAL_2="115" WEIGHT="100.0" Z="1.2030783509878225">
<NAME>Thirst</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.7309022660569493" CI_START="0.729743836429364" DF="0.0" EFFECT_SIZE="1.6500311915159076" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="7" I2="0.0" ID="CMP-001.45.02" LOG_CI_END="0.5718138725015365" LOG_CI_START="-0.13682956446741693" LOG_EFFECT_SIZE="0.21749215401705974" NO="2" P_CHI2="1.0" P_Z="0.22894602409917608" STUDIES="1" TAU2="0.0" TOTAL_1="229" TOTAL_2="115" WEIGHT="100.0" Z="1.2030783509878225">
<NAME>Olanzapine v. placebo as add-on to mood stabilizer</NAME>
<DICH_DATA CI_END="3.7309022660569493" CI_START="0.729743836429364" EFFECT_SIZE="1.6500311915159076" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="7" LOG_CI_END="0.5718138725015365" LOG_CI_START="-0.13682956446741693" LOG_EFFECT_SIZE="0.21749215401705974" ORDER="94" O_E="0.0" SE="0.41626066271714984" STUDY_ID="STD-HGFU-Trial-2002" TOTAL_1="229" TOTAL_2="115" VAR="0.17327293932572077" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="56.32112852439362" CI_START="1.0074787294962946" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="7.532751091703056" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.46" LOG_CI_END="1.7506713483181209" LOG_CI_START="0.003235885820689039" LOG_EFFECT_SIZE="0.8769536170694049" METHOD="MH" NO="46" P_CHI2="1.0" P_Q="0.0" P_Z="0.04915752217062448" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="229" TOTAL_2="115" WEIGHT="100.0" Z="1.9672228731259251">
<NAME>Speech Disorder</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="56.32112852439362" CI_START="1.0074787294962946" DF="0.0" EFFECT_SIZE="7.532751091703056" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="1" I2="0.0" ID="CMP-001.46.02" LOG_CI_END="1.7506713483181209" LOG_CI_START="0.003235885820689039" LOG_EFFECT_SIZE="0.8769536170694049" NO="2" P_CHI2="1.0" P_Z="0.04915752217062448" STUDIES="1" TAU2="0.0" TOTAL_1="229" TOTAL_2="115" WEIGHT="100.0" Z="1.9672228731259251">
<NAME>Olanzapine v. placebo as add-on to mood stabilizer</NAME>
<DICH_DATA CI_END="56.32112852439362" CI_START="1.0074787294962941" EFFECT_SIZE="7.532751091703057" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="1" LOG_CI_END="1.7506713483181209" LOG_CI_START="0.0032358858206888476" LOG_EFFECT_SIZE="0.876953617069405" ORDER="95" O_E="0.0" SE="1.0264522406160355" STUDY_ID="STD-HGFU-Trial-2002" TOTAL_1="229" TOTAL_2="115" VAR="1.0536042022656795" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-2.616911956424233" CI_START="-7.243088043575766" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.93" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.47" NO="47" P_CHI2="1.0" P_Q="1.0" P_Z="2.9490031627192124E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="150" TOTAL_2="76" UNITS="" WEIGHT="100.00000000000001" Z="4.1773690675626725">
<NAME>Mean change in YMRS for patients not experiencing psychotic symptoms</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-2.616911956424233" CI_START="-7.243088043575766" DF="0.0" EFFECT_SIZE="-4.93" ESTIMABLE="YES" I2="0.0" ID="CMP-001.47.02" NO="2" P_CHI2="1.0" P_Z="2.9490031627192124E-5" STUDIES="1" TAU2="0.0" TOTAL_1="150" TOTAL_2="76" WEIGHT="100.00000000000001" Z="4.1773690675626725">
<NAME>Olanzapine v. placebo as add-on to mood stabilizer</NAME>
<CONT_DATA CI_END="-2.616911956424233" CI_START="-7.243088043575766" EFFECT_SIZE="-4.93" ESTIMABLE="YES" MEAN_1="-13.25" MEAN_2="-8.32" ORDER="96" SD_1="7.76" SD_2="8.68" SE="1.1801686468838763" STUDY_ID="STD-HGFU-Trial-2002" TOTAL_1="150" TOTAL_2="76" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.3314482937957415" CI_END="-1.9388250930049336" CI_START="-6.022829778114666" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.9808274355597995" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.48" NO="48" P_CHI2="0.5648076758257708" P_Q="0.5648076758257708" P_Z="1.3296776598976045E-4" Q="0.3314482937957415" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="238" TOTAL_2="113" UNITS="" WEIGHT="100.0" Z="3.8208959117080514">
<NAME>Mean change in YMRS according to mood stabiliser</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="7.078006954500061E-32" CI_END="0.04161973785327744" CI_START="-6.501619737853275" DF="0.0" EFFECT_SIZE="-3.229999999999999" ESTIMABLE="YES" I2="100.0" ID="CMP-001.48.01" NO="1" P_CHI2="0.0" P_Z="0.05298656455469579" STUDIES="1" TAU2="0.0" TOTAL_1="74" TOTAL_2="41" WEIGHT="38.957119060178826" Z="1.9350304061370984">
<NAME>Olanzapine v. placebo as add-on to lithium</NAME>
<CONT_DATA CI_END="0.04161973785327788" CI_START="-6.501619737853275" EFFECT_SIZE="-3.2299999999999986" ESTIMABLE="YES" MEAN_1="-13.62" MEAN_2="-10.39" ORDER="97" SD_1="8.36" SD_2="8.69" SE="1.6692244161930503" STUDY_ID="STD-HGFU-Trial-2002" TOTAL_1="74" TOTAL_2="41" WEIGHT="38.957119060178826"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.8464023864764858" CI_START="-7.073597613523512" DF="0.0" EFFECT_SIZE="-4.459999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-001.48.02" NO="2" P_CHI2="1.0" P_Z="8.240122783903195E-4" STUDIES="1" TAU2="0.0" TOTAL_1="164" TOTAL_2="72" WEIGHT="61.04288093982117" Z="3.344600303358824">
<NAME>Olanzapine v. placebo as add-on to valproate</NAME>
<CONT_DATA CI_END="-1.8464023864764858" CI_START="-7.073597613523512" EFFECT_SIZE="-4.459999999999999" ESTIMABLE="YES" MEAN_1="-12.85" MEAN_2="-8.39" ORDER="98" SD_1="8.64" SD_2="9.76" SE="1.3334926734058572" STUDY_ID="STD-HGFU-Trial-2002" TOTAL_1="164" TOTAL_2="72" WEIGHT="61.04288093982117"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.49" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="49" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Failure to respond - YMRS (excl withdrawals)</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.49.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Olanzapine v. placebo as monotherapy</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.49.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Olanzapine v. placebo as add-on to mood stabilizer</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Olanzapine v mood stabiliser</NAME>
<CONT_OUTCOME CHI2="0.07986347754543915" CI_END="-0.0834127483960252" CI_START="-0.4972602361176497" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.29033649225683744" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.01" NO="1" P_CHI2="0.7774825164296311" P_Q="1.0" P_Z="0.005958755465388423" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="180" TOTAL_2="183" UNITS="" WEIGHT="100.0" Z="2.7500423953466933">
<NAME>Mean change in MRS</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Mood stablizer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours divalproex</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.07986347754543915" CI_END="-0.0834127483960252" CI_START="-0.4972602361176497" DF="1.0" EFFECT_SIZE="-0.29033649225683744" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.01" NO="1" P_CHI2="0.7774825164296311" P_Z="0.005958755465388423" STUDIES="2" TAU2="0.0" TOTAL_1="180" TOTAL_2="183" WEIGHT="100.0" Z="2.7500423953466933">
<NAME>Olanzapine v divalproex</NAME>
<CONT_DATA CI_END="-0.060234314662969635" CI_START="-0.5611241587488978" EFFECT_SIZE="-0.31067923670593367" ESTIMABLE="YES" MEAN_1="-13.4" MEAN_2="-10.4" ORDER="99" SD_1="8.8" SD_2="10.4" SE="0.12778036944476615" STUDY_ID="STD-HGHQ-Trial-2002" TOTAL_1="125" TOTAL_2="123" WEIGHT="68.26470126051788"/>
<CONT_DATA CI_END="0.12073739162561492" CI_START="-0.6138932310172915" EFFECT_SIZE="-0.2465779196958383" ESTIMABLE="YES" MEAN_1="-17.2" MEAN_2="-14.8" ORDER="100" SD_1="8.8" SD_2="10.4" SE="0.18740921477067413" STUDY_ID="STD-Zajecka-2000" TOTAL_1="55" TOTAL_2="60" WEIGHT="31.735298739482126"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.988037223050934" CI_START="0.6101463670279824" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7764324324324324" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="74" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-0.005226693609634993" LOG_CI_START="-0.21456597028832164" LOG_EFFECT_SIZE="-0.10989633194897831" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.03960596821494879" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="125" TOTAL_2="126" WEIGHT="100.0" Z="2.0578350710904667">
<NAME>Failure to respond - YMRS</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Mood stabilizer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours divalproex</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.988037223050934" CI_START="0.6101463670279824" DF="0.0" EFFECT_SIZE="0.7764324324324324" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="74" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="-0.005226693609634993" LOG_CI_START="-0.21456597028832164" LOG_EFFECT_SIZE="-0.10989633194897831" NO="1" P_CHI2="1.0" P_Z="0.03960596821494879" STUDIES="1" TAU2="0.0" TOTAL_1="125" TOTAL_2="126" WEIGHT="100.0" Z="2.0578350710904667">
<NAME>Olanzapine v divalproex</NAME>
<DICH_DATA CI_END="0.988037223050934" CI_START="0.6101463670279824" EFFECT_SIZE="0.7764324324324324" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="74" LOG_CI_END="-0.005226693609634993" LOG_CI_START="-0.21456597028832164" LOG_EFFECT_SIZE="-0.10989633194897831" ORDER="101" O_E="0.0" SE="0.12296692736719245" STUDY_ID="STD-HGHQ-Trial-2002" TOTAL_1="125" TOTAL_2="126" VAR="0.015120865226128384" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9738333720690949" CI_START="0.6441184066913397" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.792" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="84" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-0.011515346798626312" LOG_CI_START="-0.19103429002238667" LOG_EFFECT_SIZE="-0.10127481841050646" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.027007455280687258" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="125" TOTAL_2="126" WEIGHT="100.0" Z="2.211410039084441">
<NAME>Failure to achieve remission</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Mood stabilizer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours divalproex</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9738333720690949" CI_START="0.6441184066913397" DF="0.0" EFFECT_SIZE="0.792" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="84" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="-0.011515346798626312" LOG_CI_START="-0.19103429002238667" LOG_EFFECT_SIZE="-0.10127481841050646" NO="1" P_CHI2="1.0" P_Z="0.027007455280687258" STUDIES="1" TAU2="0.0" TOTAL_1="125" TOTAL_2="126" WEIGHT="100.0" Z="2.211410039084441">
<NAME>Olanzapine v divalproex</NAME>
<DICH_DATA CI_END="0.973833372069095" CI_START="0.6441184066913397" EFFECT_SIZE="0.792" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="84" LOG_CI_END="-0.011515346798626263" LOG_CI_START="-0.19103429002238667" LOG_EFFECT_SIZE="-0.10127481841050646" ORDER="102" O_E="0.0" SE="0.1054503158827375" STUDY_ID="STD-HGHQ-Trial-2002" TOTAL_1="125" TOTAL_2="126" VAR="0.01111976911976912" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.8623676629568113" CI_END="0.407279222596556" CI_START="-2.433232825933355" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.0129768016683995" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.04" NO="4" P_CHI2="0.3530770538267882" P_Q="1.0" P_Z="0.16213841431612291" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="176" TOTAL_2="179" UNITS="" WEIGHT="100.00000000000001" Z="1.3979155972756157">
<NAME>Mean Change in 21-item HAMD - all participants</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Mood stabilizer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours divalproex</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.8623676629568113" CI_END="0.407279222596556" CI_START="-2.433232825933355" DF="1.0" EFFECT_SIZE="-1.0129768016683995" ESTIMABLE="YES" I2="0.0" ID="CMP-002.04.01" NO="1" P_CHI2="0.3530770538267882" P_Z="0.16213841431612291" STUDIES="2" TAU2="0.0" TOTAL_1="176" TOTAL_2="179" WEIGHT="100.00000000000001" Z="1.3979155972756157">
<NAME>Olanzapine v divalproex</NAME>
<CONT_DATA CI_END="0.2450743380411209" CI_START="-3.165074338041121" EFFECT_SIZE="-1.46" ESTIMABLE="YES" MEAN_1="-4.92" MEAN_2="-3.46" ORDER="103" SD_1="7.22" SD_2="6.4" SE="0.8699518723254762" STUDY_ID="STD-HGHQ-Trial-2002" TOTAL_1="123" TOTAL_2="123" WEIGHT="69.38197271701367"/>
<CONT_DATA CI_END="2.5667172965880902" CI_START="-2.5667172965880902" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-6.9" MEAN_2="-6.9" ORDER="104" SD_1="7.22" SD_2="6.4" SE="1.3095737048405116" STUDY_ID="STD-Zajecka-2000" TOTAL_1="53" TOTAL_2="56" WEIGHT="30.618027282986347"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0082761196250434" CI_START="0.6189331291346193" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7899718309859155" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="71" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.0035794813239359833" LOG_CI_START="-0.20835627055442074" LOG_EFFECT_SIZE="-0.10238839461524236" METHOD="MH" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.05825707230834264" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="125" TOTAL_2="123" WEIGHT="100.0" Z="1.893758500886923">
<NAME>Failure to respond - YMRS (excluding early withdrawals)</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Mood Stabilizer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours divalproex</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0082761196250434" CI_START="0.6189331291346193" DF="0.0" EFFECT_SIZE="0.7899718309859155" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="71" I2="0.0" ID="CMP-002.05.01" LOG_CI_END="0.0035794813239359833" LOG_CI_START="-0.20835627055442074" LOG_EFFECT_SIZE="-0.10238839461524236" NO="1" P_CHI2="1.0" P_Z="0.05825707230834264" STUDIES="1" TAU2="0.0" TOTAL_1="125" TOTAL_2="123" WEIGHT="100.0" Z="1.893758500886923">
<NAME>Olanzapine v divalproex</NAME>
<DICH_DATA CI_END="1.0082761196250434" CI_START="0.6189331291346193" EFFECT_SIZE="0.7899718309859155" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="71" LOG_CI_END="0.0035794813239359833" LOG_CI_START="-0.20835627055442074" LOG_EFFECT_SIZE="-0.10238839461524236" ORDER="105" O_E="0.0" SE="0.12449210975223819" STUDY_ID="STD-HGHQ-Trial-2002" TOTAL_1="125" TOTAL_2="123" VAR="0.01549828539056332" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9881122496976456" CI_START="0.6505815560276456" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8017777777777778" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="81" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="-0.005193716692526726" LOG_CI_START="-0.18669825311835234" LOG_EFFECT_SIZE="-0.09594598490543954" METHOD="MH" NO="6" P_CHI2="1.0" P_Q="0.0" P_Z="0.03825313707259763" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="125" TOTAL_2="123" WEIGHT="100.00000000000001" Z="2.072131954153496">
<NAME>Failure to achieve remission (excluding early withdrawals)</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Mood stabilizer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours divalproex</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9881122496976456" CI_START="0.6505815560276456" DF="0.0" EFFECT_SIZE="0.8017777777777778" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="81" I2="0.0" ID="CMP-002.06.01" LOG_CI_END="-0.005193716692526726" LOG_CI_START="-0.18669825311835234" LOG_EFFECT_SIZE="-0.09594598490543954" NO="1" P_CHI2="1.0" P_Z="0.03825313707259763" STUDIES="1" TAU2="0.0" TOTAL_1="125" TOTAL_2="123" WEIGHT="100.00000000000001" Z="2.072131954153496">
<NAME>Olanzapine v divalproex</NAME>
<DICH_DATA CI_END="0.9881122496976456" CI_START="0.6505815560276456" EFFECT_SIZE="0.8017777777777778" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="81" LOG_CI_END="-0.005193716692526726" LOG_CI_START="-0.18669825311835234" LOG_EFFECT_SIZE="-0.09594598490543954" ORDER="106" O_E="0.0" SE="0.10661666315847547" STUDY_ID="STD-HGHQ-Trial-2002" TOTAL_1="125" TOTAL_2="123" VAR="0.011367112863047821" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="6.157049496538345" CI_END="-0.0790879913631326" CI_START="-0.5823296518182665" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.33070882159069953" ESTIMABLE="YES" I2="83.75845442590277" I2_Q="83.75845442590277" ID="CMP-002.07" NO="7" P_CHI2="0.013089010442064675" P_Q="0.013089010442064675" P_Z="0.009994820965967122" Q="6.157049496538345" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="125" TOTAL_2="126" UNITS="" WEIGHT="100.0" Z="2.576008429434237">
<NAME>Mean change in MRS and presence of psychotic features</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Mood stablizer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours divalproex</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.37878545450952034" CI_START="-0.3583306740946269" DF="0.0" EFFECT_SIZE="0.010227390207446719" ESTIMABLE="YES" I2="0.0" ID="CMP-002.07.01" NO="1" P_CHI2="1.0" P_Z="0.9566256492158463" STUDIES="1" TAU2="0.0" TOTAL_1="62" TOTAL_2="52" WEIGHT="46.610240665871615" Z="0.05438848964108916">
<NAME>Olanzapine v divalproex - patients experiencing psychotic symptoms</NAME>
<CONT_DATA CI_END="0.37878545450952034" CI_START="-0.3583306740946269" EFFECT_SIZE="0.010227390207446719" ESTIMABLE="YES" MEAN_1="-12.69" MEAN_2="-12.8" ORDER="107" SD_1="9.0" SD_2="12.4" SE="0.18804328406501986" STUDY_ID="STD-HGHQ-Trial-2002" TOTAL_1="62" TOTAL_2="52" WEIGHT="46.610240665871615"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.28398850402986414" CI_START="-0.972716290913018" DF="0.0" EFFECT_SIZE="-0.6283523974714411" ESTIMABLE="YES" I2="0.0" ID="CMP-002.07.02" NO="2" P_CHI2="1.0" P_Z="3.4849373244411747E-4" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="74" WEIGHT="53.38975933412839" Z="3.57629847988799">
<NAME>Olanzapine v divalproex - patients not experiencing psychotic symptoms</NAME>
<CONT_DATA CI_END="-0.28398850402986414" CI_START="-0.972716290913018" EFFECT_SIZE="-0.6283523974714411" ESTIMABLE="YES" MEAN_1="-14.1" MEAN_2="-8.7" ORDER="108" SD_1="8.6" SD_2="8.5" SE="0.17569909251286014" STUDY_ID="STD-HGHQ-Trial-2002" TOTAL_1="63" TOTAL_2="74" WEIGHT="53.38975933412839"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.0037857274925637" CI_START="-6.403785727492566" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.200000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.08" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.3050220654999084" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="29" TOTAL_2="24" UNITS="" WEIGHT="100.0" Z="1.0257232517319708">
<NAME>Mean change in 21-item HAMD - depressed participants</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours divalproex</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.0037857274925637" CI_START="-6.403785727492566" DF="0.0" EFFECT_SIZE="-2.200000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-002.08.01" NO="1" P_CHI2="1.0" P_Z="0.3050220654999084" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="24" WEIGHT="100.0" Z="1.0257232517319708">
<NAME>Olanzapine v divalproex</NAME>
<CONT_DATA CI_END="2.0037857274925637" CI_START="-6.403785727492566" EFFECT_SIZE="-2.200000000000001" ESTIMABLE="YES" MEAN_1="-10.3" MEAN_2="-8.1" ORDER="109" SD_1="8.2" SD_2="7.4" SE="2.1448280481945026" STUDY_ID="STD-HGHQ-Trial-2002" TOTAL_1="29" TOTAL_2="24" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.2767313988655598" CI_END="1.0828593472004568" CI_START="0.7080181160107204" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8756049536802918" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="95" I2="0.0" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="0.034572049698554166" LOG_CI_START="-0.14995562990509795" LOG_EFFECT_SIZE="-0.05769179010327193" METHOD="MH" NO="9" P_CHI2="0.7346658159600563" P_Q="0.0" P_Z="0.22036856825614448" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="212" TOTAL_2="219" WEIGHT="100.0" Z="1.2255487203754918">
<NAME>Failure to complete treatment</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Mood stabilizer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ms</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.10712493941483234" CI_END="1.117150198459241" CI_START="0.7295137215233296" DF="1.0" EFFECT_SIZE="0.902760432661139" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="90" I2="0.0" ID="CMP-002.09.01" LOG_CI_END="0.04811156700710476" LOG_CI_START="-0.13696653498941722" LOG_EFFECT_SIZE="-0.04442748399115626" NO="1" P_CHI2="0.7434414323084335" P_Z="0.34672136471956794" STUDIES="2" TAU2="0.0" TOTAL_1="182" TOTAL_2="189" WEIGHT="94.5987239216277" Z="0.9409678142045398">
<NAME>Olanzapine v divalproex</NAME>
<DICH_DATA CI_END="1.2399546100053769" CI_START="0.6154878201522963" EFFECT_SIZE="0.8736" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="45" LOG_CI_END="0.09340578759368998" LOG_CI_START="-0.2107805368723659" LOG_EFFECT_SIZE="-0.05868737463933796" ORDER="110" O_E="0.0" SE="0.17868055273795166" STUDY_ID="STD-HGHQ-Trial-2002" TOTAL_1="125" TOTAL_2="126" VAR="0.031926739926739924" WEIGHT="48.417813451544525"/>
<DICH_DATA CI_END="1.1877016306482666" CI_START="0.7334427171204984" EFFECT_SIZE="0.9333333333333333" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="45" LOG_CI_END="0.0747073527344401" LOG_CI_START="-0.13463379948932647" LOG_EFFECT_SIZE="-0.02996322337744321" ORDER="111" O_E="0.0" SE="0.12296802907165649" STUDY_ID="STD-Zajecka-2000" TOTAL_1="57" TOTAL_2="63" VAR="0.015121136173767757" WEIGHT="46.18091047008317"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.8531415452949767" CI_START="0.03894342756823292" DF="0.0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-002.09.02" LOG_CI_END="0.45532331768430767" LOG_CI_START="-1.4095658271236327" LOG_EFFECT_SIZE="-0.4771212547196625" NO="2" P_CHI2="1.0" P_Z="0.3159133624715845" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="3.2407656470233803" Z="1.0028912207598348">
<NAME>Olanzapine v lithium</NAME>
<DICH_DATA CI_END="2.8531415452949767" CI_START="0.03894342756823292" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.45532331768430767" LOG_CI_START="-1.4095658271236327" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="112" O_E="0.0" SE="1.0954451150103321" STUDY_ID="STD-Berk-1999" TOTAL_1="15" TOTAL_2="15" VAR="1.2" WEIGHT="3.2407656470233803"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.943824870337866" CI_START="0.05056813430021737" DF="0.0" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-002.09.03" LOG_CI_END="0.6940630779397805" LOG_CI_START="-1.296123069267743" LOG_EFFECT_SIZE="-0.3010299956639812" NO="3" P_CHI2="1.0" P_Z="0.5532364681192914" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="2.16051043134892" Z="0.5929173515708626">
<NAME>Olanzapine v lamotrigine</NAME>
<DICH_DATA CI_END="4.943824870337866" CI_START="0.05056813430021737" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6940630779397805" LOG_CI_START="-1.296123069267743" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="113" O_E="0.0" SE="1.1690451944500122" STUDY_ID="STD-Berk-1999" TOTAL_1="15" TOTAL_2="15" VAR="1.3666666666666667" WEIGHT="2.16051043134892"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.18264929970468893" CI_END="2.458856995018243" CI_START="1.3228551882880073" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8035275803597077" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="44" I2="0.0" I2_Q="0.0" ID="CMP-002.10" LOG_CI_END="0.39073327128428437" LOG_CI_START="0.1215123049814442" LOG_EFFECT_SIZE="0.2561227881328643" METHOD="MH" NO="10" P_CHI2="0.6691062971125983" P_Q="0.0" P_Z="1.920771732636388E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="182" TOTAL_2="189" WEIGHT="100.00000000000001" Z="3.729215055232502">
<NAME>Somnolence</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Mood stabilizer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours divalproex</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.18264929970468893" CI_END="2.458856995018243" CI_START="1.3228551882880073" DF="1.0" EFFECT_SIZE="1.8035275803597077" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="44" I2="0.0" ID="CMP-002.10.01" LOG_CI_END="0.39073327128428437" LOG_CI_START="0.1215123049814442" LOG_EFFECT_SIZE="0.2561227881328643" NO="1" P_CHI2="0.6691062971125983" P_Z="1.920771732636388E-4" STUDIES="2" TAU2="0.0" TOTAL_1="182" TOTAL_2="189" WEIGHT="100.00000000000001" Z="3.729215055232502">
<NAME>Olanzapine v divalproex</NAME>
<DICH_DATA CI_END="2.8513793801514087" CI_START="1.2656438806517902" EFFECT_SIZE="1.8996923076923078" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="26" LOG_CI_END="0.45505500466296966" LOG_CI_START="0.10231152367143467" LOG_EFFECT_SIZE="0.2786832641672022" ORDER="114" O_E="0.0" SE="0.20720326684281945" STUDY_ID="STD-HGHQ-Trial-2002" TOTAL_1="125" TOTAL_2="126" VAR="0.042933193790336645" WEIGHT="60.22924176017643"/>
<DICH_DATA CI_END="2.670673189911509" CI_START="1.0291843153372977" EFFECT_SIZE="1.6578947368421053" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="18" LOG_CI_END="0.4266207466878644" LOG_CI_START="0.012493158985678644" LOG_EFFECT_SIZE="0.21955695283677154" ORDER="115" O_E="0.0" SE="0.24326059498088445" STUDY_ID="STD-Zajecka-2000" TOTAL_1="57" TOTAL_2="63" VAR="0.05917571707045391" WEIGHT="39.770758239823586"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="10.811792533334406" CI_START="2.5902517009696115" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="5.292" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-002.11" LOG_CI_END="1.033897703462822" LOG_CI_START="0.4133419675681046" LOG_EFFECT_SIZE="0.7236198355154634" METHOD="MH" NO="11" P_CHI2="1.0" P_Q="0.0" P_Z="4.854867950332521E-6" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="125" TOTAL_2="126" WEIGHT="100.0" Z="4.570963522121814">
<NAME>Dry mouth</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Mood stabilizer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours divalproex</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="10.811792533334406" CI_START="2.5902517009696115" DF="0.0" EFFECT_SIZE="5.292" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="8" I2="0.0" ID="CMP-002.11.01" LOG_CI_END="1.033897703462822" LOG_CI_START="0.4133419675681046" LOG_EFFECT_SIZE="0.7236198355154634" NO="1" P_CHI2="1.0" P_Z="4.854867950332521E-6" STUDIES="1" TAU2="0.0" TOTAL_1="125" TOTAL_2="126" WEIGHT="100.0" Z="4.570963522121814">
<NAME>Olanzapine v divalproex</NAME>
<DICH_DATA CI_END="10.811792533334406" CI_START="2.5902517009696115" EFFECT_SIZE="5.292" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="8" LOG_CI_END="1.033897703462822" LOG_CI_START="0.4133419675681046" LOG_EFFECT_SIZE="0.7236198355154634" ORDER="116" O_E="0.0" SE="0.36451751106499103" STUDY_ID="STD-HGHQ-Trial-2002" TOTAL_1="125" TOTAL_2="126" VAR="0.13287301587301587" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="16.9802643006912" CI_START="1.4959484463952657" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="5.04" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-002.12" LOG_CI_END="1.229944445827747" LOG_CI_START="0.1749166270633034" LOG_EFFECT_SIZE="0.7024305364455253" METHOD="MH" NO="12" P_CHI2="1.0" P_Q="0.0" P_Z="0.009057873090883297" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="125" TOTAL_2="126" WEIGHT="100.0" Z="2.6098620881612304">
<NAME>Increased appetite</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Mood stablizer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours divalproex</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="16.9802643006912" CI_START="1.4959484463952657" DF="0.0" EFFECT_SIZE="5.04" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="3" I2="0.0" ID="CMP-002.12.01" LOG_CI_END="1.229944445827747" LOG_CI_START="0.1749166270633034" LOG_EFFECT_SIZE="0.7024305364455253" NO="1" P_CHI2="1.0" P_Z="0.009057873090883297" STUDIES="1" TAU2="0.0" TOTAL_1="125" TOTAL_2="126" WEIGHT="100.0" Z="2.6098620881612304">
<NAME>Olanzapine v divalproex</NAME>
<DICH_DATA CI_END="16.9802643006912" CI_START="1.495948446395266" EFFECT_SIZE="5.04" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="3" LOG_CI_END="1.229944445827747" LOG_CI_START="0.17491662706330346" LOG_EFFECT_SIZE="0.7024305364455253" ORDER="117" O_E="0.0" SE="0.6197285632141639" STUDY_ID="STD-HGHQ-Trial-2002" TOTAL_1="125" TOTAL_2="126" VAR="0.384063492063492" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.6526837570880033" CI_START="0.20300183444297848" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.364" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-002.13" LOG_CI_END="-0.1852971951710774" LOG_CI_START="-0.6925000375308106" LOG_EFFECT_SIZE="-0.438898616350944" METHOD="MH" NO="13" P_CHI2="1.0" P_Q="0.0" P_Z="6.937499434603863E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="125" TOTAL_2="126" WEIGHT="100.0" Z="3.392037303695545">
<NAME>Nausea</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Mood stabilizer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours divalproex</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.6526837570880033" CI_START="0.20300183444297848" DF="0.0" EFFECT_SIZE="0.364" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="36" I2="0.0" ID="CMP-002.13.01" LOG_CI_END="-0.1852971951710774" LOG_CI_START="-0.6925000375308106" LOG_EFFECT_SIZE="-0.438898616350944" NO="1" P_CHI2="1.0" P_Z="6.937499434603863E-4" STUDIES="1" TAU2="0.0" TOTAL_1="125" TOTAL_2="126" WEIGHT="100.0" Z="3.392037303695545">
<NAME>Olanzapine v divalproex</NAME>
<DICH_DATA CI_END="0.6526837570880033" CI_START="0.20300183444297848" EFFECT_SIZE="0.364" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="36" LOG_CI_END="-0.1852971951710774" LOG_CI_START="-0.6925000375308106" LOG_EFFECT_SIZE="-0.438898616350944" ORDER="118" O_E="0.0" SE="0.2979334602966689" STUDY_ID="STD-HGHQ-Trial-2002" TOTAL_1="125" TOTAL_2="126" VAR="0.08876434676434677" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.328725058657116" CI_START="0.11127494134288396" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.72" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.14" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.02043598777183496" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="122" TOTAL_2="119" UNITS="" WEIGHT="100.0" Z="2.3182454029114123">
<NAME>SAS Scale</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Mood stabilizer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours divalproex</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.328725058657116" CI_START="0.11127494134288396" DF="0.0" EFFECT_SIZE="0.72" ESTIMABLE="YES" I2="0.0" ID="CMP-002.14.01" NO="1" P_CHI2="1.0" P_Z="0.02043598777183496" STUDIES="1" TAU2="0.0" TOTAL_1="122" TOTAL_2="119" WEIGHT="100.0" Z="2.3182454029114123">
<NAME>Olanzapine v divalproex</NAME>
<CONT_DATA CI_END="1.328725058657116" CI_START="0.11127494134288396" EFFECT_SIZE="0.72" ESTIMABLE="YES" MEAN_1="0.41" MEAN_2="-0.31" ORDER="119" SD_1="2.5" SD_2="2.32" SE="0.31057971649410987" STUDY_ID="STD-HGHQ-Trial-2002" TOTAL_1="122" TOTAL_2="119" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.2669615327969802" CI_START="-0.22696153279698014" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.020000000000000018" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.15" NO="15" P_CHI2="1.0" P_Q="1.0" P_Z="0.8738845504921537" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="122" TOTAL_2="119" UNITS="" WEIGHT="100.0" Z="0.15872625686618855">
<NAME>Barnes Akathisia Scale</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Mood stabilizer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours divalproex</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.2669615327969802" CI_START="-0.22696153279698014" DF="0.0" EFFECT_SIZE="0.020000000000000018" ESTIMABLE="YES" I2="0.0" ID="CMP-002.15.01" NO="1" P_CHI2="1.0" P_Z="0.8738845504921537" STUDIES="1" TAU2="0.0" TOTAL_1="122" TOTAL_2="119" WEIGHT="100.0" Z="0.15872625686618855">
<NAME>Olanzapine v divalproex</NAME>
<CONT_DATA CI_END="0.2669615327969802" CI_START="-0.22696153279698014" EFFECT_SIZE="0.020000000000000018" ESTIMABLE="YES" MEAN_1="-0.24" MEAN_2="-0.26" ORDER="120" SD_1="0.91" SD_2="1.04" SE="0.12600309737575854" STUDY_ID="STD-HGHQ-Trial-2002" TOTAL_1="122" TOTAL_2="119" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.2748536513423666" CI_START="-0.6148536513423666" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.17" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.16" NO="16" P_CHI2="1.0" P_Q="1.0" P_Z="0.45385925388439474" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="124" TOTAL_2="123" UNITS="" WEIGHT="100.0" Z="0.7489966112818929">
<NAME>AIMS</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours divalproex</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.2748536513423666" CI_START="-0.6148536513423666" DF="0.0" EFFECT_SIZE="-0.17" ESTIMABLE="YES" I2="0.0" ID="CMP-002.16.01" NO="1" P_CHI2="1.0" P_Z="0.45385925388439474" STUDIES="1" TAU2="0.0" TOTAL_1="124" TOTAL_2="123" WEIGHT="100.0" Z="0.7489966112818929">
<NAME>Olanzapine v divalproex</NAME>
<CONT_DATA CI_END="0.2748536513423665" CI_START="-0.6148536513423666" EFFECT_SIZE="-0.17" ESTIMABLE="YES" MEAN_1="-0.27" MEAN_2="-0.1" ORDER="121" SD_1="2.08" SD_2="1.43" SE="0.22697031927694353" STUDY_ID="STD-HGHQ-Trial-2002" TOTAL_1="124" TOTAL_2="123" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.03219886035047813" CI_END="2.049769552471036" CI_START="1.0247845623008272" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.5372770573859316" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.17" NO="17" P_CHI2="0.857591949493507" P_Q="1.0" P_Z="4.124397344405688E-9" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="180" TOTAL_2="186" UNITS="" WEIGHT="100.0" Z="5.879125442092183">
<NAME>Weight change (continuous data)</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Mood stabilizer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours divalproex</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.03219886035047813" CI_END="2.049769552471036" CI_START="1.0247845623008272" DF="1.0" EFFECT_SIZE="1.5372770573859316" ESTIMABLE="YES" I2="0.0" ID="CMP-002.17.01" NO="1" P_CHI2="0.857591949493507" P_Z="4.124397344405688E-9" STUDIES="2" TAU2="0.0" TOTAL_1="180" TOTAL_2="186" WEIGHT="100.0" Z="5.879125442092183">
<NAME>Olanzapine v divalproex</NAME>
<CONT_DATA CI_END="2.194818695982372" CI_START="0.9451813040176286" EFFECT_SIZE="1.5700000000000003" ESTIMABLE="YES" MEAN_1="2.49" MEAN_2="0.92" ORDER="122" SD_1="2.51" SD_2="2.49" SE="0.31879090682832023" STUDY_ID="STD-HGHQ-Trial-2002" TOTAL_1="123" TOTAL_2="123" WEIGHT="67.27705738593123"/>
<CONT_DATA CI_END="2.365903709139098" CI_START="0.5740962908609026" EFFECT_SIZE="1.4700000000000002" ESTIMABLE="YES" MEAN_1="3.91" MEAN_2="2.44" ORDER="123" SD_1="2.51" SD_2="2.49" SE="0.45710212851147863" STUDY_ID="STD-Zajecka-2000" TOTAL_1="57" TOTAL_2="63" WEIGHT="32.72294261406878"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="220.38246177987733" CI_START="0.7157401214109045" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="12.559322033898304" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.18" LOG_CI_END="2.3431770300377903" LOG_CI_START="-0.1452446373634223" LOG_EFFECT_SIZE="1.098966196337184" METHOD="MH" NO="18" P_CHI2="1.0" P_Q="0.0" P_Z="0.08342235174991341" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="117" TOTAL_2="113" WEIGHT="100.0" Z="1.7311649333911479">
<NAME>Raised ALT/SGPT</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Mood stabilizer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours divalproex</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="220.38246177987733" CI_START="0.7157401214109045" DF="0.0" EFFECT_SIZE="12.559322033898304" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" I2="0.0" ID="CMP-002.18.01" LOG_CI_END="2.3431770300377903" LOG_CI_START="-0.1452446373634223" LOG_EFFECT_SIZE="1.098966196337184" NO="1" P_CHI2="1.0" P_Z="0.08342235174991341" STUDIES="1" TAU2="0.0" TOTAL_1="117" TOTAL_2="113" WEIGHT="100.0" Z="1.7311649333911479">
<NAME>Olanzapine v divalproex</NAME>
<DICH_DATA CI_END="220.38246177987733" CI_START="0.7157401214109045" EFFECT_SIZE="12.559322033898304" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.3431770300377903" LOG_CI_START="-0.1452446373634223" LOG_EFFECT_SIZE="1.098966196337184" ORDER="124" O_E="0.0" SE="1.4617112053173862" STUDY_ID="STD-HGHQ-Trial-2002" TOTAL_1="117" TOTAL_2="113" VAR="2.136599647750406" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.8705319664611413" CI_START="0.0030195969866574843" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.05127041742286751" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-002.19" LOG_CI_END="-0.060215276697387445" LOG_CI_START="-2.520051016695268" LOG_EFFECT_SIZE="-1.2901331466963277" METHOD="MH" NO="19" P_CHI2="1.0" P_Q="0.0" P_Z="0.03979009038525229" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="115" TOTAL_2="112" WEIGHT="100.0" Z="2.0559214273293804">
<NAME>Lowered platelet count</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Mood stabilizer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours divalproex</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8705319664611413" CI_START="0.0030195969866574843" DF="0.0" EFFECT_SIZE="0.05127041742286751" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="9" I2="0.0" ID="CMP-002.19.01" LOG_CI_END="-0.060215276697387445" LOG_CI_START="-2.520051016695268" LOG_EFFECT_SIZE="-1.2901331466963277" NO="1" P_CHI2="1.0" P_Z="0.03979009038525229" STUDIES="1" TAU2="0.0" TOTAL_1="115" TOTAL_2="112" WEIGHT="100.0" Z="2.0559214273293804">
<NAME>Olanzapine v divalproex</NAME>
<DICH_DATA CI_END="0.8705319664611413" CI_START="0.0030195969866574843" EFFECT_SIZE="0.05127041742286751" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="9" LOG_CI_END="-0.060215276697387445" LOG_CI_START="-2.520051016695268" LOG_EFFECT_SIZE="-1.2901331466963277" ORDER="125" O_E="0.0" SE="1.4449196900580463" STUDY_ID="STD-HGHQ-Trial-2002" TOTAL_1="115" TOTAL_2="112" VAR="2.0877929107174404" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="317.8565750614173" CI_START="1.1070585848676138" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="18.75862068965517" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.20" LOG_CI_END="2.5022311995115047" LOG_CI_START="0.04417060408694279" LOG_EFFECT_SIZE="1.2732009017992238" METHOD="MH" NO="20" P_CHI2="1.0" P_Q="0.0" P_Z="0.04231550032571086" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="57" TOTAL_2="63" WEIGHT="100.0" Z="2.030403902373595">
<NAME>Oedema</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Mood Stabilizer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours divalproex</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="317.8565750614173" CI_START="1.1070585848676138" DF="0.0" EFFECT_SIZE="18.75862068965517" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" I2="0.0" ID="CMP-002.20.01" LOG_CI_END="2.5022311995115047" LOG_CI_START="0.04417060408694279" LOG_EFFECT_SIZE="1.2732009017992238" NO="1" P_CHI2="1.0" P_Z="0.04231550032571086" STUDIES="1" TAU2="0.0" TOTAL_1="57" TOTAL_2="63" WEIGHT="100.0" Z="2.030403902373595">
<NAME>Olanzapine v divalproex</NAME>
<DICH_DATA CI_END="317.8565750614173" CI_START="1.1070585848676138" EFFECT_SIZE="18.75862068965517" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" LOG_CI_END="2.5022311995115047" LOG_CI_START="0.04417060408694279" LOG_EFFECT_SIZE="1.2732009017992238" ORDER="126" O_E="0.0" SE="1.4438769613485716" STUDY_ID="STD-Zajecka-2000" TOTAL_1="57" TOTAL_2="63" VAR="2.0847806795131847" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="19.962852340750096" CI_START="0.9791038894423201" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="4.421052631578948" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-002.21" LOG_CI_END="1.3002225944336088" LOG_CI_START="-0.009171224215503248" LOG_EFFECT_SIZE="0.6455256851090527" METHOD="MH" NO="21" P_CHI2="1.0" P_Q="0.0" P_Z="0.053296820707214504" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="57" TOTAL_2="63" WEIGHT="100.0" Z="1.9325081207647494">
<NAME>Rhinitis</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Mood Stabilizer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours divalproex</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="19.962852340750096" CI_START="0.9791038894423201" DF="0.0" EFFECT_SIZE="4.421052631578948" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" I2="0.0" ID="CMP-002.21.01" LOG_CI_END="1.3002225944336088" LOG_CI_START="-0.009171224215503248" LOG_EFFECT_SIZE="0.6455256851090527" NO="1" P_CHI2="1.0" P_Z="0.053296820707214504" STUDIES="1" TAU2="0.0" TOTAL_1="57" TOTAL_2="63" WEIGHT="100.0" Z="1.9325081207647494">
<NAME>Olanzapine v divalproex</NAME>
<DICH_DATA CI_END="19.962852340750096" CI_START="0.9791038894423201" EFFECT_SIZE="4.421052631578948" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="1.3002225944336088" LOG_CI_START="-0.009171224215503248" LOG_EFFECT_SIZE="0.6455256851090527" ORDER="127" O_E="0.0" SE="0.7691444106784248" STUDY_ID="STD-Zajecka-2000" TOTAL_1="57" TOTAL_2="63" VAR="0.5915831244778613" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5363795799935458" CI_START="0.6165135196641194" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9732413793103448" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-002.22" LOG_CI_END="0.18649852632764943" LOG_CI_START="-0.21005739522211028" LOG_EFFECT_SIZE="-0.011779434447230381" METHOD="MH" NO="22" P_CHI2="1.0" P_Q="0.0" P_Z="0.9073047088126077" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="125" TOTAL_2="126" WEIGHT="100.0" Z="0.11643889812360322">
<NAME>Headache</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Mood Stabilizer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours divalproex</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5363795799935458" CI_START="0.6165135196641194" DF="0.0" EFFECT_SIZE="0.9732413793103448" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="29" I2="0.0" ID="CMP-002.22.01" LOG_CI_END="0.18649852632764943" LOG_CI_START="-0.21005739522211028" LOG_EFFECT_SIZE="-0.011779434447230381" NO="1" P_CHI2="1.0" P_Z="0.9073047088126077" STUDIES="1" TAU2="0.0" TOTAL_1="125" TOTAL_2="126" WEIGHT="100.0" Z="0.11643889812360322">
<NAME>Olanzapine v divalproex</NAME>
<DICH_DATA CI_END="1.5363795799935458" CI_START="0.6165135196641194" EFFECT_SIZE="0.9732413793103448" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="29" LOG_CI_END="0.18649852632764943" LOG_CI_START="-0.21005739522211028" LOG_EFFECT_SIZE="-0.011779434447230381" ORDER="128" O_E="0.0" SE="0.2329389113017991" STUDY_ID="STD-HGHQ-Trial-2002" TOTAL_1="125" TOTAL_2="126" VAR="0.05426053639846743" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.1550902827596228" CI_START="0.6525559352513495" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1858823529411764" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-002.23" LOG_CI_END="0.3334654686884024" LOG_CI_START="-0.1853822558979749" LOG_EFFECT_SIZE="0.07404160639521372" METHOD="MH" NO="23" P_CHI2="1.0" P_Q="0.0" P_Z="0.5758961985339097" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="125" TOTAL_2="126" WEIGHT="100.0" Z="0.5593891040296938">
<NAME>Asthenia</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Mood Stabilizer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours divalproex</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1550902827596228" CI_START="0.6525559352513495" DF="0.0" EFFECT_SIZE="1.1858823529411764" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="17" I2="0.0" ID="CMP-002.23.01" LOG_CI_END="0.3334654686884024" LOG_CI_START="-0.1853822558979749" LOG_EFFECT_SIZE="0.07404160639521372" NO="1" P_CHI2="1.0" P_Z="0.5758961985339097" STUDIES="1" TAU2="0.0" TOTAL_1="125" TOTAL_2="126" WEIGHT="100.0" Z="0.5593891040296938">
<NAME>Olanzapine v divalproex</NAME>
<DICH_DATA CI_END="2.1550902827596228" CI_START="0.6525559352513495" EFFECT_SIZE="1.1858823529411764" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="17" LOG_CI_END="0.3334654686884024" LOG_CI_START="-0.1853822558979749" LOG_EFFECT_SIZE="0.07404160639521372" ORDER="129" O_E="0.0" SE="0.3047737217596963" STUDY_ID="STD-HGHQ-Trial-2002" TOTAL_1="125" TOTAL_2="126" VAR="0.09288702147525676" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.503535424755323" CI_START="0.7215140565372817" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.344" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-002.24" LOG_CI_END="0.39855374099832425" LOG_CI_START="-0.1417552035627114" LOG_EFFECT_SIZE="0.12839926871780646" METHOD="MH" NO="24" P_CHI2="1.0" P_Q="0.0" P_Z="0.35157767275961704" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="125" TOTAL_2="126" WEIGHT="100.0" Z="0.9315335045309534">
<NAME>Dizziness</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Mood Stabilizer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours divalproex</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.503535424755323" CI_START="0.7215140565372817" DF="0.0" EFFECT_SIZE="1.344" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="15" I2="0.0" ID="CMP-002.24.01" LOG_CI_END="0.39855374099832425" LOG_CI_START="-0.1417552035627114" LOG_EFFECT_SIZE="0.12839926871780646" NO="1" P_CHI2="1.0" P_Z="0.35157767275961704" STUDIES="1" TAU2="0.0" TOTAL_1="125" TOTAL_2="126" WEIGHT="100.0" Z="0.9315335045309534">
<NAME>Olanzapine v divalproex</NAME>
<DICH_DATA CI_END="2.503535424755323" CI_START="0.7215140565372817" EFFECT_SIZE="1.344" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="15" LOG_CI_END="0.39855374099832425" LOG_CI_START="-0.1417552035627114" LOG_EFFECT_SIZE="0.12839926871780646" ORDER="130" O_E="0.0" SE="0.3173801486075629" STUDY_ID="STD-HGHQ-Trial-2002" TOTAL_1="125" TOTAL_2="126" VAR="0.10073015873015873" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.291638781306425" CI_START="0.6384654387660051" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2096" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-002.25" LOG_CI_END="0.3601461631869606" LOG_CI_START="-0.19486260687269794" LOG_EFFECT_SIZE="0.08264177815713131" METHOD="MH" NO="25" P_CHI2="1.0" P_Q="0.0" P_Z="0.5594328414033022" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="125" TOTAL_2="126" WEIGHT="100.0" Z="0.583684141743978">
<NAME>Constipation</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Mood Stabilizer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours divalproex</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.291638781306425" CI_START="0.6384654387660051" DF="0.0" EFFECT_SIZE="1.2096" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" I2="0.0" ID="CMP-002.25.01" LOG_CI_END="0.3601461631869606" LOG_CI_START="-0.19486260687269794" LOG_EFFECT_SIZE="0.08264177815713131" NO="1" P_CHI2="1.0" P_Z="0.5594328414033022" STUDIES="1" TAU2="0.0" TOTAL_1="125" TOTAL_2="126" WEIGHT="100.0" Z="0.583684141743978">
<NAME>Olanzapine v divalproex</NAME>
<DICH_DATA CI_END="2.291638781306425" CI_START="0.6384654387660051" EFFECT_SIZE="1.2096" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.3601461631869606" LOG_CI_START="-0.19486260687269794" LOG_EFFECT_SIZE="0.08264177815713131" ORDER="131" O_E="0.0" SE="0.32601489887076374" STUDY_ID="STD-HGHQ-Trial-2002" TOTAL_1="125" TOTAL_2="126" VAR="0.10628571428571429" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.490334991582416" CI_START="0.6744538408195171" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.296" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-002.26" LOG_CI_END="0.39625777087493697" LOG_CI_START="-0.17104776780578787" LOG_EFFECT_SIZE="0.11260500153457456" METHOD="MH" NO="26" P_CHI2="1.0" P_Q="0.0" P_Z="0.43652767665241343" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="125" TOTAL_2="126" WEIGHT="100.0" Z="0.7780701313090932">
<NAME>Dyspepsia</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Mood Stabilizer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours divalproex</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.490334991582416" CI_START="0.6744538408195171" DF="0.0" EFFECT_SIZE="1.296" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="14" I2="0.0" ID="CMP-002.26.01" LOG_CI_END="0.39625777087493697" LOG_CI_START="-0.17104776780578787" LOG_EFFECT_SIZE="0.11260500153457456" NO="1" P_CHI2="1.0" P_Z="0.43652767665241343" STUDIES="1" TAU2="0.0" TOTAL_1="125" TOTAL_2="126" WEIGHT="100.0" Z="0.7780701313090932">
<NAME>Olanzapine v divalproex</NAME>
<DICH_DATA CI_END="2.490334991582416" CI_START="0.6744538408195171" EFFECT_SIZE="1.296" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="14" LOG_CI_END="0.39625777087493697" LOG_CI_START="-0.17104776780578787" LOG_EFFECT_SIZE="0.11260500153457456" ORDER="132" O_E="0.0" SE="0.3332380816287644" STUDY_ID="STD-HGHQ-Trial-2002" TOTAL_1="125" TOTAL_2="126" VAR="0.11104761904761903" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.4134985356836464E-31" CI_END="1.7607844734869897" CI_START="0.514716033476369" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9520000000000001" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="18" I2="100.0" I2_Q="0.0" ID="CMP-002.27" LOG_CI_END="0.24570619997427068" LOG_CI_START="-0.2884323032053219" LOG_EFFECT_SIZE="-0.02136305161552562" METHOD="MH" NO="27" P_CHI2="0.0" P_Q="0.0" P_Z="0.8754191371942381" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="125" TOTAL_2="126" WEIGHT="100.0" Z="0.15677885610961947">
<NAME>Pain</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Mood Stabilizer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours divalproex</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.4134985356836464E-31" CI_END="1.7607844734869897" CI_START="0.514716033476369" DF="0.0" EFFECT_SIZE="0.9520000000000001" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="18" I2="100.0" ID="CMP-002.27.01" LOG_CI_END="0.24570619997427068" LOG_CI_START="-0.2884323032053219" LOG_EFFECT_SIZE="-0.02136305161552562" NO="1" P_CHI2="0.0" P_Z="0.8754191371942381" STUDIES="1" TAU2="0.0" TOTAL_1="125" TOTAL_2="126" WEIGHT="100.0" Z="0.15677885610961947">
<NAME>Olanzapine v divalproex</NAME>
<DICH_DATA CI_END="1.7607844734869893" CI_START="0.514716033476369" EFFECT_SIZE="0.952" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="18" LOG_CI_END="0.2457061999742706" LOG_CI_START="-0.2884323032053219" LOG_EFFECT_SIZE="-0.021363051615525673" ORDER="133" O_E="0.0" SE="0.31375560079592574" STUDY_ID="STD-HGHQ-Trial-2002" TOTAL_1="125" TOTAL_2="126" VAR="0.09844257703081233" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8022303912313395" CI_END="3.3686391946666956" CI_START="1.0720425545199348" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9003485384282697" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-002.28" LOG_CI_END="0.5274544974291422" LOG_CI_START="0.030212024933597474" LOG_EFFECT_SIZE="0.27883326118136986" METHOD="MH" NO="28" P_CHI2="0.3704274077212142" P_Q="0.0" P_Z="0.027939455927453918" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="182" TOTAL_2="189" WEIGHT="100.0" Z="2.198135436277447">
<NAME>Weight Gain (dichotomous data)</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Mood Stabilizer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours divalproex</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.8022303912313395" CI_END="3.3686391946666956" CI_START="1.0720425545199348" DF="1.0" EFFECT_SIZE="1.9003485384282697" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="16" I2="0.0" ID="CMP-002.28.01" LOG_CI_END="0.5274544974291422" LOG_CI_START="0.030212024933597474" LOG_EFFECT_SIZE="0.27883326118136986" NO="1" P_CHI2="0.3704274077212142" P_Z="0.027939455927453918" STUDIES="2" TAU2="0.0" TOTAL_1="182" TOTAL_2="189" WEIGHT="100.0" Z="2.198135436277447">
<NAME>Olanzapine v divalproex</NAME>
<DICH_DATA CI_END="3.23610143526659" CI_START="0.706450043588225" EFFECT_SIZE="1.512" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="10" LOG_CI_END="0.5100221260694462" LOG_CI_START="-0.15091854373907068" LOG_EFFECT_SIZE="0.1795517911651877" ORDER="134" O_E="0.0" SE="0.3882398211546038" STUDY_ID="STD-HGHQ-Trial-2002" TOTAL_1="125" TOTAL_2="126" VAR="0.15073015873015874" WEIGHT="63.60190296893683"/>
<DICH_DATA CI_END="6.259475055405541" CI_START="1.0625442980785182" EFFECT_SIZE="2.5789473684210527" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" LOG_CI_END="0.7965379130666452" LOG_CI_START="0.026347045084724345" LOG_EFFECT_SIZE="0.4114424790756847" ORDER="135" O_E="0.0" SE="0.45241392835886407" STUDY_ID="STD-Zajecka-2000" TOTAL_1="57" TOTAL_2="63" VAR="0.2046783625730994" WEIGHT="36.398097031063166"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.0263242116093747" CI_START="0.5014320976765154" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.008" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-002.29" LOG_CI_END="0.30670893364423385" LOG_CI_START="-0.2997878694252209" LOG_EFFECT_SIZE="0.0034605321095064895" METHOD="MH" NO="29" P_CHI2="1.0" P_Q="0.0" P_Z="0.9821558318260976" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="125" TOTAL_2="126" WEIGHT="100.0" Z="0.02236621287252002">
<NAME>Agitation</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Mood Stabilizer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours divalproex</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0263242116093747" CI_START="0.5014320976765154" DF="0.0" EFFECT_SIZE="1.008" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" I2="0.0" ID="CMP-002.29.01" LOG_CI_END="0.30670893364423385" LOG_CI_START="-0.2997878694252209" LOG_EFFECT_SIZE="0.0034605321095064895" NO="1" P_CHI2="1.0" P_Z="0.9821558318260976" STUDIES="1" TAU2="0.0" TOTAL_1="125" TOTAL_2="126" WEIGHT="100.0" Z="0.02236621287252002">
<NAME>Olanzapine v divalproex</NAME>
<DICH_DATA CI_END="2.0263242116093743" CI_START="0.5014320976765155" EFFECT_SIZE="1.008" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="0.30670893364423374" LOG_CI_START="-0.2997878694252208" LOG_EFFECT_SIZE="0.0034605321095064895" ORDER="136" O_E="0.0" SE="0.35625922433059176" STUDY_ID="STD-HGHQ-Trial-2002" TOTAL_1="125" TOTAL_2="126" VAR="0.1269206349206349" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1904226346898001" CI_START="0.32709055477718085" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.624" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-002.30" LOG_CI_END="0.07570117595333596" LOG_CI_START="-0.48533199658848797" LOG_EFFECT_SIZE="-0.204815410317576" METHOD="MH" NO="30" P_CHI2="1.0" P_Q="0.0" P_Z="0.1524183713800371" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="125" TOTAL_2="126" WEIGHT="100.0" Z="1.4310413264246562">
<NAME>Nervouseness</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Mood Stabilizer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours divalproex</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1904226346898001" CI_START="0.32709055477718085" DF="0.0" EFFECT_SIZE="0.624" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="21" I2="0.0" ID="CMP-002.30.01" LOG_CI_END="0.07570117595333596" LOG_CI_START="-0.48533199658848797" LOG_EFFECT_SIZE="-0.204815410317576" NO="1" P_CHI2="1.0" P_Z="0.1524183713800371" STUDIES="1" TAU2="0.0" TOTAL_1="125" TOTAL_2="126" WEIGHT="100.0" Z="1.4310413264246562">
<NAME>Olanzapine v divalproex</NAME>
<DICH_DATA CI_END="1.1904226346898001" CI_START="0.32709055477718085" EFFECT_SIZE="0.624" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="21" LOG_CI_END="0.07570117595333596" LOG_CI_START="-0.48533199658848797" LOG_EFFECT_SIZE="-0.204815410317576" ORDER="137" O_E="0.0" SE="0.3295536627100609" STUDY_ID="STD-HGHQ-Trial-2002" TOTAL_1="125" TOTAL_2="126" VAR="0.1086056166056166" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="9.12287158924358" CI_START="1.0023791204933772" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.024" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-002.31" LOG_CI_END="0.960131561910225" LOG_CI_START="0.0010320117481127681" LOG_EFFECT_SIZE="0.4805817868291689" METHOD="MH" NO="31" P_CHI2="1.0" P_Q="0.0" P_Z="0.04950899974806227" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="125" TOTAL_2="126" WEIGHT="100.0" Z="1.9641819113602292">
<NAME>Tremor</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Mood Stabilizer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours divalproex</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.12287158924358" CI_START="1.0023791204933772" DF="0.0" EFFECT_SIZE="3.024" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" I2="0.0" ID="CMP-002.31.01" LOG_CI_END="0.960131561910225" LOG_CI_START="0.0010320117481127681" LOG_EFFECT_SIZE="0.4805817868291689" NO="1" P_CHI2="1.0" P_Z="0.04950899974806227" STUDIES="1" TAU2="0.0" TOTAL_1="125" TOTAL_2="126" WEIGHT="100.0" Z="1.9641819113602292">
<NAME>Olanzapine v divalproex</NAME>
<DICH_DATA CI_END="9.12287158924358" CI_START="1.0023791204933774" EFFECT_SIZE="3.024" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" LOG_CI_END="0.960131561910225" LOG_CI_START="0.0010320117481128642" LOG_EFFECT_SIZE="0.4805817868291689" ORDER="138" O_E="0.0" SE="0.5633798233845665" STUDY_ID="STD-HGHQ-Trial-2002" TOTAL_1="125" TOTAL_2="126" VAR="0.31739682539682534" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1647825767062365" CI_START="0.2692347964946349" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.56" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-002.32" LOG_CI_END="0.06624486566321701" LOG_CI_START="-0.5698688116508162" LOG_EFFECT_SIZE="-0.25181197299379954" METHOD="MH" NO="32" P_CHI2="1.0" P_Q="0.0" P_Z="0.12072378592380259" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="125" TOTAL_2="126" WEIGHT="100.0" Z="1.5517427640536978">
<NAME>Vomiting</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Mood Stabilizer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours divalproex</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1647825767062365" CI_START="0.2692347964946349" DF="0.0" EFFECT_SIZE="0.56" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="18" I2="0.0" ID="CMP-002.32.01" LOG_CI_END="0.06624486566321701" LOG_CI_START="-0.5698688116508162" LOG_EFFECT_SIZE="-0.25181197299379954" NO="1" P_CHI2="1.0" P_Z="0.12072378592380259" STUDIES="1" TAU2="0.0" TOTAL_1="125" TOTAL_2="126" WEIGHT="100.0" Z="1.5517427640536978">
<NAME>Olanzapine v divalproex</NAME>
<DICH_DATA CI_END="1.1647825767062365" CI_START="0.2692347964946349" EFFECT_SIZE="0.56" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="18" LOG_CI_END="0.06624486566321701" LOG_CI_START="-0.5698688116508162" LOG_EFFECT_SIZE="-0.25181197299379954" ORDER="139" O_E="0.0" SE="0.3736563228677492" STUDY_ID="STD-HGHQ-Trial-2002" TOTAL_1="125" TOTAL_2="126" VAR="0.13961904761904761" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.774719791737043E-5" CI_END="53.251243423259005" CI_START="1.8898791824020618" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="10.031870034178171" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.33" LOG_CI_END="1.7263297530601713" LOG_CI_START="0.27643404116094283" LOG_EFFECT_SIZE="1.0013818971105573" METHOD="MH" NO="33" P_CHI2="0.9934327911754874" P_Q="0.0" P_Z="0.006782697506725103" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="182" TOTAL_2="189" WEIGHT="100.0" Z="2.707329136846908">
<NAME>Speech Disorder</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Mood Stabilizer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours divalproex</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.774719791737043E-5" CI_END="53.251243423259005" CI_START="1.8898791824020618" DF="1.0" EFFECT_SIZE="10.031870034178171" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="1" I2="0.0" ID="CMP-002.33.01" LOG_CI_END="1.7263297530601713" LOG_CI_START="0.27643404116094283" LOG_EFFECT_SIZE="1.0013818971105573" NO="1" P_CHI2="0.9934327911754874" P_Z="0.006782697506725103" STUDIES="2" TAU2="0.0" TOTAL_1="182" TOTAL_2="189" WEIGHT="100.0" Z="2.707329136846908">
<NAME>Olanzapine v divalproex</NAME>
<DICH_DATA CI_END="77.57427086168705" CI_START="1.3097951017955634" EFFECT_SIZE="10.08" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" LOG_CI_END="1.8897177022422293" LOG_CI_START="0.11720336197678365" LOG_EFFECT_SIZE="1.0034605321095065" ORDER="140" O_E="0.0" SE="1.0411836975594135" STUDY_ID="STD-HGHQ-Trial-2002" TOTAL_1="125" TOTAL_2="126" VAR="1.0840634920634922" WEIGHT="67.69053220293844"/>
<DICH_DATA CI_END="180.498032284562" CI_START="0.5464073189576606" EFFECT_SIZE="9.931034482758621" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.2564724717673568" LOG_CI_START="-0.2624834920468073" LOG_EFFECT_SIZE="0.9969944898602747" ORDER="141" O_E="0.0" SE="1.4796472021775589" STUDY_ID="STD-Zajecka-2000" TOTAL_1="57" TOTAL_2="63" VAR="2.1893558429118776" WEIGHT="32.309467797061565"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="20.575683370343125" CI_START="0.999981173391126" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="4.536" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-002.34" LOG_CI_END="1.313354268139014" LOG_CI_START="-8.176369313814737E-6" LOG_EFFECT_SIZE="0.6566730458848501" METHOD="MH" NO="34" P_CHI2="1.0" P_Q="0.0" P_Z="0.05000285261096424" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="125" TOTAL_2="126" WEIGHT="100.0" Z="1.9599395809347187">
<NAME>Neck Rigidity</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Mood Stabilizer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours divalproex</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="20.575683370343125" CI_START="0.999981173391126" DF="0.0" EFFECT_SIZE="4.536" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" I2="0.0" ID="CMP-002.34.01" LOG_CI_END="1.313354268139014" LOG_CI_START="-8.176369313814737E-6" LOG_EFFECT_SIZE="0.6566730458848501" NO="1" P_CHI2="1.0" P_Z="0.05000285261096424" STUDIES="1" TAU2="0.0" TOTAL_1="125" TOTAL_2="126" WEIGHT="100.0" Z="1.9599395809347187">
<NAME>Olanzapine v divalproex</NAME>
<DICH_DATA CI_END="20.575683370343125" CI_START="0.9999811733911258" EFFECT_SIZE="4.536" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="1.313354268139014" LOG_CI_START="-8.17636931391117E-6" LOG_EFFECT_SIZE="0.6566730458848501" ORDER="142" O_E="0.0" SE="0.771475601153143" STUDY_ID="STD-HGHQ-Trial-2002" TOTAL_1="125" TOTAL_2="126" VAR="0.5951746031746032" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.341813283580656E-32" CI_END="1.0589442045653883" CI_START="0.21248590042108684" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.47435294117647053" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="17" I2="100.0" I2_Q="0.0" ID="CMP-002.35" LOG_CI_END="0.02487307787166346" LOG_CI_START="-0.6726698824253113" LOG_EFFECT_SIZE="-0.3238984022768239" METHOD="MH" NO="35" P_CHI2="0.0" P_Q="0.0" P_Z="0.0687305806153895" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="125" TOTAL_2="126" WEIGHT="100.0" Z="1.820186681670091">
<NAME>Diarrhoea</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Mood Stabilizer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours divalproex</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.341813283580656E-32" CI_END="1.0589442045653883" CI_START="0.21248590042108684" DF="0.0" EFFECT_SIZE="0.47435294117647053" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="17" I2="100.0" ID="CMP-002.35.01" LOG_CI_END="0.02487307787166346" LOG_CI_START="-0.6726698824253113" LOG_EFFECT_SIZE="-0.3238984022768239" NO="1" P_CHI2="0.0" P_Z="0.0687305806153895" STUDIES="1" TAU2="0.0" TOTAL_1="125" TOTAL_2="126" WEIGHT="100.0" Z="1.820186681670091">
<NAME>Olanzapine v divalproex</NAME>
<DICH_DATA CI_END="1.0589442045653883" CI_START="0.21248590042108687" EFFECT_SIZE="0.4743529411764706" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="17" LOG_CI_END="0.02487307787166346" LOG_CI_START="-0.6726698824253112" LOG_EFFECT_SIZE="-0.32389840227682387" ORDER="143" O_E="0.0" SE="0.40974018777178395" STUDY_ID="STD-HGHQ-Trial-2002" TOTAL_1="125" TOTAL_2="126" VAR="0.16788702147525678" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="56.51509903495644" CI_START="0.8809528223458479" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="7.056" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.36" LOG_CI_END="1.7521644929790439" LOG_CI_START="-0.05504734873151738" LOG_EFFECT_SIZE="0.8485585721237633" METHOD="MH" NO="36" P_CHI2="1.0" P_Q="0.0" P_Z="0.06568552413044638" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="125" TOTAL_2="126" WEIGHT="100.0" Z="1.8405636813015918">
<NAME>Sleep disorder</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Mood Stabilizer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours divalproex</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="56.51509903495644" CI_START="0.8809528223458479" DF="0.0" EFFECT_SIZE="7.056" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" I2="0.0" ID="CMP-002.36.01" LOG_CI_END="1.7521644929790439" LOG_CI_START="-0.05504734873151738" LOG_EFFECT_SIZE="0.8485585721237633" NO="1" P_CHI2="1.0" P_Z="0.06568552413044638" STUDIES="1" TAU2="0.0" TOTAL_1="125" TOTAL_2="126" WEIGHT="100.0" Z="1.8405636813015918">
<NAME>Olanzapine v divalproex</NAME>
<DICH_DATA CI_END="56.51509903495644" CI_START="0.8809528223458484" EFFECT_SIZE="7.056" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.7521644929790439" LOG_CI_START="-0.055047348731517155" LOG_EFFECT_SIZE="0.8485585721237633" ORDER="144" O_E="0.0" SE="1.0615651816636766" STUDY_ID="STD-HGHQ-Trial-2002" TOTAL_1="125" TOTAL_2="126" VAR="1.1269206349206349" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="230.1470439113463" CI_START="0.7460151638854723" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="13.103174603174603" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.37" LOG_CI_END="2.3620054010364884" LOG_CI_START="-0.12725234474602648" LOG_EFFECT_SIZE="1.1173765281452308" METHOD="MH" NO="37" P_CHI2="1.0" P_Q="0.0" P_Z="0.0784799066180633" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="125" TOTAL_2="126" WEIGHT="100.0" Z="1.759574922320157">
<NAME>Tongue Oedema</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Mood Stabilizer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours divalproex</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="230.1470439113463" CI_START="0.7460151638854723" DF="0.0" EFFECT_SIZE="13.103174603174603" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" I2="0.0" ID="CMP-002.37.01" LOG_CI_END="2.3620054010364884" LOG_CI_START="-0.12725234474602648" LOG_EFFECT_SIZE="1.1173765281452308" NO="1" P_CHI2="1.0" P_Z="0.0784799066180633" STUDIES="1" TAU2="0.0" TOTAL_1="125" TOTAL_2="126" WEIGHT="100.0" Z="1.759574922320157">
<NAME>Olanzapine v divalproex</NAME>
<DICH_DATA CI_END="230.1470439113463" CI_START="0.7460151638854723" EFFECT_SIZE="13.103174603174603" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.3620054010364884" LOG_CI_START="-0.12725234474602648" LOG_EFFECT_SIZE="1.1173765281452308" ORDER="145" O_E="0.0" SE="1.4622023218972175" STUDY_ID="STD-HGHQ-Trial-2002" TOTAL_1="125" TOTAL_2="126" VAR="2.1380356301616144" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Olanzapine v other antipsychotic</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3790948813119561" CI_START="0.7662179179436804" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0279529213955443" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="61" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.13959414653313096" LOG_CI_START="-0.11564769629306121" LOG_EFFECT_SIZE="0.011973225120034873" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.8541066423289151" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="234" TOTAL_2="219" WEIGHT="100.0" Z="0.18388121441388133">
<NAME>Failure to respond - (at least 50% reduction in YMRS)</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Haloperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours haloperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3790948813119561" CI_START="0.7662179179436804" DF="0.0" EFFECT_SIZE="1.0279529213955443" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="61" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="0.13959414653313096" LOG_CI_START="-0.11564769629306121" LOG_EFFECT_SIZE="0.011973225120034873" NO="1" P_CHI2="1.0" P_Z="0.8541066423289151" STUDIES="1" TAU2="0.0" TOTAL_1="234" TOTAL_2="219" WEIGHT="100.0" Z="0.18388121441388133">
<NAME>Olanzapine v. haloperidol</NAME>
<DICH_DATA CI_END="1.3790948813119561" CI_START="0.7662179179436804" EFFECT_SIZE="1.0279529213955443" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="61" LOG_CI_END="0.13959414653313096" LOG_CI_START="-0.11564769629306121" LOG_EFFECT_SIZE="0.011973225120034873" ORDER="146" O_E="0.0" SE="0.1499303219436042" STUDY_ID="STD-HGHD-Trial-2002" TOTAL_1="234" TOTAL_2="219" VAR="0.022479101438112804" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.064960402265152" CI_START="0.7409605492943635" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.888309430682312" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="118" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.027333459983723368" LOG_CI_START="-0.1302049143956599" LOG_EFFECT_SIZE="-0.051435727205968264" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.200600472658105" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="234" TOTAL_2="219" WEIGHT="100.0" Z="1.279842746117836">
<NAME>Failure to achieve remission - YMRS &lt;=12 and HAMD-21 &lt;= 8</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>haloperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours haloperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.064960402265152" CI_START="0.7409605492943635" DF="0.0" EFFECT_SIZE="0.888309430682312" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="118" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="0.027333459983723368" LOG_CI_START="-0.1302049143956599" LOG_EFFECT_SIZE="-0.051435727205968264" NO="1" P_CHI2="1.0" P_Z="0.200600472658105" STUDIES="1" TAU2="0.0" TOTAL_1="234" TOTAL_2="219" WEIGHT="100.0" Z="1.279842746117836">
<NAME>Olanzapine v. haloperidol</NAME>
<DICH_DATA CI_END="1.064960402265152" CI_START="0.7409605492943635" EFFECT_SIZE="0.888309430682312" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="118" LOG_CI_END="0.027333459983723368" LOG_CI_START="-0.1302049143956599" LOG_EFFECT_SIZE="-0.051435727205968264" ORDER="147" O_E="0.0" SE="0.09253882093797984" STUDY_ID="STD-HGHD-Trial-2002" TOTAL_1="234" TOTAL_2="219" VAR="0.008563433380591496" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4607848314536003" CI_START="0.7881040612262409" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0729634002361275" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="55" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.16458625057206783" LOG_CI_START="-0.10341643449959442" LOG_EFFECT_SIZE="0.03058490803623672" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.6546233547970127" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="231" TOTAL_2="213" WEIGHT="100.0" Z="0.4473486391038555">
<NAME>Failure to respond - excluding withdrawals (at least 50% reduction in YMRS)</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>haloperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours haloperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4607848314536003" CI_START="0.7881040612262409" DF="0.0" EFFECT_SIZE="1.0729634002361275" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="55" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="0.16458625057206783" LOG_CI_START="-0.10341643449959442" LOG_EFFECT_SIZE="0.03058490803623672" NO="1" P_CHI2="1.0" P_Z="0.6546233547970127" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="213" WEIGHT="100.0" Z="0.4473486391038555">
<NAME>Olanzapine v. haloperidol</NAME>
<DICH_DATA CI_END="1.4607848314536003" CI_START="0.7881040612262409" EFFECT_SIZE="1.0729634002361275" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="55" LOG_CI_END="0.16458625057206783" LOG_CI_START="-0.10341643449959442" LOG_EFFECT_SIZE="0.03058490803623672" ORDER="148" O_E="0.0" SE="0.15742610384578118" STUDY_ID="STD-HGHD-Trial-2002" TOTAL_1="231" TOTAL_2="213" VAR="0.02478297817206268" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.0306431406438533E-30" CI_END="1.0665989879131665" CI_START="0.6241428038931383" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8159105851413543" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="78" I2="100.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.028001167248662147" LOG_CI_START="-0.20471603235719932" LOG_EFFECT_SIZE="-0.08835743255426863" METHOD="MH" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.13666979802860404" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="234" TOTAL_2="219" WEIGHT="100.0" Z="1.488307575598994">
<NAME>Failure to complete treatment (acute phase)</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>haloperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours haloperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.0306431406438533E-30" CI_END="1.0665989879131665" CI_START="0.6241428038931383" DF="0.0" EFFECT_SIZE="0.8159105851413543" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="78" I2="100.0" ID="CMP-003.04.01" LOG_CI_END="0.028001167248662147" LOG_CI_START="-0.20471603235719932" LOG_EFFECT_SIZE="-0.08835743255426863" NO="1" P_CHI2="0.0" P_Z="0.13666979802860404" STUDIES="1" TAU2="0.0" TOTAL_1="234" TOTAL_2="219" WEIGHT="100.0" Z="1.488307575598994">
<NAME>Olanzapine v. haloperidol</NAME>
<DICH_DATA CI_END="1.0665989879131665" CI_START="0.6241428038931383" EFFECT_SIZE="0.8159105851413544" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="78" LOG_CI_END="0.028001167248662147" LOG_CI_START="-0.20471603235719932" LOG_EFFECT_SIZE="-0.08835743255426858" ORDER="149" O_E="0.0" SE="0.1366992350171998" STUDY_ID="STD-HGHD-Trial-2002" TOTAL_1="234" TOTAL_2="219" VAR="0.018686680854287624" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9497349331021073" CI_START="0.1550896353928187" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3837890625" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="-0.02239758750476904" LOG_CI_START="-0.8094172250240015" LOG_EFFECT_SIZE="-0.41590740626438527" METHOD="MH" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.0383102090283157" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="128" TOTAL_2="131" WEIGHT="100.0" Z="2.0715201967542862">
<NAME>Treatment emergent depression</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Haloperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours haloperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9497349331021073" CI_START="0.1550896353928187" DF="0.0" EFFECT_SIZE="0.3837890625" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="16" I2="0.0" ID="CMP-003.05.01" LOG_CI_END="-0.02239758750476904" LOG_CI_START="-0.8094172250240015" LOG_EFFECT_SIZE="-0.41590740626438527" NO="1" P_CHI2="1.0" P_Z="0.0383102090283157" STUDIES="1" TAU2="0.0" TOTAL_1="128" TOTAL_2="131" WEIGHT="100.0" Z="2.0715201967542862">
<NAME>Olanzapine v. haloperidol</NAME>
<DICH_DATA CI_END="0.9497349331021072" CI_START="0.15508963539281873" EFFECT_SIZE="0.3837890625" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="16" LOG_CI_END="-0.022397587504769088" LOG_CI_START="-0.8094172250240015" LOG_EFFECT_SIZE="-0.41590740626438527" ORDER="150" O_E="0.0" SE="0.4622992308888336" STUDY_ID="STD-HGHD-Trial-2002" TOTAL_1="128" TOTAL_2="131" VAR="0.2137205788804071" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2829646748338916" CI_START="0.4741102275871749" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7799145299145299" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="0.1082146986696143" LOG_CI_START="-0.32412067590491295" LOG_EFFECT_SIZE="-0.10795298861764932" METHOD="MH" NO="6" P_CHI2="1.0" P_Q="0.0" P_Z="0.3276810230553784" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="234" TOTAL_2="219" WEIGHT="100.0" Z="0.9787955469629591">
<NAME>Insomnia</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Haloperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours haloperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2829646748338916" CI_START="0.4741102275871749" DF="0.0" EFFECT_SIZE="0.7799145299145299" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="30" I2="0.0" ID="CMP-003.06.01" LOG_CI_END="0.1082146986696143" LOG_CI_START="-0.32412067590491295" LOG_EFFECT_SIZE="-0.10795298861764932" NO="1" P_CHI2="1.0" P_Z="0.3276810230553784" STUDIES="1" TAU2="0.0" TOTAL_1="234" TOTAL_2="219" WEIGHT="100.0" Z="0.9787955469629591">
<NAME>Olanzapine v. haloperidol</NAME>
<DICH_DATA CI_END="1.2829646748338916" CI_START="0.4741102275871749" EFFECT_SIZE="0.7799145299145299" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="30" LOG_CI_END="0.1082146986696143" LOG_CI_START="-0.32412067590491295" LOG_EFFECT_SIZE="-0.10795298861764932" ORDER="151" O_E="0.0" SE="0.25395593911969644" STUDY_ID="STD-HGHD-Trial-2002" TOTAL_1="234" TOTAL_2="219" VAR="0.06449361901416696" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.77868563366478" CI_START="0.8069693958046944" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4974358974358974" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-003.07" LOG_CI_END="0.4438394156915829" LOG_CI_START="-0.09314293551978231" LOG_EFFECT_SIZE="0.17534824008590028" METHOD="MH" NO="7" P_CHI2="1.0" P_Q="0.0" P_Z="0.20053527186490908" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="234" TOTAL_2="219" WEIGHT="100.0" Z="1.280028047646469">
<NAME>Somnolence</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Haloperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours haloperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.77868563366478" CI_START="0.8069693958046944" DF="0.0" EFFECT_SIZE="1.4974358974358974" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="15" I2="0.0" ID="CMP-003.07.01" LOG_CI_END="0.4438394156915829" LOG_CI_START="-0.09314293551978231" LOG_EFFECT_SIZE="0.17534824008590028" NO="1" P_CHI2="1.0" P_Z="0.20053527186490908" STUDIES="1" TAU2="0.0" TOTAL_1="234" TOTAL_2="219" WEIGHT="100.0" Z="1.280028047646469">
<NAME>Olanzapine v. haloperidol</NAME>
<DICH_DATA CI_END="2.77868563366478" CI_START="0.8069693958046944" EFFECT_SIZE="1.4974358974358974" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="15" LOG_CI_END="0.4438394156915829" LOG_CI_START="-0.09314293551978231" LOG_EFFECT_SIZE="0.17534824008590028" ORDER="152" O_E="0.0" SE="0.31542609120706383" STUDY_ID="STD-HGHD-Trial-2002" TOTAL_1="234" TOTAL_2="219" VAR="0.09949361901416696" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="8.643982140932252" CI_START="1.489003865509515" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.5876068376068377" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-003.08" LOG_CI_END="0.9367138609295532" LOG_CI_START="0.17289582519829638" LOG_EFFECT_SIZE="0.5548048430639247" METHOD="MH" NO="8" P_CHI2="1.0" P_Q="0.0" P_Z="0.004409615512891651" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="234" TOTAL_2="219" WEIGHT="100.0" Z="2.847268485386437">
<NAME>Weight Gain (dichotomous data)</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Haloperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours haloperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.643982140932252" CI_START="1.489003865509515" DF="0.0" EFFECT_SIZE="3.5876068376068377" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="6" I2="0.0" ID="CMP-003.08.01" LOG_CI_END="0.9367138609295532" LOG_CI_START="0.17289582519829638" LOG_EFFECT_SIZE="0.5548048430639247" NO="1" P_CHI2="1.0" P_Z="0.004409615512891651" STUDIES="1" TAU2="0.0" TOTAL_1="234" TOTAL_2="219" WEIGHT="100.0" Z="2.847268485386437">
<NAME>Olanzapine v. haloperidol</NAME>
<DICH_DATA CI_END="8.643982140932252" CI_START="1.489003865509515" EFFECT_SIZE="3.5876068376068377" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="6" LOG_CI_END="0.9367138609295532" LOG_CI_START="0.17289582519829638" LOG_EFFECT_SIZE="0.5548048430639247" ORDER="153" O_E="0.0" SE="0.4486704951487957" STUDY_ID="STD-HGHD-Trial-2002" TOTAL_1="234" TOTAL_2="219" VAR="0.2013052132170655" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.3787707657040574" CI_START="0.12028654650777568" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2134502923976608" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="57" I2="0.0" I2_Q="0.0" ID="CMP-003.09" LOG_CI_END="-0.42162354810424585" LOG_CI_START="-0.9197829437671124" LOG_EFFECT_SIZE="-0.6707032459356792" METHOD="MH" NO="9" P_CHI2="1.0" P_Q="0.0" P_Z="1.3085469771890725E-7" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="234" TOTAL_2="219" WEIGHT="100.0" Z="5.277644937716589">
<NAME>Akathisia</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Haloperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours haloperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.3787707657040574" CI_START="0.12028654650777568" DF="0.0" EFFECT_SIZE="0.2134502923976608" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="57" I2="0.0" ID="CMP-003.09.01" LOG_CI_END="-0.42162354810424585" LOG_CI_START="-0.9197829437671124" LOG_EFFECT_SIZE="-0.6707032459356792" NO="1" P_CHI2="1.0" P_Z="1.3085469771890725E-7" STUDIES="1" TAU2="0.0" TOTAL_1="234" TOTAL_2="219" WEIGHT="100.0" Z="5.277644937716589">
<NAME>Olanzapine v. haloperidol</NAME>
<DICH_DATA CI_END="0.3787707657040574" CI_START="0.12028654650777568" EFFECT_SIZE="0.2134502923976608" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="57" LOG_CI_END="-0.42162354810424585" LOG_CI_START="-0.9197829437671124" LOG_EFFECT_SIZE="-0.6707032459356792" ORDER="154" O_E="0.0" SE="0.29262129494114636" STUDY_ID="STD-HGHD-Trial-2002" TOTAL_1="234" TOTAL_2="219" VAR="0.08562722225303336" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.6442737218678426" CI_START="0.1711780518621017" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3320926385442515" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="31" I2="0.0" I2_Q="0.0" ID="CMP-003.10" LOG_CI_END="-0.1909295819557312" LOG_CI_START="-0.7665519205364131" LOG_EFFECT_SIZE="-0.4787407512460721" METHOD="MH" NO="10" P_CHI2="1.0" P_Q="0.0" P_Z="0.0011134369362484787" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="234" TOTAL_2="219" WEIGHT="100.0" Z="3.260174484150712">
<NAME>Tremor</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Haloperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours haloperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.6442737218678426" CI_START="0.1711780518621017" DF="0.0" EFFECT_SIZE="0.3320926385442515" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="31" I2="0.0" ID="CMP-003.10.01" LOG_CI_END="-0.1909295819557312" LOG_CI_START="-0.7665519205364131" LOG_EFFECT_SIZE="-0.4787407512460721" NO="1" P_CHI2="1.0" P_Z="0.0011134369362484787" STUDIES="1" TAU2="0.0" TOTAL_1="234" TOTAL_2="219" WEIGHT="100.0" Z="3.260174484150712">
<NAME>Olanzapine v. haloperidol</NAME>
<DICH_DATA CI_END="0.6442737218678426" CI_START="0.1711780518621017" EFFECT_SIZE="0.3320926385442515" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="31" LOG_CI_END="-0.1909295819557312" LOG_CI_START="-0.7665519205364131" LOG_EFFECT_SIZE="-0.4787407512460721" ORDER="155" O_E="0.0" SE="0.33812341105882265" STUDY_ID="STD-HGHD-Trial-2002" TOTAL_1="234" TOTAL_2="219" VAR="0.11432744110605357" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="72.50728193823466" CI_START="1.2080221284057155" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="9.35897435897436" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.11" LOG_CI_END="1.8603816251472922" LOG_CI_START="0.08207488971265887" LOG_EFFECT_SIZE="0.9712282574299755" METHOD="MH" NO="11" P_CHI2="1.0" P_Q="0.0" P_Z="0.032283558217513525" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="234" TOTAL_2="219" WEIGHT="100.0" Z="2.140881960799748">
<NAME>Infection</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Haloperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours haloperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="72.50728193823466" CI_START="1.2080221284057155" DF="0.0" EFFECT_SIZE="9.35897435897436" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" I2="0.0" ID="CMP-003.11.01" LOG_CI_END="1.8603816251472922" LOG_CI_START="0.08207488971265887" LOG_EFFECT_SIZE="0.9712282574299755" NO="1" P_CHI2="1.0" P_Z="0.032283558217513525" STUDIES="1" TAU2="0.0" TOTAL_1="234" TOTAL_2="219" WEIGHT="100.0" Z="2.140881960799748">
<NAME>Olanzapine v. haloperidol</NAME>
<DICH_DATA CI_END="72.50728193823466" CI_START="1.2080221284057155" EFFECT_SIZE="9.35897435897436" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" LOG_CI_END="1.8603816251472922" LOG_CI_START="0.08207488971265887" LOG_EFFECT_SIZE="0.9712282574299755" ORDER="156" O_E="0.0" SE="1.0445861791546132" STUDY_ID="STD-HGHD-Trial-2002" TOTAL_1="234" TOTAL_2="219" VAR="1.0911602856808338" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.834270583887256E-31" CI_END="0.447630844268122" CI_START="0.10976258748206483" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.22165991902834006" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="38" I2="100.0" I2_Q="0.0" ID="CMP-003.12" LOG_CI_END="-0.34907999579444526" LOG_CI_START="-0.9595456637005744" LOG_EFFECT_SIZE="-0.6543128297475098" METHOD="MH" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="2.6517593185926628E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="234" TOTAL_2="219" WEIGHT="100.0" Z="4.201479782888645">
<NAME>Hypertonia</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Haloperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours haloperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.834270583887256E-31" CI_END="0.447630844268122" CI_START="0.10976258748206483" DF="0.0" EFFECT_SIZE="0.22165991902834006" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="38" I2="100.0" ID="CMP-003.12.01" LOG_CI_END="-0.34907999579444526" LOG_CI_START="-0.9595456637005744" LOG_EFFECT_SIZE="-0.6543128297475098" NO="1" P_CHI2="0.0" P_Z="2.6517593185926628E-5" STUDIES="1" TAU2="0.0" TOTAL_1="234" TOTAL_2="219" WEIGHT="100.0" Z="4.201479782888645">
<NAME>Olanzapine v. haloperidol</NAME>
<DICH_DATA CI_END="0.44763084426812205" CI_START="0.10976258748206487" EFFECT_SIZE="0.2216599190283401" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="38" LOG_CI_END="-0.3490799957944452" LOG_CI_START="-0.9595456637005741" LOG_EFFECT_SIZE="-0.6543128297475097" ORDER="157" O_E="0.0" SE="0.3585905551818521" STUDY_ID="STD-HGHD-Trial-2002" TOTAL_1="234" TOTAL_2="219" VAR="0.12858718626562893" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="274.09891822952835" CI_START="0.9240599724987119" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="15.914893617021276" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.13" LOG_CI_END="2.4379073215377707" LOG_CI_START="-0.03429984168028263" LOG_EFFECT_SIZE="1.201803739928744" METHOD="MH" NO="13" P_CHI2="1.0" P_Q="0.0" P_Z="0.056704951815382154" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="234" TOTAL_2="219" WEIGHT="100.0" Z="1.905578207029992">
<NAME>Fever</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Haloperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours haloperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="274.09891822952835" CI_START="0.9240599724987119" DF="0.0" EFFECT_SIZE="15.914893617021276" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" I2="0.0" ID="CMP-003.13.01" LOG_CI_END="2.4379073215377707" LOG_CI_START="-0.03429984168028263" LOG_EFFECT_SIZE="1.201803739928744" NO="1" P_CHI2="1.0" P_Z="0.056704951815382154" STUDIES="1" TAU2="0.0" TOTAL_1="234" TOTAL_2="219" WEIGHT="100.0" Z="1.905578207029992">
<NAME>Olanzapine v. haloperidol</NAME>
<DICH_DATA CI_END="274.09891822952835" CI_START="0.9240599724987119" EFFECT_SIZE="15.914893617021276" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" LOG_CI_END="2.4379073215377707" LOG_CI_START="-0.03429984168028263" LOG_EFFECT_SIZE="1.201803739928744" ORDER="158" O_E="0.0" SE="1.4521867252971081" STUDY_ID="STD-HGHD-Trial-2002" TOTAL_1="234" TOTAL_2="219" VAR="2.1088462851291387" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.23524786945722964" CI_START="0.03876847024066635" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.09549973835688122" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="49" I2="0.0" I2_Q="0.0" ID="CMP-003.14" LOG_CI_END="-0.6284743011086059" LOG_CI_START="-1.4115213354164329" LOG_EFFECT_SIZE="-1.0199978182625193" METHOD="MH" NO="14" P_CHI2="1.0" P_Q="0.0" P_Z="3.288723316125301E-7" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="234" TOTAL_2="219" WEIGHT="100.0" Z="5.106101933892446">
<NAME>EPS</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Haloperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours haloperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.23524786945722964" CI_START="0.03876847024066635" DF="0.0" EFFECT_SIZE="0.09549973835688122" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="49" I2="0.0" ID="CMP-003.14.01" LOG_CI_END="-0.6284743011086059" LOG_CI_START="-1.4115213354164329" LOG_EFFECT_SIZE="-1.0199978182625193" NO="1" P_CHI2="1.0" P_Z="3.288723316125301E-7" STUDIES="1" TAU2="0.0" TOTAL_1="234" TOTAL_2="219" WEIGHT="100.0" Z="5.106101933892446">
<NAME>Olanzapine v. haloperidol</NAME>
<DICH_DATA CI_END="0.23524786945722959" CI_START="0.03876847024066637" EFFECT_SIZE="0.09549973835688122" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="49" LOG_CI_END="-0.6284743011086059" LOG_CI_START="-1.4115213354164327" LOG_EFFECT_SIZE="-1.0199978182625193" ORDER="159" O_E="0.0" SE="0.4599657040977509" STUDY_ID="STD-HGHD-Trial-2002" TOTAL_1="234" TOTAL_2="219" VAR="0.21156844894613974" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.6883629315703742" CI_START="0.058428599610864794" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.20054945054945056" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-003.15" LOG_CI_END="-0.1621825245267663" LOG_CI_START="-1.2333745225304338" LOG_EFFECT_SIZE="-0.6977785235286" METHOD="MH" NO="15" P_CHI2="1.0" P_Q="0.0" P_Z="0.010665977791062166" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="234" TOTAL_2="219" WEIGHT="100.0" Z="2.55345592172153">
<NAME>Dystonia</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Haloperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours haloperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.6883629315703742" CI_START="0.058428599610864794" DF="0.0" EFFECT_SIZE="0.20054945054945056" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="14" I2="0.0" ID="CMP-003.15.01" LOG_CI_END="-0.1621825245267663" LOG_CI_START="-1.2333745225304338" LOG_EFFECT_SIZE="-0.6977785235286" NO="1" P_CHI2="1.0" P_Z="0.010665977791062166" STUDIES="1" TAU2="0.0" TOTAL_1="234" TOTAL_2="219" WEIGHT="100.0" Z="2.55345592172153">
<NAME>Olanzapine v. haloperidol</NAME>
<DICH_DATA CI_END="0.6883629315703742" CI_START="0.058428599610864794" EFFECT_SIZE="0.20054945054945056" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="14" LOG_CI_END="-0.1621825245267663" LOG_CI_START="-1.2333745225304338" LOG_EFFECT_SIZE="-0.6977785235286" ORDER="160" O_E="0.0" SE="0.6292234821132618" STUDY_ID="STD-HGHD-Trial-2002" TOTAL_1="234" TOTAL_2="219" VAR="0.3959221904427384" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9277262053744906" CI_START="0.014752197453386575" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.11698717948717949" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-003.16" LOG_CI_END="-0.032580175763420594" LOG_CI_START="-1.8311432833605155" LOG_EFFECT_SIZE="-0.9318617295619681" METHOD="MH" NO="16" P_CHI2="1.0" P_Q="0.0" P_Z="0.04225786069884024" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="234" TOTAL_2="219" WEIGHT="100.0" Z="2.030971747166301">
<NAME>Hypokinesia</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Haloperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours haloperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9277262053744906" CI_START="0.014752197453386575" DF="0.0" EFFECT_SIZE="0.11698717948717949" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" I2="0.0" ID="CMP-003.16.01" LOG_CI_END="-0.032580175763420594" LOG_CI_START="-1.8311432833605155" LOG_EFFECT_SIZE="-0.9318617295619681" NO="1" P_CHI2="1.0" P_Z="0.04225786069884024" STUDIES="1" TAU2="0.0" TOTAL_1="234" TOTAL_2="219" WEIGHT="100.0" Z="2.030971747166301">
<NAME>Olanzapine v. haloperidol</NAME>
<DICH_DATA CI_END="0.9277262053744906" CI_START="0.014752197453386575" EFFECT_SIZE="0.11698717948717949" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" LOG_CI_END="-0.032580175763420594" LOG_CI_START="-1.8311432833605155" LOG_EFFECT_SIZE="-0.9318617295619681" ORDER="161" O_E="0.0" SE="1.0564848724335023" STUDY_ID="STD-HGHD-Trial-2002" TOTAL_1="234" TOTAL_2="219" VAR="1.1161602856808337" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.4683859610686019" CI_START="0.008311322364440718" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.062393162393162394" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-003.17" LOG_CI_END="-0.3293961305121643" LOG_CI_START="-2.0803298727392474" LOG_EFFECT_SIZE="-1.2048630016257058" METHOD="MH" NO="17" P_CHI2="1.0" P_Q="0.0" P_Z="0.00698823711913376" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="234" TOTAL_2="219" WEIGHT="100.0" Z="2.6974042849703">
<NAME>Increased Salivation</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Haloperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours haloperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.4683859610686019" CI_START="0.008311322364440718" DF="0.0" EFFECT_SIZE="0.062393162393162394" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="15" I2="0.0" ID="CMP-003.17.01" LOG_CI_END="-0.3293961305121643" LOG_CI_START="-2.0803298727392474" LOG_EFFECT_SIZE="-1.2048630016257058" NO="1" P_CHI2="1.0" P_Z="0.00698823711913376" STUDIES="1" TAU2="0.0" TOTAL_1="234" TOTAL_2="219" WEIGHT="100.0" Z="2.6974042849703">
<NAME>Olanzapine v. haloperidol</NAME>
<DICH_DATA CI_END="0.4683859610686019" CI_START="0.008311322364440718" EFFECT_SIZE="0.062393162393162394" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="15" LOG_CI_END="-0.3293961305121643" LOG_CI_START="-2.0803298727392474" LOG_EFFECT_SIZE="-1.2048630016257058" ORDER="162" O_E="0.0" SE="1.0285071474459964" STUDY_ID="STD-HGHD-Trial-2002" TOTAL_1="234" TOTAL_2="219" VAR="1.0578269523475003" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2708052071051699" CI_START="0.004080787186072867" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.07201309328968904" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-003.18" LOG_CI_END="0.10407898567384519" LOG_CI_START="-2.389256053186579" LOG_EFFECT_SIZE="-1.1425885337563668" METHOD="MH" NO="18" P_CHI2="1.0" P_Q="0.0" P_Z="0.07244127035518216" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="234" TOTAL_2="219" WEIGHT="100.0" Z="1.7963349011727177">
<NAME>Dyskinesia</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Haloperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours haloperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2708052071051699" CI_START="0.004080787186072867" DF="0.0" EFFECT_SIZE="0.07201309328968904" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" I2="0.0" ID="CMP-003.18.01" LOG_CI_END="0.10407898567384519" LOG_CI_START="-2.389256053186579" LOG_EFFECT_SIZE="-1.1425885337563668" NO="1" P_CHI2="1.0" P_Z="0.07244127035518216" STUDIES="1" TAU2="0.0" TOTAL_1="234" TOTAL_2="219" WEIGHT="100.0" Z="1.7963349011727177">
<NAME>Olanzapine v. haloperidol</NAME>
<DICH_DATA CI_END="1.2708052071051699" CI_START="0.004080787186072867" EFFECT_SIZE="0.07201309328968904" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.10407898567384519" LOG_CI_START="-2.389256053186579" LOG_EFFECT_SIZE="-1.1425885337563668" ORDER="163" O_E="0.0" SE="1.464597344034108" STUDY_ID="STD-HGHD-Trial-2002" TOTAL_1="234" TOTAL_2="219" VAR="2.145045380151763" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2645636756418799" CI_START="0.3394000424190973" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6551282051282051" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-003.19" LOG_CI_END="0.10194070262755389" LOG_CI_START="-0.4692881077390892" LOG_EFFECT_SIZE="-0.18367370255576765" METHOD="MH" NO="19" P_CHI2="1.0" P_Q="0.0" P_Z="0.20751825198235785" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="234" TOTAL_2="219" WEIGHT="100.0" Z="1.2604190663470394">
<NAME>Failure to complete treatment due to adverse effects</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Haloperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours haloperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2645636756418799" CI_START="0.3394000424190973" DF="0.0" EFFECT_SIZE="0.6551282051282051" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="20" I2="0.0" ID="CMP-003.19.01" LOG_CI_END="0.10194070262755389" LOG_CI_START="-0.4692881077390892" LOG_EFFECT_SIZE="-0.18367370255576765" NO="1" P_CHI2="1.0" P_Z="0.20751825198235785" STUDIES="1" TAU2="0.0" TOTAL_1="234" TOTAL_2="219" WEIGHT="100.0" Z="1.2604190663470394">
<NAME>Olanzapine v. haloperidol</NAME>
<DICH_DATA CI_END="1.2645636756418799" CI_START="0.3394000424190973" EFFECT_SIZE="0.6551282051282051" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="20" LOG_CI_END="0.10194070262755389" LOG_CI_START="-0.4692881077390892" LOG_EFFECT_SIZE="-0.18367370255576765" ORDER="164" O_E="0.0" SE="0.33554263083758085" STUDY_ID="STD-HGHD-Trial-2002" TOTAL_1="234" TOTAL_2="219" VAR="0.11258885710940505" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4267192903788783" CI_START="0.9286392415184461" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1510462717359269" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="87" I2="0.0" I2_Q="0.0" ID="CMP-003.20" LOG_CI_END="0.15433853328861047" LOG_CI_START="-0.03215296829547722" LOG_EFFECT_SIZE="0.061092782496566606" METHOD="MH" NO="20" P_CHI2="1.0" P_Q="0.0" P_Z="0.19909651984009666" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="234" TOTAL_2="219" WEIGHT="100.0" Z="1.2841298653453097">
<NAME>Failure to respond - (at least 70% reduction in YMRS)</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Haloperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours haloperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4267192903788783" CI_START="0.9286392415184461" DF="0.0" EFFECT_SIZE="1.1510462717359269" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="87" I2="0.0" ID="CMP-003.20.01" LOG_CI_END="0.15433853328861047" LOG_CI_START="-0.03215296829547722" LOG_EFFECT_SIZE="0.061092782496566606" NO="1" P_CHI2="1.0" P_Z="0.19909651984009666" STUDIES="1" TAU2="0.0" TOTAL_1="234" TOTAL_2="219" WEIGHT="100.0" Z="1.2841298653453097">
<NAME>Olanzapine v. haloperidol</NAME>
<DICH_DATA CI_END="1.4267192903788783" CI_START="0.928639241518446" EFFECT_SIZE="1.1510462717359269" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="87" LOG_CI_END="0.15433853328861047" LOG_CI_START="-0.03215296829547728" LOG_EFFECT_SIZE="0.061092782496566606" ORDER="165" O_E="0.0" SE="0.10954603117831431" STUDY_ID="STD-HGHD-Trial-2002" TOTAL_1="234" TOTAL_2="219" VAR="0.012000332946920211" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4795622395719579" CI_START="0.9473242374196291" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1839025172358506" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="81" I2="0.0" I2_Q="0.0" ID="CMP-003.21" LOG_CI_END="0.17013323900264588" LOG_CI_START="-0.023501351069197787" LOG_EFFECT_SIZE="0.07331594396672403" METHOD="MH" NO="21" P_CHI2="1.0" P_Q="0.0" P_Z="0.13775482783595652" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="231" TOTAL_2="213" WEIGHT="99.99999999999999" Z="1.4842039287920663">
<NAME>Failure to respond - excluding withdrawals (at least 70% reduction in YMRS)</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>haloperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours haloperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4795622395719579" CI_START="0.9473242374196291" DF="0.0" EFFECT_SIZE="1.1839025172358506" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="81" I2="0.0" ID="CMP-003.21.01" LOG_CI_END="0.17013323900264588" LOG_CI_START="-0.023501351069197787" LOG_EFFECT_SIZE="0.07331594396672403" NO="1" P_CHI2="1.0" P_Z="0.13775482783595652" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="213" WEIGHT="99.99999999999999" Z="1.4842039287920663">
<NAME>Olanzapine v. haloperidol</NAME>
<DICH_DATA CI_END="1.4795622395719579" CI_START="0.9473242374196291" EFFECT_SIZE="1.1839025172358506" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="81" LOG_CI_END="0.17013323900264588" LOG_CI_START="-0.023501351069197787" LOG_EFFECT_SIZE="0.07331594396672403" ORDER="166" O_E="0.0" SE="0.11374191671488042" STUDY_ID="STD-HGHD-Trial-2002" TOTAL_1="231" TOTAL_2="213" VAR="0.012937223617974792" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.311723396742336" CI_START="0.9208336754058952" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0990355210538696" ESTIMABLE="YES" EVENTS_1="128" EVENTS_2="109" I2="0.0" I2_Q="0.0" ID="CMP-003.22" LOG_CI_END="0.11784226496859351" LOG_CI_START="-0.03581880669415312" LOG_EFFECT_SIZE="0.0410117291372202" METHOD="MH" NO="22" P_CHI2="1.0" P_Q="0.0" P_Z="0.2954602740822446" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="234" TOTAL_2="219" WEIGHT="100.0" Z="1.046218293063631">
<NAME>Failure to respond - (at least 80% reduction in YMRS)</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Haloperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours haloperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.311723396742336" CI_START="0.9208336754058952" DF="0.0" EFFECT_SIZE="1.0990355210538696" ESTIMABLE="YES" EVENTS_1="128" EVENTS_2="109" I2="0.0" ID="CMP-003.22.01" LOG_CI_END="0.11784226496859351" LOG_CI_START="-0.03581880669415312" LOG_EFFECT_SIZE="0.0410117291372202" NO="1" P_CHI2="1.0" P_Z="0.2954602740822446" STUDIES="1" TAU2="0.0" TOTAL_1="234" TOTAL_2="219" WEIGHT="100.0" Z="1.046218293063631">
<NAME>Olanzapine v. haloperidol</NAME>
<DICH_DATA CI_END="1.311723396742336" CI_START="0.9208336754058952" EFFECT_SIZE="1.0990355210538696" ESTIMABLE="YES" EVENTS_1="128" EVENTS_2="109" LOG_CI_END="0.11784226496859351" LOG_CI_START="-0.03581880669415312" LOG_EFFECT_SIZE="0.0410117291372202" ORDER="167" O_E="0.0" SE="0.09026127412926947" STUDY_ID="STD-HGHD-Trial-2002" TOTAL_1="234" TOTAL_2="219" VAR="0.008147097607439131" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3432791273705216" CI_START="0.932211716821906" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1190266044634978" ESTIMABLE="YES" EVENTS_1="125" EVENTS_2="103" I2="0.0" I2_Q="0.0" ID="CMP-003.23" LOG_CI_END="0.12816626648930074" LOG_CI_START="-0.030485442790345367" LOG_EFFECT_SIZE="0.04884041184947767" METHOD="MH" NO="23" P_CHI2="1.0" P_Q="0.0" P_Z="0.2275334459852294" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="231" TOTAL_2="213" WEIGHT="100.0" Z="1.206737055020944">
<NAME>Failure to respond - excluding withdrawals (at least 80% reduction in YMRS)</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>haloperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours haloperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3432791273705216" CI_START="0.932211716821906" DF="0.0" EFFECT_SIZE="1.1190266044634978" ESTIMABLE="YES" EVENTS_1="125" EVENTS_2="103" I2="0.0" ID="CMP-003.23.01" LOG_CI_END="0.12816626648930074" LOG_CI_START="-0.030485442790345367" LOG_EFFECT_SIZE="0.04884041184947767" NO="1" P_CHI2="1.0" P_Z="0.2275334459852294" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="213" WEIGHT="100.0" Z="1.206737055020944">
<NAME>Olanzapine v. haloperidol</NAME>
<DICH_DATA CI_END="1.3432791273705216" CI_START="0.932211716821906" EFFECT_SIZE="1.1190266044634978" ESTIMABLE="YES" EVENTS_1="125" EVENTS_2="103" LOG_CI_END="0.12816626648930074" LOG_CI_START="-0.030485442790345367" LOG_EFFECT_SIZE="0.04884041184947767" ORDER="168" O_E="0.0" SE="0.09319279936949082" STUDY_ID="STD-HGHD-Trial-2002" TOTAL_1="231" TOTAL_2="213" VAR="0.008684897854322167" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK>
<FEEDBACK_ITEM ID="FBK-01" NO="1">
<TITLE>Olanzapine alone or in combination for acute mania</TITLE>
<DATE_SUBMITTED>
<DATE DAY="" MONTH="" YEAR=""/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY>
<P>This abstract is not clear, and seems to minimize or maximize various results about olanzapine. NB: I am referring only to the abstract. </P>
<P>High rate of failure to complete treatment needs to be in the conclusion section, not buried in the main results. One study shows a difference between olanzapine and divalproex in mania of -0.29, barely significant, but the conclusion mentions this as the main finding. One 49 week study of olanzapine v divalproex used suboptimal doses of divalproex as compared to normal doese of olanzapine ( v placebo). A study showing divalproex superior to olanzapine for acute mania was not included. (Perhaps these two studies came out after the abstract). Olanzapine showed more weight gain and movement disorders (read EPS) than divalproex. These are serious problems, with long term consequences (diabetes, hyperlipidemia, EPS, etc.) "Weight gain" is not an adequate description of neuroleptic-induced adverse events. The conclusion in the abstract that olanzapine is an effective treatment for mania, and that it many be more efficatious than divalproex, is not supported by the limited data. Weight gain (without consequences) was the only adverse event mentioned in the conclusion, leaving out EPS, prolactin levels, and somnolence. There are other agents for acute mania which were not included, specifically lithium (except in combination with olanzapine). Olanzapine may be more useful for psychotic mania (or depression), where it can be used for a shorter time. This attempted review is ambitious, but with only six studies with many different aspects of the use of olanzapine, there could have been a clearer presentation, with reliance on evidence-based medicine. Although not an objective of this study, surely mention of other studies of other drugs for acute mania is required for a quality practice. Also, author involvement with the drug firm producing olanzapine needs to be noted. </P>
<P>I certify that I have no affiliations with or involvement in any organisation or entity with a direct financial interest in the subject matter of my criticisms.</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY>
<P>Response to comments on:<BR/>Olanzapine alone or in combination for acute mania.<BR/>This abstract is not clear, and seems to minimize or maximize various results about olanzapine. NB: I am referring only to the abstract. <BR/>High rate of failure to complete treatment needs to be in the conclusion section, not buried in the main results. <BR/>We agree that the high rates of failure to complete treatment are an important feature of the trials and limit the confidence that can be placed in the results. We do not agree, however, that this is "buried" in the results section. The conclusions are our view of the clinical bottom line and, in our opinion, are justified by the data. Conclusions are inevitably judgements - this is precisely why the objective data on trial withdrawals should be properly reported in the results section.<BR/>One study shows a difference between olanzapine and divalproex in mania of -0.29, barely significant, but the conclusion mentions this as the main finding. <BR/>We are not sure if the comment refers to clinical or statistical significance. In terms of clinical significance, an effect size of 0.29 could be quite substantial although we have drawn attention in the review to the difficulties in interpreting the trial outcomes. The statistical imprecision of the result is described by the wide confidence interval and this reflects the uncertainty about the true difference between the treatments.<BR/>One 49 week study of olanzapine v divalproex used suboptimal doses of divalproex as compared to normal doese of olanzapine ( v placebo). A study showing divalproex superior to olanzapine for acute mania was not included. (Perhaps these two studies came out after the abstract). <BR/>Despite our extensive search, we did not find either of these studies. We would be delighted to examine these trials for inclusion in an updated review if the commentator could provide further details.<BR/>Olanzapine showed more weight gain and movement disorders (read EPS) than divalproex. These are serious problems, with long term consequences (diabetes, hyperlipidemia, EPS, etc.) "Weight gain" is not an adequate description of neuroleptic-induced adverse events. <BR/>The potential link between weight gain and alterations in glucose metabolism is mentioned in the review. In view of recent concerns which have been expressed by regulatory authorities since the review was published, we will consider including it in the abstract when the review is updated.</P>
<P>The conclusion in the abstract that olanzapine is an effective treatment for mania, and that it many be more efficatious than divalproex, is not supported by the limited data. <BR/>In our opinion the data do support the superiority of olanzapine over both placebo and divalproex in reduction of manic symptoms. <BR/>Weight gain (without consequences) was the only adverse event mentioned in the conclusion, leaving out EPS, prolactin levels, and somnolence. <BR/>As above, we do not think that the conclusions section is the place to present the results. The results section of the review and abstract clearly describe all adverse events<BR/>There are other agents for acute mania which were not included, specifically lithium (except in combination with olanzapine). <BR/>The aim, as clearly described in both the peer-reviewed protocol and the review, was to review evidence for use of olanzapine not to review all treatment options in bipolar disorder. <BR/>Olanzapine may be more useful for psychotic mania (or depression), where it can be used for a shorter time. <BR/>There was no data in the papers to support or refute this and we do not think such recommendations about subgroups of patients are justifiable at this time<BR/>This attempted review is ambitious, but with only six studies with many different aspects of the use of olanzapine, there could have been a clearer presentation, with reliance on evidence-based medicine. <BR/>We used the usual methods of systematic reviews, but we will consider how to make the review clearer when we revise it. The identification of any specific issues would be helpful.<BR/>Although not an objective of this study, surely mention of other studies of other drugs for acute mania is required for a quality practice. <BR/>Our conclusion is that "Clinicians should consider both the relative efficacy and the different incidence of specific adverse effects of available drugs". It is beyond the scope of this paper to refer to other studies.<BR/>Also, author involvement with the drug firm producing olanzapine needs to be noted. <BR/>All authors have signed the Cochrane Collaboration License for Publication and indicated that they have no conflicts of interest.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS>
<P>Sender Eileen McGinn <BR/>Sender Description MPH <BR/>Sender Email qedeileen@aol.com <BR/>Sender Address 210 East 15th Street NY NY 10003 <BR/>Date Received 20/08/2003 16:00:46</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>